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Serum/glucocorticoid regulated kinase 1 (SGK1) is a key component of the pathway that 
leads to activation of the epithelial sodium channel (ENaC) in the aldosterone-sensitive 
distal nephron (ASDN).  Regulation of ENaC is a major determinant of renal Na+ 
absorption and overall body fluid homeostasis and blood pressure.  Studies from our 
laboratory have shown that human skin cells express multiple SGK1 isoforms (A-F) that 
arise from alternative transcriptional start sites and RNA splicing at the SGK1 locus.  The 
aim of this study was to investigate if SGK1 isoforms are also expressed in the ASDN and 
to assess their potential role in regulating Na+ transport. For these studies the mouse 
cortical collecting duct cell line mpkCCDcl4, was used as an in vitro model of the ASDN. 
Comparison of mouse Sgk1 expressed sequence tags (ESTs) with genomic DNA, 
identified four potential Sgk1 isoforms (Sgk1a-1d).  Each isoform has a unique amino 
terminus of varying size, but otherwise an identical sequence.  Using sequence specific 
primers, mRNA expression of all four isoforms was confirmed by RT-PCR from purified 
mpkCCDcl4 cell and mouse renal tissue RNA.  mpkCCDcl4 cells exposed to aldosterone 
(Aldo) or Aldo plus insulin (Ins) showed a time-dependent increase in the endogenous 
expression levels of multiple Sgk1 bands within 1 hour of treatment.  These Aldo and Aldo 
+ Ins-induced endogenous Sgk1 bands co-migrated with overexpressed Sgk1 a-d isoform 
bands.  Aldosterone also produced a significant increase in amiloride-sensitive (ENaC-
mediated) equivalent short circuit current within 2 hours of exposure, peaking after 4 
hours.  Insulin potentiated the Aldo response, but had no effect alone.  Specific inhibitors 
showed that the hormonal response involved both PI3Kinase and mTOR-dependent and 
independent pathways.  Immunofluorescence studies utilising cloned and tagged SGK1 
isoforms in transfected HEK293T cells revealed cytoplasmic network-like staining for all 
 III
SGK1 isoforms except for SGK1D, which produced plasma membrane staining.  In mouse 
renal tissue, endogenous Sgk1d localised to the basolateral membrane of collecting duct 
epithelial cells.  Furthermore co-immunoprecipitation of cloned human SGK1 and mouse 
Sgk1 proteins with the Aldo induced regulatory protein, glucocorticoid-induced leucine 
zipper protein 1 (GILZ1), showed isoform-specific interactions.  Collectively, these results 
build upon our understanding of SGK1 gene expression, protein localisation and function 
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Chapter 1 - Introduction 
Elevated blood pressure (hypertension) is widely considered to be a main cause of 
cardiovascular disease and stroke, however, the causes of hypertension and the 
mechanisms by which hypertension causes cardiovascular disease and stroke are poorly 
understood (Titze and Ritz, 2009; Staessen et al., 2003; Beevers et al., 2001).  Regulation 
of body salt represents a major determinant of blood pressure homeostasis, and the 
principle regulation of salt balance occurs in the kidneys (O'Shaughnessy and Karet, 2006).  
The final composition of the kidney filtrate is regulated in the cortical collecting duct 
(CCD), where the principal cells mediate the hormone-regulated sodium reabsorption 
required for the fine control of salt homeostasis (Greger, 2000).  Serum/glucocorticoid 
regulated kinase 1 (SGK1) plays a key role in regulation of transepithelial sodium transport 
by principal cells and for this reason is vital for the control of blood pressure (McCormick 
et al., 2005). 
 
1.1 Renal regulation of sodium balance 
The primary function of the kidneys is to filter the blood of waste products such as urea 
and pass it to the urinary bladder for excretion.  Additional functions of the kidneys 
include: regulation of plasma osmolality, long-term regulation of blood pressure, 
regulation of bicarbonate excretion to help regulate acid-base balance, and secretion of 
hormones such as calcitriol, erythropoietin, and renin (Marieb, 2000).  As well as waste, 
the kidneys also filter water, glucose, amino acids, and ions from blood which must be 
reabsorbed before being excreted in urine.  Every day the kidneys process approximately 
180 litres of fluid, but only about 1% gets excreted as urine.  A kidney is comprised of 
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about 1.2 million individual filtering and reabsorption/secretion units called nephrons 
(Figure 1.1).  The nephrons are responsible for the filtration of blood and the reabsorption 
and secretion of electrolytes by the kidney.  Connecting the nephrons to the renal pelvis is 
the collecting duct system, which is responsible for the final reabsorption and secretion of 




Figure 1.1  Structure of a nephron indicating the different segments and vasculature.  
Image used from (http://www.tutorvista.com/content/biology/biology-
iv/excretion/nephron-structure.php). 
 
1.1.1 Renal regulation of blood pressure 
The kidneys regulate blood pressure by controlling the volume of extracellular fluid (ECF), 
mainly through controlling the plasma concentration of Na+.  An increase of plasma Na+ 
concentration increases the osmotic pressure of the blood, thereby increasing fluid 
retention, ECF volume and blood pressure.  The renin-angiotensin-aldosterone system 
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(RAAS) mediates the response of the kidneys to low blood pressure and, together with the 
baroreceptor reflex, is responsible for long-term control of blood pressure and body fluid 
homeostasis.  The RAAS is stimulated by sympathetic nervous system activity or in 
response to low arterial blood pressure, as detected by the baroreceptors or by the kidney 
through a lowering of glomerular filtration rate (GFR).  The juxtaglomerular apparatus is a 
structure located at the junction of the glomerulus, distal convoluted tubule (DCT), and 
afferent and efferent arterioles of the renal nephrons.  The macula densa of the 
juxtaglomerular apparatus detects changes in GFR through altered Na+ concentration in the 
nephron filtrate flowing through the DCT.  In response to lowered DCT filtrate Na+ 
concentration, the macula densa stimulates granular cells, another part of the 
juxtaglomerular apparatus, to release renin into the bloodstream, which activates RAAS. 
 
1.1.2 The renin-angiotensin-aldosterone system 
The renin-angiotensin-aldosterone system (RAAS) is activated upon the release of renin 
from the juxtaglomerular apparatus into the bloodstream.  Renin causes hydrolysis of 
angiotensinogen into angiotensin I, which is then converted into angiotensin II by 
pulmonary and renal angiotensin converting enzyme (ACE).  Angiotensin II stimulates 
vasoconstriction and release of arginine vasopressin (AVP) from the pituitary gland and 
aldosterone from the adrenal cortex.  ADH acts on the collecting duct to stimulate water 
absorption, whereas aldosterone acts on the aldosterone-sensitive distal nephron (ASDN) 
to stimulate Na+ reabsorption, K+ excretion, and water retention.  These effects cause an 
increase in plasma volume, which in turn causes increased arterial blood pressure and 
GFR, thereby reducing the stimulation of renin release by the macula densa in a negative 
feedback mechanism. 
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1.1.3 The aldosterone-sensitive distal nephron 
The aldosterone-sensitive distal nephron (ASDN) consists of the late distal convoluted 
tubule (DCT), connecting tubule (CNT), cortical collecting duct (CCD), and medullary 
collecting duct (MCD) (Meneton et al., 2004; Loffing et al., 2001).  The DCT is defined by 
the presence of the Na+/Cl- cotransporter (NCC) in the apical membrane of its simple 
cuboidal epithelial cells.  The other segments of the ASDN each contain two epithelial cell 
types; intercalated cells and segment-specific cells.  The intercalated cells perform the 
acid-base homeostasis role of the kidneys.  There are two intercalated cell types: α; acid 
absorbing and bicarbonate secreting and β; bicarbonate absorbing and acid secreting.  The 
ASDN segment-specific cells are specialised for their respective segments and are named 
accordingly as connecting tubule cells, principal cells of the collecting duct, or inner 
medullary collecting duct cells. 
 
1.1.4 The principal cells of the collecting duct 
Principal cells comprise approximately 71% of the cells of the cortical collecting duct 
(CCD) epithelium and are solely responsible for the Na+ reabsorption and K+ secretion that 
occurs in the CCD (O'Neil and Hayhurst, 1985).  These cells are characterised by having a 
large number of water channels (aquaporins) which coupled with Na+ reabsorption, are 
used to reabsorb water.  Principal cells are responsible for the fine control of salt balance 
through regulated reabsorption of the remaining 2-5% of filtered Na+.  Reabsorption of Na+ 
occurs because of the generation of an inward Na+ electrochemical gradient into the cell by 
the basolateral Na+/K+-ATPase, which actively transports 3 Na+ out of the cell and 2 K+ 
into the cell.  The Na+ electrochemical gradient allows Na+ to flow into the cell from the 
CCD lumen through the apical epithelial sodium channel (ENaC).  ENaC is the rate 
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limiting step for reabsorption of Na+ and therefore is tightly regulated, as discussed later in 
section 1.4.1.  The Na+/K+-ATPase also creates a K+ electrochemical gradient out of the 
cell, which is either used to secrete K+ via the apical ROMK K+ channel, which is also 
under tight regulation, or is used to transport Cl- across the basolateral membrane via the 
K+,Cl- cotransporter (KCC4).  The movement of K+ is important for the maintenance of 
cell membrane potential.  Cl- may also be transported across the basolateral membrane by 
CLC-K2, but this transporter is only present in the intercalated cells of the CCD.  Water 
reabsorption by principal cells is mediated by water channels aquaporin 2 (AQP2) in the 
apical membrane and aquaporin 3 (AQP3) in the basolateral membrane.  AQP2 is the rate 
limiting step in water reabsorption, and AQP2 channels are inserted into the membrane 
following stimulation by argenine vasopressin (AVP) hormone in response to dehydration.  
Ion transport across principal cells is summarised in Figure 1.2. 
 
 
Figure 1.2  Routes of the major ion and water transport in principal cells.  Figure 
adapted from (Fenton and Knepper, 2007). 
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1.2 Regulation of sodium transport in principal cells 
Sodium transport in principal cells is mostly regulated at the point of Na+ entry across the 
apical membrane via ENaC.  ENaC is controlled through various mechanisms, but the 
most important is the regulation by hormones such as aldosterone and insulin via SGK1.  
The basic pathway of aldosterone and insulin regulation of sodium transport in principal 
cells is summarised in Figure 1.3.  Aldosterone induces expression of SGK1, whilst insulin 
stimulates the PI3K pathway causing phosphorylation and activation of SGK1.  Active 
SGK1 stimulates ENaC by phosphorylating and inactivating Nedd4-2, which would 
otherwise cause ENaC internalisation and degradation (McCormick et al., 2005).  
Regulation of ENaC is reviewed in more detail in section 1.4.1.  ENaC-mediated sodium 
transport is also sensitive to both intracellular and extracellular [Na+].  Increased 
intracellular [Na+] blocks further Na+ entry into the cell via ENaC possibly to protect the 
cell from osmotic damage (Anantharam et al., 2006).  Increased intracellular [Na+] has also 
been shown to increase the activity of Na+,K+-ATPase at the cell surface of isolated rat 
CCD cells and mpkCCDcl4 cells (Vinciguerra et al., 2003).  ENaC is also blocked by high 
extracellular Na+ which is suggested to be mediated by a Na+-sensing self-inhibition site on 




Figure 1.3  Simplified SGK1-regulated Na+ transport in a CCD principal cell.  Figure 
used from (McCormick et al., 2005). 
 
1.2.1 The mineralocorticoid receptor 
Mineralocorticoid receptors (MRs) mediate the aldosterone-induced signalling and 
upregulated gene expression involved in the regulation of sodium transport in principal 
cells.  The MR is a member of the steroid hormone receptor family that has high affinity 
for mineralocorticoids such as aldosterone.  MRs are expressed in various tissues, 
including kidney, brain, heart, blood vessels, adipose tissue, and circulating monocytes 
(Gomez-Sanchez, 2010; Urbanet et al., 2010; Fuller and Young, 2005).  MRs are bound by 
both aldosterone and cortisol, but 11 β-hydroxysteroid dehydrogenase 2 (11β-HSD2) acts 
to protect MRs from cortisol (Morris et al., 2000).  Aldosterone enters the principal cells of 
the ASDN and binds to MRs present in the cytosol.  The aldosterone-MR complexes then 
translocate from the cytosol to the nucleus, where they bind to DNA hormone response 
elements in order to transcriptionally upregulate various proteins such as SGK1 (Chen et 
al., 1999; Naray-Fejes-Toth et al., 1999), ENaC, Na+,K+-ATPase (Feraille et al., 2003; 
Verrey et al., 2003), K-Ras, and corticosterone hormone-induced factor (CHIF).  SGK1 is 
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a critical component of the aldosterone-induced increase in ENaC-mediated Na+ transport 
(Naray-Fejes-Toth and Fejes-Toth, 2000).  SGK1 is also able to stimulate Na+,K+-ATPase 
activity, however, this is separate to the activation by aldosterone (Alvarez de la Rosa et 
al., 2006; Zecevic et al., 2004).  Osmotic stress caused by hypertonic conditions reduces 
expression of MR in CCD cells (Viengchareun et al., 2009).  Mice deficient in MR show 
impaired salt balance (Ronzaud et al., 2007). 
 
1.2.2 The phosphoinositide 3-kinase pathway 
The phosphoinositide 3-kinase (PI3K) pathway regulates SGK1 activity by controlling the 
phosphorylation of SGK1 by phosphoinositide-dependent protein kinase 1 (PDPK1) and 
mammalian target of rapamycin complex 2 (mTORC2) (Lu et al., 2010; Kobayashi and 
Cohen, 1999).  The PI3K pathway can be activated by various substances including 
insulin, insulin-like growth factor 1 (IGF-1), and pervanadate and is involved in many 
cellular processes including regulation of cell proliferation, differentiation, motility, 
survival and intracellular trafficking (Gonzalez-Rodriguez et al., 2007; Gamper et al., 
2002; Park et al., 1999; Alessi et al., 1996).  The diverse functions of this pathway are 
mediated by the actions of the PI3Ks; a family of intracellular signalling proteins that are 
split into three classes based on their structure, regulation, and substrate specificity, which 



























PtdIns → PtdIns(3)P 





III G protein-coupled 
receptors? 
PtdIns → PtdIns(3)P Vps34 Vps15 
 
Table 1.1  A summary of the PI3K classes and their respective regulation, substrate 
reactions, and constituting subunits. 
 
The PI3Ks are defined by their phosphorylation of a hydroxyl group in the 3-position of 
the inositol ring of phosphatidylinositol (PtdIns) in order to regulate the levels of PtdIns 
and its phosphorylated forms; PtdIns(3)P, PtdIns(4)P, PtdIns(3,4)P2, PtdIns(4,5)P2, and 
PtdIns(3,4,5)P3 in cells.  The PI3Ks perform their role in conjunction with various 
phosphatases, which dephosphorylate the 3- 4- or 5-positions of PtdIns enabling regulation 
of the relative levels of the different PtdIns species.  The class I PI3Ks are activated by 
tyrosine kinases, G protein coupled receptors (GPCRs), or Ras and produce PtdIns(3,4,5)P3 
from PtdIns(4,5)P2.  The PtdIns(3,4,5)P3 product of class I PI3Ks is subject to conversion 
into the other lipid second messengers; PtdIns(4,5)P2 and PtsIns(3,4)P2, by PtdIns 3- and 
PtdIns 5-phosphatases, respectively.  The principle PtdIns 3-phosphatase is the 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which counteracts 
the phosphorylation performed by the class I PI3Ks to produce PtdIns(4,5)P2.  Two 
important PtdIns 5-phosphatases are the SH2 domain-containing inositol 5-phosphatase 
type 2 (SHIP2) and the inositol polyphosphate-5-phosphatase E (IPP5E), which convert 
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PtdIns(3,4,5)P3 into PtsIns(3,4)P2.  Both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 are bound by 
proteins that possess a PH domain and, through this interaction, regulate the localisation 
and function of kinases such as PKB and PDPK1.  PtdIns(3,4)P2 is also produced from 
PtdIns(4)P by class II PI3Ks, which may be activated by the same route as class I PI3Ks, 
but the routes of activation of class II PI3Ks are not yet fully understood.  Class II PI3Ks 
also share production of PtdIns(3)P from PtdIns with class III PI3K, which may also be 
produced from phosphorylation of PtdIns(3,4)P2 by inositol polyphosphate-4-phosphatase 
(INPP4).  Class II PI3Ks are primarily present in intracellular membranes and, 
concurrently, basal PtdIns(3)P is localised mainly on endosomes or organelles.  PtdIns(3)P 
is bound by proteins that possess a Phagocyte Oxidase homology (PX) domain or a Fab1, 
YOTB/ZK632.12, Vac1, and EEA1 (FYVE) zinc finger domain, which may involve 
downstream kinases, vesicle sorting proteins, or scaffold proteins (Vanhaesebroeck et al., 
2010). 
SGK1 has been shown to be able to bind PtdIns(3)P, PtdIns(4)P, and PtdIns(5)P, but not 
bind PtdIns(3,4,5)P3 in vitro and mutation of a specific residue involved in PI binding 
reduced SGK1 effects on ENaC and FOXO3 (Pao et al., 2007).  Interestingly, PDPK1 is 
recruited to PtdIns(3,4,5)P3 via a pleckstrin homology (PH) domain in order to maintain 
activity of the kinase (Komander et al., 2004; McManus et al., 2004).  However, sodium 
hydrogen exchanger regulating factor 2 (NHERF2) has been shown to bind both SGK1 and 
PDPK1 via a PSD-95/Dlg/ZO-1 (PDZ) domain and a 3-phosphoinositide-dependent 
protein kinase 1 (PDK1) interacting fragment (PIF), respectively, acting as a scaffold 
protein to recruit SGK1 to PDPK1 for activation (Chun et al., 2002). 
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1.2.3 The mitogen-activated protein kinase/extracellular signal-regulated 
kinase pathway 
The mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) 
pathway is an intracellular signalling pathway that typically mediates the effects of growth 
factors on gene transcription.  Activation of the MAPK/ERK pathway by epidermal growth 
factor (EGF), transforming growth factor α (TGFα), or phorbol myristate acetate (PMA) 
was shown to cause decreased Na+ transport in CCD cells (Shen and Cotton, 2003).  The 
MAPK/ERK pathway is stimulated by the binding of growth factors such as epidermal 
growth factor (EGF) and insulin-like growth factor 1 (IGF-1) to their cell surface tyrosine 
kinase receptors such as EGF receptor (EGFR) and IGF-1 receptor (IGF1R).  Growth 
factor receptor binding induces phosphorylation of the receptor substrate or 
autophosphorylation of the receptor itself.  Phosphorylation of the receptor provides sites 
for recruitment of Src homology 2 (SH2) domain-containing effector proteins such as 
growth factor receptor-bound protein 2 (GRB2) or insulin receptor substrate 1 (IRS-1).  
Phosphorylated IRS-1 binds to the SH2 domain of GRB2.  GRB2 forms a complex with 
the guanine nucleotide exchange factor son of sevenless (SOS) via an SH3 domain and 
recruitment of this GRB2-SOS complex causes activation of SOS.  Activated SOS 
promotes the activation of Ras by removing bound GDP allowing Ras to bind GTP and 
become active.  Active Ras binds and activates Raf to initiate the MAPK signalling 
cascade of MAPKKK (Raf)-MAPKK (MEK)-MAPK (ERK1/2)-various downstream 
targets, whereby each member is phosphorylated and activated by the last.  ERK1/2 
phosphorylate ENaC stimulating its interaction with Nedd4-2.  The components of the 
MAPK/ERK pathway cascade exist in a multiprotein complex (Kyriakis, 2007).  
Interestingly, a recent study has described the existence of a complex of ENaC-Raf-Nedd4-
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2, which GILZ1 and SGK1 interact with to cooperatively stimulate ENaC (Soundararajan 
et al., 2009). 
 
1.2.4 The protein kinase A pathway 
In principal cells, the protein kinase A (PKA) pathway mediates the response to the AVP.  
AVP is released into the bloodstream from the pituitary gland in response to a drop in 
plasma osmotic pressure as detected by the hypothalamus.  AVP binds to the AVP receptor 
2 (AVPR2) on the basolateral membrane of CCD principal cells.  AVPR2 is a G protein 
coupled-receptor that activates adenylate cyclase (AC) through the GS pathway.  AC 
catalyses the conversion of ATP into the second messenger 3’,5’-cyclic adenosine 
monophosphate (cAMP).  The increased cAMP activates PKA, which has been shown to 
increase ENaC activity via phosphorylation of SGK1 (Vasquez et al., 2008; Perrotti et al., 
2001).  cAMP has also been suggested to phosphorylate equivalent sites on Nedd4-2 to 
SGK1 in order to stimulate ENaC (Snyder et al., 2004).  In addition, cAMP/PKA also 
cause the translocation of Na+,K+-ATPase to the plasma membrane, thereby promoting Na+ 
reabsorption (Feraille et al., 2003; Verrey et al., 2003; Gonin et al., 2001).  cAMP/PKA are 
also reported to induce SGK1 and αENaC protein expression in the rat salivary 
submandibular gland cell line SMG-C6 (Vasquez et al., 2008).  The cAMP/PKA induction 
of SGK1 and αENaC in SMG-C6 cells has also been linked to the PI3K and MAPK 
pathways (Mustafa et al., 2008; Vasquez et al., 2008). 
 
1.3 Serum/glucocorticoid regulated kinase 1 
The serum/glucocorticoid regulated kinases (SGKs) are members of the AGC protein 
kinase subfamily of serine/threonine protein kinases.  Other members of this subfamily 
 13
include PKA, PKB, PKC, PKG, protein kinase C related kinase (PRK), mitogen- and 
stress-activated protein kinase (MSK), and 3-phosphoinositide dependent protein kinase-1 
(PDPK1) (Pearce et al., 2010).  SGK1 was originally characterised as a 49 kDa protein 
kinase whose mRNA was rapidly induced by serum and dexamethasone in a rat mammary 
tumour cell line and was therefore named serum/glucocorticoid regulated kinase (SGK) 
(Webster et al., 1993a; Webster et al., 1993b).  The later discovery of the SGK paralogues 
SGK2 and SGK3 led to the original SGK being renamed SGK1.  SGK2 and SGK3 were 
discovered as products of distinct genes, but with 80% amino acid identity between the 
catalytic domains of the three SGK paralogues (Kobayashi et al., 1999).  In humans, the 
SGK1 gene locus is on chromosome 6q23, the SGK2 gene locus is on chromosome 20q12, 
and the SGK3 gene locus is on chromosome 8q12.3.  SGKs are broadly conserved and are 
present in mammals, shark, chicken, C. elegans, and two orthologues also exist in yeast.  
The human SGK1 gene consists of 12 exons separated by relatively short introns 
(Waldegger et al., 1998).  SGK1 consists of an N-terminus domain of ~100 residues; 
which is thought to be responsible for regulating localisation, and the remaining ~330 
residues constitute a kinase domain containing various putative binding sites and motifs.   
In mammals, SGK1 and SGK3 are expressed in most tissues including brain, heart, 
intestine, kidney, liver, lung, and muscle, whereas SGK2 is expressed more exclusively in 
epithelial tissues of the kidney, liver and pancreas (Lang et al., 2006).  SGK1, 2, and 3 are 
all expressed in cortical collecting duct cells, however, only expression of SGK1 is 
induced by aldosterone and dexamethasone (Naray-Fejes-Toth et al., 2004a).  To date, 
most research has focussed on SGK1 due to its regulation by hormones and comparatively 
little is known about SGK3 and particularly SGK2 because of their less obvious regulation.  
SGK1 is involved in regulation of many different cellular processes including proliferation, 
signalling, survival, and trafficking (Leong et al., 2003; Mikosz et al., 2001).  SGK1 
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performs its roles through acting on ion channels and transporters, other enzymes, and 
transcription factors as discussed further in section 1.3.2.  SGK2 and SGK3 are also 
thought to be involved in regulation of transport and transcription, but their exact roles 
remain to be established.  SGK1 has recently been shown to be expressed as multiple 
isoforms in humans and are thought to confer functional diversity and specificity to SGK1 
(Hall, 2007; Simon et al., 2007), which is discussed further in chapter 3. 
 
1.3.1 Regulation of serum/glucocorticoid regulated kinase 1 
Following its characterisation as a serum and glucocorticoid regulated kinase in 1993, sgk1 
was later shown to be upregulated by aldosterone in A6 cells, rat kidney distal nephron, 
and rabbit cortical collecting duct cells (Chen et al., 1999; Naray-Fejes-Toth et al., 1999).  
The induction of sgk1 by aldosterone was confirmed in vivo by other researchers studying 
rat kidney and colon (Bhargava et al., 2001; Brennan and Fuller, 2000; Shigaev et al., 
2000).  These studies of aldosterone action on sgk1 also showed that sgk1 increased 
activity of ENaC, suggesting sgk1 involvement in regulation of sodium reabsorption.  This 
led to the investigation of the possible involvement of sgk1 in other diseases associated 
with hypertension.  Sgk1 was shown to be upregulated by transforming growth factor Β 
(TGF-β), increased extracellular glucose concentration, osmotic cell shrinkage, and 
thrombin, suggesting Sgk1 may have a role in the pathogenesis of diabetic nephropathy 
(Hills et al., 2006; Lang et al., 2000; Kumar et al., 1999).  SGK1 has also been shown to be 
induced by endothelin-1 (ET-1) and suggested to be involved in blood pressure changes 
during renal failure (Wolf et al., 2006).  Peroxisome proliferator-activated receptor gamma 
(PPAR-γ) agonists, which sensitise cells to insulin and are used clinically in treatment of 
type 2 diabetes, stimulated SGK1 activity in a human CCD cell line (Vallon and Lang, 
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2005; Hong et al., 2003).  The MAPK/ERK pathway is known to regulate SGK1 and 
mediates induction of SGK1 in response to cell stress allowing SGK1 to protect cells from 
stress-induced apoptosis by negatively regulating forkhead box protein O3 (FOXO3) 
(Leong et al., 2003; Brunet et al., 2001). The MAPK/ERK pathway also mediates 
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and 12-O-
tetradecanoylphorbol-13-acetate (TPA) induction of Sgk1 (Mizuno and Nishida, 2001).  
Sgk1 has also been shown to be induced by follicle stimulating hormone (FSH) in 
granulosa cells via a cAMP-dependent pathway (Gonzalez-Robayna et al., 2000). 
Transcriptional regulation of SGK1 occurs through several intracellular signalling 
pathways and as such a number of different signalling proteins have been shown to be 
involved.  In addition to components of the PI3K, MAPK/ERK, and cAMP/PKA pathways 
discussed earlier, SGK1 expression is also induced by PKC increases of intracellular 
[Ca2+] in endothelial cells (Lang et al., 2000).  SGK1 may also be transcriptionally 
regulated by changes in nitric oxide, and interleukin 2 (IL-2) (Amato et al., 2007).  
However, the transcriptional regulation of SGK1 probably involves many more potential 
players as the SGK1 promoter region in rat has been suggested to contain various 
transcription factor binding sites such as for progesterone receptor (PR), vitamin D 
receptor (VDR), retinoid X receptor (RXR), farsenoid X receptor (FXR), sterol regulatory 
element binding protein (SREBP), p53, Sp1 transcription factor, activating protein 1 
(AP1), activating transcription factor 6 (ATF6), heat shock factor (HSF), 
reticuloendotheliosis viral oncogene homolog (c-Rel), NFkB, signal transducers and 
activators of transcription (STAT).  As well as binding sites for GR, MR, cAMP response 
element binding protein (CREB), PPARγ, TGF-β-dependent transcription factors SMAD3 
and SMAD4, and forkhead activin signal transducer (FAST) (Lang et al., 2006; Itani et al., 
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2002).  Not all of these binding sites may be used universally, but this does suggest that 
transcription regulation of SGK1 is complex. 
The activity of SGK1 inside the cell is governed by its phosphorylation, which may occur 
at various phosphorylation sites that are each substrate for different activators.  The most 
well documented phosphorylation of SGK1 is performed by 3-phosphoinositide-dependent 
protein kinase 1 (PDPK1) at threonine 256 and by mechanistic target of rapamycin 
complex 2 (mTORC2) at serine 422, which promotes its actions in inhibiting Nedd4-2 (Lu 
et al., 2010; Garcia-Martinez and Alessi, 2008; Kobayashi and Cohen, 1999).  Activation 
of SGK1 via the PI3K pathway may be stimulated by hormones such as insulin (Fuster et 
al., 2007). Phosphorylation of SGK1 at threonine 256 is first dependent on the 
phosphorylation of serine 422 (Kobayashi and Cohen, 1999).  The interaction of SGK1 
with PDPK1 is enabled by Na+/H+ Exchanger Regulatory Factor 2 (NHERF2), which 
contains two PDZ binding domains that are able to interact with PDZ binding motifs such 
as is found at the C-terminus of SGK1 (DSFL) 6 residues away from serine 422 (Chun et 
al., 2002).  Also, PDPK1 contains a PDPK interacting fragment (PIF)-binding pocket 
which may bind SGK1 directly or require NHERF2 as a scaffold protein for interaction 
with SGK1.  PDPK1 is activated by the PI3K pathway and binds to PtdIns(3,4,5)P3 via its 
PH domain.  SGK1 has also been shown to bind to phosphoinositides, possibly due to 
being localised with PDPK1 by NHERF2 (Pao et al., 2007).  The findings of these studies 
suggest that activation of SGK1 by via the PI3K pathway may occur at the plasma 
membrane.  The activity of SGK1 has been shown to be dependent on its N-terminal 
domain, which may contain amino-acid sequence required for specific localisation (Pao et 
al., 2007; Naray-Fejes-Toth et al., 2004a). 
SGK1 is also phosphorylated by big mitogen-activated protein kinase 1/extracellular signal 
regulated kinase 5 (BMK1/ERK5) at serine 78 during growth-factor-induced cell 
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proliferation as part of the MAPK/ERK signalling pathway (Hayashi et al., 2001).  The 
cAMP/PKA pathway is also involved in regulating activity of SGK1 as PKA has been 
shown to phosphorylate SGK1 at threonine 369 (Perrotti et al., 2001).  The study by 
Perrotti et al. (2001) also showed that phosphorylation and activation of SGK1 by PKA is 
dependent on the prior phosphorylation of threonine 256 or serine 422.  Additionally, 
phosphorylation of SGK1 at threonine 369 by NIMA (never in mitosis, gene A)-related 
kinase-6 (NEK6) links SGK1 with cell-cycle progression, however, this study also found 
that this phosphorylation was unlikely in vivo (Lizcano et al., 2002).  Recently, it has also 
been argued that phosphorylation of SGK1 at serine 397 and serine 401 is required for 
maximum SGK1 activity, which was dependent on co-expression with active PKB and 
with no lysine kinase 1 (WNK1) (Chen et al., 2009). 
SGK1 has a half life of ~30 min in the cell and is degraded through being ubiquitin-tagged 
at a specific six-amino-acid motif in its N-terminal domain, signalling it for degradation by 
the 26S proteasome (Brickley et al., 2002).  The ubiquitin-binding motif of SGK1 consists 
of amino acids 19-24 (GMVAIL) and is required for correct regulation of SGK1 (Bogusz 
et al., 2006).  Ubiquitination of SGK1 is performed by phosphorylated Nedd4-2, which 
itself is produced by SGK1 forming a negative feedback loop of regulation of SGK1 (Zhou 
and Snyder, 2005).  SGK1 has also been shown to be ubiquitinated in vitro by Nedd4-2 
(Zhou and Snyder, 2005), stress-induced-phosphoprotein 1 (STIP1) homology and U-box 




1.3.2 Functions of serum/glucocorticoid regulated kinase 1 
The SGK1 kinase consensus sequence has been identified as R-X-R-X-X-(S/T)-φ, 
containing arginine (R), any amino acid (X), and a hydrophobic amino acid (φ) (Lang et 
al., 2006).  This sequence is shared with the other SGK isoforms SGK2 and SGK3 as well 
as with PKB.  SGK1 has been shown to be involved in regulation of Na+ reabsorption in 
the distal nephron, primarily via stimulating ENaC (Chen et al., 1999; Naray-Fejes-Toth et 
al., 1999), which is discussed in more detail later in section 1.4.2.  SGK1 also increases 
activity and cell-surface expression of the renal Na+/K+-ATPase, suggesting an additional 
stimulation of sodium reabsorption in the distal nephron by SGK1 separate to the 
stimulation of ENaC (Alvarez de la Rosa et al., 2006; Verrey et al., 2003).  The renal K+ 
channel (ROMK1), which is important for the secretion of K+ into the nephron filtrate, is 
also stimulated by SGK1 via interaction with sodium hydrogen exchanger regulating factor 
2 (NHERF2) (Palmada et al., 2005; Vallon and Lang, 2005; Yun et al., 2002).  SGK1 and 
NHERF2 are also involved in regulation of the renal Ca2+ channels, TRPV5 and TRPV6 
that are important for reabsorption of Ca2+ (Bohmer et al., 2007; Palmada et al., 2005; 
Embark et al., 2004b) and also regulate the renal Na+-dicarboxylate cotransporter (NaDC1) 
(Boehmer et al., 2004).  NHERF2 acts as a scaffold protein by binding SGK1 and 
regulating/effector proteins to facilitate their interaction. 
Sodium transport across the apical membrane of the proximal tubule by the Na+/H+ 
exchanger (NHE3) is stimulated by insulin and SGK1 (Fuster et al., 2007).  Sodium is also 
reabsorbed in the proximal tubule with glucose via the Na+-glucose cotransporter (SGLT1) 
and SGK1 has been shown to stimulate SGLT1 activity via phosphorylation of Nedd4-2 in 
a mechanism similar to regulation of ENaC (Dieter et al., 2004).  SGK1 and Nedd4-2 
regulation has also been shown for the renal and inner ear Cl- channel (ClC-Ka) (Embark 
et al., 2004a) and the ubiquitous Cl- channel (ClC2) (Palmada et al., 2004a).  NHE3 and 
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SGLT1 are also used in absorption of Na+ and glucose in the intestine and their 
dysregulation by SGK1 may cause diarrhoea or underlie obesity.  SGK1 stimulates activity 
of the intestinal Na+-phosphate cotransporter (NAPiIIb), also through phosphorylation of 
Nedd4-2 (Palmada et al., 2004b). 
SGK1 is also suggested to be involved in the maintenance of cardiac function via 
regulation of  the cardiac voltage-gated Na+ channel (SCN5A) (Boehmer et al., 2003) and 
the cardiac K+ channels (KCNE1 and KCNQ1) (Busjahn et al., 2004).  SGK1 also 
regulates other KCNQ channels involved in neuronal excitability (Schuetz et al., 2008). 
SGK1 has also been shown to play a role in regulation of insulin secretion from glucose-
sensitive cells, in part through regulation of voltage-gated K+ channels (Kv1.3, Kv1.5, and 
Kv4.3) (Laufer et al., 2009; Boehmer et al., 2008a; Vallon and Lang, 2005).  SGK1 also 
increased the abundance of glucose transporter (GLUT1) in plasma membrane suggesting 
that SGK1 has a role in regulating glucose uptake by cells (Palmada et al., 2006). 
Further transporters that have been shown to be regulated by SGK include the cystic 
fibrosis transmembrane conductance regulator Cl- channel (CFTR) (Sato et al., 2007), 
various amino acid transporters (Boehmer et al., 2006; Boehmer et al., 2005; Bohmer et al., 
2004), the creatinine transporter (SLC6A8) (Strutz-Seebohm et al., 2007), and the peptide 
transporter (PEPT2) (Boehmer et al., 2008b). 
SGK1 mediates its effects through phosphorylation of downstream targets such as 
regulatory proteins and transcription factors.  An important role for SGK1 in regulation of 
many channels and transporters including ENaC is SGK1 regulation of the ubiquitin ligase 
Nedd4-2.  Nedd4-2 regulates its target proteins through ubiquitination, signalling the target 
protein for degradation by the proteasome.  SGK1 phosphorylation of Nedd4-2 induces 
binding of Nedd4-2 by members of the 14-3-3 family of regulatory proteins which block 
the tryptophan-rich WW domains of Nedd4-2 that are involved in PY motif interactions 
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such as Nedd4-2 uses to bind and inhibit ENaC (Bhalla et al., 2005; Debonneville et al., 
2001). 
N-myc downstream-regulated gene proteins 1 and 2 (NDRG1 and 2) have been identified 
as substrates for SGK1 phosphorylation and NDRG1 phosphorylation has since been used 
as an assay for SGK1 activity (Inglis et al., 2008; Murray et al., 2004).  SGK1 also 
phosphorylates and inactivates the proapoptotic enzyme glycogen synthase kinase 3β 
(GSK3β), which is involved in regulation of β-Catenin  (Failor et al., 2007; Aoyama et al., 
2005; Kobayashi and Cohen, 1999).  SGK1 also phosphorylates members of the 
MAPK/ERK signalling pathway in regulation of cell proliferation including mitogen-
activated kinase kinase kinase 3 (MEKK3) (Chun et al., 2003) and B-Raf (Zhang et al., 
2001).  Microtubule-associated protein tau interacts with microtubules as part of being 
involved in cell proliferation and apoptosis and is inhibited upon phosphorylation by SGK1 
(Chun et al., 2004).  SGK1 also showed possible regulatory effects on insulin stimulated 
glycosylation of glycoproteins involving phosphomannose mutase 2 (PMM2) (Menniti et 
al., 2005).  SGK1 also acts to enhance transcription factors such as cAMP responsive 
element binding protein (CREB) (Tyan et al., 2007), NFκB (Leroy et al., 2008), and 
FOXO3a (Dehner et al., 2008; You et al., 2004; Brunet et al., 2001) to mediate cell 
survival and rescue from apoptosis. 
 
1.4 Epithelial sodium channel 
The epithelial sodium channel (ENaC) is a member of the degenerin/epithelial sodium 
channel (DEG/ENaC) family of ion channels.  It constitutes the rate-limiting step in Na+ 
transport across many epithelia, such as the kidney distal nephron, airway, colon, sweat 
glands, and salivary ducts.  ENaC mediates the final regulation of Na+ reabsorption by the 
 21
kidney in the aldosterone-sensitive distal nephron (ASDN) (Bachmann et al., 1999; Duc et 
al., 1994).  Principal cells of the cortical collecting duct (CCD) express apical ENaC, 
allowing entry of Na+ into the cell, which is then extruded across the basolateral membrane 
by the Na+/K+-ATPase (Garty and Palmer, 1997).  ENaC is a heterotrimeric Na+ channel 
made up of three homologous subunits named α, β, and γ (Butterworth et al., 2008) (Figure 
1.4).  A fourth subunit has been identified named δ, which replaces the αENaC subunit to 
create a Na+ channel with different functional properties, and is present in brain, pancreas, 
ovaries, and testes (Ji et al., 2006).  Channels of δβγENaC had increased channel activity 
and much reduced sensitivity to amiloride compared to αβγENaC (Haerteis et al., 2009).  
In humans, the four genes that encode the ENaC subunits are named SCNN1A (αENaC), 
SCNN1B (βENaC), SCNN1G (γENaC), and SCNN1D (δENaC).  Each of the ENaC 
subunits consists of two transmembrane helices with a large extracellular loop and 
intracellular N- and C-termini (Canessa et al., 1994a).  PY motifs (xPPxY) at the C-termini 
of the ENaC subunits just distal to the second transmembrane domain have been identified 
and are required for normal channel regulation (Booth et al., 2003; Abriel et al., 1999).  
Mutations of the PY motifs of ENaC subunits cause dysregulation of ENaC activity and 
Liddle’s syndrome (Schild et al., 1996).  Formation of a fully functional channel requires 
all α, β, and γ subunits, however, the α subunit appears to be most important for channel 
activity and can form partially functional channels when expressed alone or with βENaC or 




Figure 1.4  Structure of the epithelial sodium channel (ENaC).  ENaC consists of three 
homologous subunits (α, β, and γ), each of which has two transmembrane domains (M1 & 
M2), a large extracellular loop, and cytosolic N- and C-termini with PY motifs close to the 
C-terminus.  Figure used from (Bhalla and Hallows, 2008). 
 
1.4.1 Regulation of epithelial sodium channel 
ENaC is regulated through changes in expression, trafficking, and channel open probability 
(Po).  ENaC protein expression is upregulated hormonally by aldosterone (Mick et al., 
2001), AVP (Perlewitz et al., 2010), and insulin.  Aldosterone induces expression of SGK1 
and αENaC in the ASDN and causes ENaC translocation to the apical membrane in 
principal CCD cells (Loffing et al., 2001).  Aldosterone stimulates αENaC expression in 
part by relieving gene repression by a repressor complex of disruptor of telomeric silencing 
1a (Dot1a) and ALL-1 fused gene from chromosome 9 (AF9) via a) downregulating 
expression of Dot1a and AF9 and b) upregulating SGK1, which phosphorylates AF9 
preventing its interaction with Dot1a to form the repression complex (Reisenauer et al., 
2010; Zhang et al., 2007).  In mouse kidney ASDN, αENaC was upregulated in response to 
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low salt diet or aldosterone and this caused translocation of cytosolic βENaC and γENaC to 
the apical membrane (Loffing et al., 2000). 
 
 
Figure 1.5  A model of a principal cell highlighting the signalling pathways involved 
in regulation of ENaC.  Aldosterone and the signalling components that are upregulated 
by aldosterone are coloured blue.  Components and actions that cause reduced expression 
of ENaC at the apical membrane are coloured red.  Figure adapted from (Verrey et al., 
2007). 
 
ENaC is bound to and requires PtdIns(4,5)P2 for normal channel gating, whilst ENaC 
binding to PtdIns(3,4,5)P3 via PY motifs caused increased activity of ENaC (Zhang et al., 
2009; Pochynyuk et al., 2005).  ENaC may also be regulated through mechanosensitivity 
associated with laminar shear stress.  In isolated rabbit CCDs and Xenopus oocytes, 
increasing shear stress associated with fluid flow caused an increase in ENaC Po that was 
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sensitive to temperature (Carattino et al., 2007).  The large extracellular loops in the 
structure of ENaC subunits are also involved in Na+ self-inhibition (Sheng et al., 2007). 
The large extracellular loops of the ENaC subunits play a considerable role in limiting 
channel Po, however, cleavage of the loops by intra and extracellular proteases greatly 
increases ENaC Po and subsequent Na+ transport.  Prostasin/channel-activating protease 1 
(CAP1) increased ENaC currents when coexpressed in oocytes and other systems (Planes 
et al., 2010; Andreasen et al., 2006; Vuagniaux et al., 2000).  Trypsin has also been shown 
to increase ENaC activity (Nesterov et al., 2008).  Proteolytic cleavage of an inhibitory 
peptide out of the extracellular loop of αENaC by furin and of γENaC by prostasin caused 
a step-wise increase in ENaC open probability (Carattino et al., 2008).  Prostasin is 
regulated itself by PN-1, which is upregulated by aldosterone and TGFβ (Wakida et al., 
2006).  Extracellular proteolytic cleavage of ENaC removed the self-inhibition caused by 
extracellular [Na+] (Chraibi and Horisberger, 2002).  Short palate, lung, and nasal 
epithelial clone 1 (SPLUNC1) has been identified as an anti-protease regulatory protein of 
extracellular ENaC cleavage in airway surface fluid volume (Garcia-Caballero et al., 
2009).  The extracellular protein SPLUNC binds to the extracellular loops of non-cleaved 
ENaC and prevents ENaC cleavage and thereby reducing ENaC currents. 
ENaC apical membrane half-life is estimated to be approximately 20-30 min from various 
studies (Kabra et al., 2008; Lu et al., 2007; Alvarez de la Rosa et al., 2002).  It has been 
suggested that ENaC is present in a large sub-apical pool and its recycling or degradation 
from this pool is dependent on PY motifs near the C-termini of each subunit (Lu et al., 
2007).  ENaC endosomes (recycling and late) are coordinated by sorting proteins syntaxin 
and Rab GTPases (Saxena et al., 2007).  The ubiquitin ligase Nedd4-2 binds and 
ubiquitinates ENaC, causing it to be internalised by endocytosis.  SGK1 phosphorylates 
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Nedd4-2, preventing its ubiquitination of ENaC (Flores et al., 2005; Kamynina and Staub, 
2002). 
SGK1 binds via a PY motif to WW domains of Nedd4-2 and phosphorylates it primarily at 
serine 444, but also at serine 338, causing its reduced interaction with ENaC (Debonneville 
et al., 2001).  Another protein upregulated by aldosterone, 14-3-3β, binds to the 
phosphorylated Nedd4-2 blocking its interaction with ENaC (Liang et al., 2006; Nagaki et 
al., 2006) (Figure 1.5).  Dysregulated ubiquitination and internalisation of ENaC by 
Nedd4-2 is linked to Liddle’s syndrome (Abriel et al., 1999; Goulet et al., 1998), which is 
characterised by increased Na+ transport due to increased apical membrane half-life of 
ENaC.  ENaC subunits may be either polyubiquitinated or multi-monoubiquitinated at the 
cell surface (Butterworth et al., 2007; Wiemuth et al., 2007).  Polyubiquitination through 
ubiquitin lysine 48 targets ENaC for degradation by the proteasome, whereas 
monoubiquitination or polyubiquitination through ubiquitin lysine 63 targets ENaC for 
internalisation (Abriel and Staub, 2005).  ENaC recycling following ubiquitination and 
internalisation is associated with deubiquitination by enzymes such as Usp-45 (Fakitsas et 
al., 2007) and UCH-L3 (Butterworth et al., 2007).  Ubiquitin-specific protease Usp2-45 is 
induced by aldosterone in vivo and has been shown to deubiquitinate ENaC and cause 
increased ENaC-mediated sodium transport in HEK293, Xenopus oocytes, and mpkCCDcl4 
cells (Fakitsas et al., 2007) (Figure 1.5).  Another deubiquitinating enzyme USP10 requires 
sorting nexin 3 (SNX3) for upregulation of ENaC (Butterworth and Johnson, 2008). 
ENaC is subject to feedback inhibition by increased intracellular [Na+] causing binding of 
Nedd4-2 and Nedd4 to PY motifs present in the C-terminal domains of β and γENaC 
(Rauh et al., 2006).  In addition to indirect effects of SGK1 on ENaC via Nedd4-2, SGK1 
can also directly phosphorylate and stimulate αENaC activity.  ENaC regulation can also 
occur via Nedd4-2 phosphorylation and inactivation by IκB kinase-β (IKKβ) (Edinger et 
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al., 2009).  A recent publication by Hallows et al. (2010) has shown that c-Jun N-terminal 
kinase 1 (JNK1) of MAPK/ERK signalling phosphorylates Nedd4-2 at several novel 
phosphorylation sites causing increased interaction and inhibition of ENaC (Hallows et al., 
2010). 
In an opposing system to SGK1 stimulation of ENaC, MAPK/ERK phosphorylates β and 
γENaC C-termini increasing their interaction with Nedd4-2 and subsequent internalisation.  
MAPK/ERK inhibition of ENaC has also been shown to be induced by PKC.  Casein 
kinase 2 (CSNK2) has also been shown to phosphorylate Nedd4-2 removing its inhibition 
of ENaC (Bachhuber et al., 2008).  ENaC has been shown to be maintained in its active 
state by G-protein-coupled receptor kinase 2 (GRK2), an enzyme implicated in the 
development of essential hypertension.  Also, GRK2 binds and phosphorylates βENaC, 
Nedd4 and Nedd4-2, but only the phosphorylation of the C-terminus of βENaC inhibits 
binding of Nedd4-2 (Sanchez-Perez et al., 2007).  cAMP/protein kinase A can induce 
phosphorylation and inhibition of Nedd4-2 independently of SGK1 (Vallon and Lang, 
2005).  Protein Kinase D1 also modulates aldosterone-induced ENaC activity in M1-CCD 
cells (McEneaney et al., 2010). 
ENaC has also been shown to be regulated by members of the With No Lysine (WNK) 
kinase family, which are structurally classified as MAPKKK that lack a conserved lysine 
residue within their kinase domain.  There are four WNK kinases in mammals, named 
WNK1, WNK2, WNK3, and WNK4.  WNK kinases phosphorylate and activate oxidative 
stress responsive kinase 1 (OSR1) and STE20-like proline and alanine-rich kinase (SPAK), 
which, in turn, phosphorylate and activate the Na+/Cl- cotransporter (NCC) (Moriguchi et 
al., 2005).  Mutations in WNK1 and WNK4 have been identified as causing 
pseudohypoaldosteronism type 2 (PHA2) – an autosomal dominant disorder resulting in 
hypertension and hyperkalemia (Wilson et al., 2001).  Both WNK1 and WNK4 are 
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expressed in the distal nephron (Wilson et al., 2001), however, in situ hybridisation (ISH) 
studies have shown that the kidney-specific WNK1-S (short WNK1) is the primary WNK 
isoform expressed in kidney (O'Reilly et al., 2003).  ISH studies have also shown that 
WNK1-S is predominantly expressed in DCT, but WNK4 is expressed throughout the 
distal nephron (O'Reilly et al., 2006).  WNK1 activates SGK1 resulting in increased ENaC 
activity in a SGK1 and Nedd4-2 dependent manner (Xu et al., 2005a).  WNK1 activation 
of SGK1 is PI3K-dependent and requires the N-terminal 220 residues of WNK1, but not its 
kinase domain (Xu et al., 2005b).  WNK1 has been shown to be induced by hyperosmotic 
stress and to redistribute from cytosol to vesicles that could be recycling endosomes 
(Zagorska et al., 2007).  Aldosterone rapidly increases the expression of (the short kidney-
specific) WNK1-S isoform and overexpression of this isoform results in increased activity 
of ENaC (Naray-Fejes-Toth et al., 2004b).  In Xenopus oocytes, coexpression of WNK4 
with ENaC caused inhibition of sodium transport, whereas coexpression with WNK4 
carrying a mutation that causes PHAII did not inhibit ENaC (Ring et al., 2007a).  SGK1 
phosphorylates wild-type WNK4 preventing its inhibitory effect on ENaC and ROMK 
(Ring et al., 2007b). 
 
1.5 Hypertension 
Hypertension is a chronic condition of elevated blood pressure that causes an increased 
risk of heart attack, heart disease, kidney disease, and stroke.  In the UK, guidelines state 
that a patient should be treated for hypertension if their blood pressure readings are 
consistently 140 mm Hg systolic and 90 mm Hg diastolic or higher (Higgins and Williams, 
2007).  However, changes in blood pressure by as little as 1 to 3 mm Hg systolic can alter 
the risk of stroke by up to 20 to 30% (Staessen et al., 2003).  In 2001, approximately 
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13.5% of total global premature deaths were attributed to high blood pressure (Lawes et 
al., 2008). 
Several studies have found polymorphisms in the SGK1 gene that are linked to increased 
risk of hypertension.  Studies by von Wowern et al. (2005) and Busjahn et al. (2002) found 
that polymorphisms in intron 6 and exon 8 of the SGK1 gene were linked to increased 
diastolic and systolic blood pressure and also caused greater blood pressure increase in 
response to insulin (von Wowern et al., 2005; Busjahn et al., 2002).  However, a 
conflicting report published by Trochen et al. (2004) demonstrated that SGK1 
polymorphisms did not show increased prevalence in hypertensive or renal disease patients 
and showed no relation to blood pressure (Trochen et al., 2004).  Despite the conflicting 
reports in links between SGK1 and hypertension, it is still highly likely that SGK1 is 
involved in hypertension, as Nedd4-2 deficient mice show salt-sensitive hypertension (Shi 
et al., 2008).  Also, SGK1 knockout and double SGK1/SGK3 knockout mice display an 
inability to restrict salt excretion when given a low-salt diet (Grahammer et al., 2006; 
Wulff et al., 2002) and SGK1 knockout mice were also protected against high salt and 
desoxycorticosterone acetate (DOCA)-induced renal fibrosis and albuminuria (Artunc et 
al., 2006). 
In humans, the majority of inherited genetic disorders that cause hypertension do so by 
causing dysregulation of renal Na+ reabsorption.  Liddle’s syndrome is an autosomal 
dominant condition that causes early-onset hypertension with low potassium, alkalosis and 
reduced plasma aldosterone concentration.  Liddle’s syndrome is caused by gain-of-
function mutations in ENaC subunits through deletion or disruption of the PY motifs 
resulting in reduced channel downregulation by Nedd4-2, increased number and activity of 
ENaC, and increased Na+ reabsorption (Knight et al., 2006; Schild et al., 1996). 
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Pseudohypoaldosteronism type 1 (PHA1) causes renal salt wasting with metabolic 
acidosis, high potassium levels and high renin and aldosterone.  Autosomal recessive 
PHA1 is caused by loss-of-function mutation of any ENaC subunit, causing reduced Na+ 
reabsorption in the CCD (Riepe, 2009).  The reduced Na+ reabsorption also removes the 
driving force for K+ and H+ excretion in the CCD causing hyperkalemia and acidosis.  The 
hyperkalemia and decreased hydration/blood pressure stimulates the RAAS causing the 
high levels of renin and aldosterone, but without effects of functional ENaC.  Autosomal 
dominant PHA1 also exists and causes milder salt wasting than the autosomal recessive 
form through loss-of-function mutations in the mineralocorticoid receptor (Uchida et al., 
2009). 
Pseudohypoaldosteronism type 2 (PHA2) is an autosomal dominant condition causing 
hypertension, high potassium, hyperchloremic acidosis and low renin and aldosterone.  
PHA2 is caused by mutations in WNK1 and WNK4, which regulate Na+ transport in the 
distal nephron primarily via NCC and ROMK (Vitari et al., 2005).  WNK4 acts as a 
negative regulator of NCC and ROMK, whereas WNK1 acts as a negative regulator of 
WNK4 (Kahle et al., 2005; Choate et al., 2003).  Loss-of-function mutations of either 
WNK1 or WNK4 therefore cause increased NCC and ROMK activity, and then lead to 
enhanced Na+ and K+ retention.  Additional conditions affecting renal electrolyte 
regulation include Bartter and Gitelman syndromes, both of which cause hypotension, are 
autosomal recessive, and occur through dysregulated calcium handling (O'Shaughnessy 
and Karet, 2006). 
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1.5.1 SGK1 and other diseases 
Sgk1 is involved in pulmonary vascular remodelling (BelAiba et al., 2006).  SGK1 
upregulated CFTR in a kinase-dependent manner in Xenopus oocytes (Sato et al., 2007).  
ENaC has been linked to regulation of the cystic transmembrane conductance regulator 
(CFTR) associated with cystic fibrosis (CF) (Fajac et al., 2009; Mall, 2008).  Recently 
novel gain-of-function or loss-of-function mutations were identified in the αENaC of 
atypical CF patients that possibly contribute to the symptoms of CF (Huber et al., 2010; 
Rauh et al., 2010). 
SGK1 contributes to tissue fibrosis during diabetic neuropathy (Feng et al., 2005; Wang et 
al., 2005; Kumar et al., 1999).  Polymorphisms in the SGK1 gene have been linked to type 
2 diabetes (Schwab et al., 2008) and SGK1 has been shown to mediate salt-sensitive 
cellular uptake of glucose (Boini et al., 2006).  In patients suffering from type 2 diabetes, it 
has been suggested that SGK1 enhances hypertension and tissue fibrosis (Lang et al., 
2009).  A role for SGK1 in stress induced tissue fibrosis was further confirmed in 
doxorubicin-induced nephrotic syndrome (Artunc et al., 2008).  SGK1 is also involved in 
cardiac fibrosis as a result of high mineralocorticoid levels (Vallon et al., 2006).  SGK1 is 
also expressed in brain and is involved in neuronal function as well as Parkinson’s disease, 
neuronal damage and neurodegenerative diseases (Lang et al., 2010; Schoenebeck et al., 
2005; Stichel et al., 2005). 
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1.6 Aims 
The primary aim of this thesis was to determine which of the sodium/glucocorticoid 
regulated kinase 1 (SGK1) isoforms identified in human are expressed in renal cortical 
collecting duct epithelial cells.  Following identification of the SGK1 isoforms expressed 
in CCD cells, the requirements for SGK1 isoforms in regulation of ENaC-mediated sodium 
transport would be investigated.  The mouse cortical collecting duct model cell line 
(mpkCCDcl4) was used for this project as a model of CCD cells in which ENaC is known 
to be regulated by aldosterone-stimulated Sgk1 (Flores et al., 2005; Bens et al., 1999).  The 
aim therefore became to investigate the requirements for Sgk1 isoforms in regulation of 
ENaC-mediated sodium transport in mpkCCDcl4 cells including investigation of the 
subcellular distribution of human and mouse SGK1 isoforms in regulation of sodium 
transport in renal epithelial cells. 
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Chapter 2 - Materials and Methods 
2.1 Cell Culture 
The mpkCCDcl4 transimmortalized mouse cortical collecting duct cell line was a gift from 
Prof. Alain Vandewalle (Institut National de la Santé et de la Recherche Médicale 
(INSERM), Paris, France).  mpkCCDcl4 cells were maintained in growth medium 
consisting of: Dulbecco’s modified Eagle’s medium (DMEM) minus phenol red (Sigma-
Aldrich Ltd., Gillingham, UK):HAM’s F12 (Sigma-Aldrich) at 1:1 vol/vol, supplemented 
with: 60 nM sodium selenate (Sigma-Aldrich); 5 mg/ml transferrin (Sigma-Aldrich); 2 mM 
L-glutamine (Lonza Biologics plc, Slough, UK); 50 nM dexamethasone (Sigma-Aldrich); 
1 nM triiodothyronine (Sigma-Aldrich); 10 nM epidermal growth factor (EGF) (Sigma-
Aldrich); 5 mg/ml insulin (Sigma-Aldrich); 20 mM D-glucose (Sigma-Aldrich); 2% fetal 
calf serum (FCS) (Biosera, Ringmer, East Sussex, UK) and 20 mM HEPES (Sigma-
Aldrich/Invitrogen Ltd., Paisley, UK) (Bens et al., 1999).  HEK293T cell growth medium 
was DMEM (Lonza) supplemented with 10% FCS (Biosera) (Tai et al., 2009). 
Cells were grown to ~90% confluency in T25 or T75 tissue culture flasks (TPP AG, 
Trasadingen, Switzerland/SARSTEDT Ltd., Leicester, UK) containing 10 or 20 ml growth 
medium at 37°C and 5% CO2.  For passage, cells were detached using 2.5 ml (T25) or 5 ml 
(T75) trypsin-EDTA solution (21.5 mM porcine trypsin and 685 mM EDTA in Hank's 
Balanced Salt Solution with phenol red) (Sigma-Aldrich) incubated at 37°C and 5% CO2.  
Once detached, an equal volume of growth medium was used to neutralise the enzyme 
prior to centrifugation at 300 x g for 3 minutes and resuspension in 5 ml growth medium 
and transfer to new tissue culture flasks.  Cells were then seeded at the following densities 
depending on application: 4 x 103 cells/cm2 in tissue culture flasks for cell line 
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maintenance, 5 x 104 cells/cm2 on cell culture-treated polystyrene plates (TPP/Corning 
B.V. Life Sciences, Amsterdam, The Netherlands) for transfection studies, 2.5 x 104 
cells/cm2 on glass coverslips for use in immunofluorescence microscopy, or 1 x 106 
cells/cm2 on Transwell® permeable supports (Corning) for equivalent short circuit current 
experiments.  All experiments in this thesis were performed on cells of between passage 30 
and 50 for mpkCCDcl4 cells and between passage 20 and 50 for HEK293T cells. 
 
2.1.1 Culture of mpkCCDcl4 cells on Transwell supports 
mpkCCDcl4 cells were seeded at high density (1 x 106 cells/cm2) onto 12-well Transwell® 
permeable supports containing 12 mm diameter (1.12 cm2 surface area) polyester (PET) 
insert membranes of 0.4 µm pore size (Corning).  Cells were seeded in growth medium, 
which was replaced every 2 days until transepithelial resistance had stabilised at >2 
kiloohms (kΩ) after 6-8 days ((Bens et al., 1999)).  Prior to being used for equivalent short 
circuit current experiments, cell monolayers were washed in phosphate buffered saline 
(PBS) (Sigma-Aldrich) and then cultured for 24 hours in starvation medium 
(DMEM:HAM’s F12 at 1:1 vol/vol) to remove the stimulatory effects of the serum, 
hormones and EGF that are present in growth medium. 
 
2.1.2 Hormone and drug treatments 
Prior to hormone or drug treatment, mpkCCDcl4 cells grown to ~80% confluency were 
washed in PBS and then cultured for 24 hours in starvation medium.  Unless otherwise 
stated, hormone and drug treatments were for 24 hours in starvation medium at the final 




Hormone/drug name Stock solution Final 
concentration 
Aldosterone (Sigma-Aldrich/Fisher 
Scientific UK Ltd., Loughborough, UK) 
1 mM in ethanol 10 nM 
Amiloride (Sigma-Aldrich) 10 mM in dimethyl 
sulfoxide (DMSO) 
1 µM 
Insulin (Sigma-Aldrich) 10 mg/ml or 1.72 mM in 
acidified H2O (1% acetic 
acid) 
1 µM 
Rapamycin (Enzo Life Sciences (UK) Ltd., 
Exeter, UK) 
20 µM in DMSO 20 nM 
LY294002 (Merck Chemicals Ltd., 
Nottingham, UK/Promega UK Ltd., 
Southampton, UK) 
10 mM in DMSO 10 µM 
Spironolactone (Sigma-Aldrich) 10 mM in DMSO 10 µM 
Mifepristone (Sigma-Aldrich) 10 mM in DMSO 10 µM 
 
Table 2.1  Hormone and drug treatments. 
 
2.1.3 Transient transfection of plasmid DNA 
The following transfection reagents: LipofectamineTM, LipofectamineTM 2000, 
Lipofectamine PLUSTM (Invitrogen) and FuGENE® 6 (Roche Diagnostics Ltd., Burgess 
Hill, UK) were tested for their ability to transiently transfect mpkCCDcl4 cells, used 
according to manufacturer’s instructions.  Transfection efficiency was assessed using the 
pLEGFP-N1 plasmid (Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France) 
(Figure 2.1) and fluorescence microscopy.  LipofectamineTM 2000 was found to give the 
highest transfection efficiency, which was estimated to be 10%, for mpkCCDcl4 cells 
grown on glass coverslips.  The same transfection procedure was used for HEK293T cells, 
and using these cells was estimated to achieve around 65% transfection efficiency. 
Using cells grown on a tissue culture 6-well plate, 4 µg of plasmid DNA (0.2-2 mg/ml in 
Buffer TE (Qiagen Ltd., Crawley, UK) or H2O) and 10 µl of LipofectamineTM 2000 were 
each added to 250 µl of serum-free medium and incubated at room temperature for 5 min.  
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The diluted DNA and LipofectamineTM 2000 were then combined and incubated for a 
further 20 min before being added to wells containing the cells and 2 ml of growth 
medium.  Cells were then incubated for 6 hours at 37°C and 5% CO2, at which point they 
were given fresh growth medium and incubated for a further 24 hours before lysis. 
 
 
Figure 2.1  A vector map of the pLEGFP-N1 vector.  Image used from 
(http://www.clontech.com/images/pt/dis_vectors/PT3233-5.pdf). 
 
2.1.4 siRNA knockdown 
Cells grown on cell culture-treated polystyrene plates were transiently transfected with 
siRNA using LipofectamineTM 2000 according to manufacturer’s instructions.  mpkCCDcl4 
cells were seeded at 5 x 104 cells/cm2 on cell culture-treated polystyrene 6-well plates 
(TPP/Corning) and grown for 24 hours prior to transfection with siRNA.  To prepare the 
transfection mix, 30 µl of 20 µM siRNA stock solution and 30 µl of Lipofectamine 2000 
were each diluted in 250 µl of serum-free cell culture medium.  The diluted siRNA and 
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Lipofectamine 2000 were incubated for 5 min at 21°C before being combined and 
incubated for a further 20 min.  Transfection mix was then added to cells containing 2 ml 
growth medium so the final concentration of siRNA exposed to cells was 40 nM.  Cells 
were then incubated for 24 hours at 37°C, 5% CO2 before being lysed and knockdown 
assessed by Western blotting.  Mouse Sgk1-specific and scrambled controls siRNAs were 
purchased from Qiagen.  The Sgk1 siRNA targets a sequence that is conserved in all 
mouse Sgk1 isoform mRNAs and therefore should knockdown all Sgk1 isoforms (Table 
2.2).  For experiments using Transwell permeable supports, cells were first transfected on 
cell culture-treated 6-well plates before being washed with PBS, detached using trypsin-
EDTA solution, resuspended in growth medium, and then seeded onto the Transwell 
membranes.  These cells were then treated as described in section 2.1.2.  The siRNA 
transfection procedure was adapted from the procedure described for siRNA transfection 
using Lipofectamine 2000 in Hallows et al. (2009). 
 
siRNA Name Target sequence Target gene 
Mm_Sgk_2_HP CTG GGA TGA TCT CAT CAA TAA Sgk1 
Allstars Negative Control Scrambled n/a 
 
Table 2.2  Qiagen siRNA data. 
 
2.2 Molecular Biology 
2.2.1 DNA cloning 
Mouse Sgk1a was purchased from Geneservice (Source BioScience, Cambridge, UK) 
cloned in the pCMV-SPORT6 expression vector between the SalI (5’) and NotI (3’) 
restriction sites in its multiple cloning site (Figure 2.2).  Sgk1b was cloned into pCMV-
SPORT6 through replacement of the N-terminus of Sgk1a in pCMV-SPORT6 with that of 
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Sgk1b.  The N-terminus of Sgk1b was generated by RT-PCR from purified mpkCCDcl4 
cell RNA using the primers MmSGK1bSalIF and MmSGK1PacIR, which are described in 
Table 2.4.  These primers encompass the N-terminus of Sgk1b from an introduced SalI 
restriction site at its 5’ end to a PacI restriction site at its 3’ end.  Digestion of Sgk1a in 
pCMV-SPORT6 and the Sgk1b RT-PCR product at these restriction sites produced the 2-4 
base overhanging ends required for ligation.  The digestion fragments were separated, 
according to size, in an agarose gel using electrophoresis.  The fragments desired for 
ligation were then extracted using a QIAquick Gel Extraction Kit (Qiagen).  T4 DNA 
Ligase (Promega) was then used according to the manufacturer’s instructions to ligate the 
Sgk1b DNA fragment into the expression vector. 
Sgk1c was also cloned into pCMV-SPORT6 through replacement of the Sgk1a sequence in 
pCMV-SPORT6, but, due to difficulties in its production by RT-PCR, Sgk1c was 
generated by combinatorial PCR. This first involved generating the Sgk1c N-terminus by 
PCR from purified mpkCCDcl4 cell DNA using the primers New MmSGK1cSalIF and 
MmSgk1cCombiR, described in Table 2.4.  Then the Sgk1 common sequence was 
generated by PCR from the Sgk1a in pCMV-SPORT6 plasmid DNA, using the primers 
MmSgk1cCombiF and New MmSgk1cR, described in Table 2.4.  And, finally, the purified 
PCR products from these two reactions were combined, to form complete Sgk1c, using 
PCR with the primers New MmSGK1cSalIF and New MmSgk1cR, which generated the 
full-length Sgk1c DNA due to a complimentary overlap of the two preliminary DNAs.  
The insertion of this DNA into pCMV-SPORT6 was then performed as described for 
Sgk1b. 
Sgk1d was subcloned from pYX-Asc (in which it was purchased from Geneservice) into 
pCMV-SPORT6 by digestion of both vectors at NotI and EcoRI restriction sites before 




Figure 2.2  pCMV-SPORT6 vector map.  Image used from 
(http://tools.invitrogen.com/content/sfs/vectors/pcmvsport6_map.pdf). 
 
Cloning of the mouse Sgk1 isoforms into pFLAG-CMV-2 (Sigma-Aldrich) (Figure 2.3) 
involved PCR of each isoforms complete sequence from their respective plasmid DNA 
using the primers described in Table 2.5.  The resulting PCR products and empty pFLAG-
CMV-2 vector were then digested using NotI and SalI before ligation of the desired 
fragments as described previously.  All cloned DNA vectors were sequenced to confirm 








Additional constructs referred to in this thesis include a myr and myc-tagged constitutively 
active 3-phosphoinositide-dependent protein kinase 1 (PDPK1) construct (pCMV3-myr-
PDPK1-myc) from Dr. K. Anderson (Babraham Institute, Cambridge) and a FLAG-tagged 
kinase-dead SGK1A construct (pFLAG-CMV-2-SGK1A(K127M)), which was created in-
house by Dr Quan Long. 
 
2.2.2 Restriction enzyme digests 
Restriction enzymes were bought from NEB (New England Biolabs, Hitchin, 
Hertfordshire, UK), Promega or Fermentas (Fermentas GmbH, St. Leon-Rot, Germany).  
Restriction enzyme digests were conducted according to manufacturer’s instructions, in 
recommended buffer with 0.1 µg/µl bovine serum albumin (BSA) (Sigma-Aldrich) and 2 
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units of enzyme per µg of DNA.  Reactions were incubated for 2 hours at 37°C then 
inactivated by incubation at 60°C for 10 min. 
 
2.2.3 Bacterial culture 
E.coli was grown in Lysogeny broth (LB) or on LB agar plates containing carbenicillin 
antibiotic (Sigma-Aldrich) (a more stable analogue of ampicillin). Small 5 ml and large 
350 ml LB cultures were incubated overnight at 37°C, 5% CO2 swirling at 300 rpm.  LB 
consisted of 10 g/L tryptone (Fisher), 5 g/L yeast extract (Fisher), 10 g/L NaCl (Fisher), 
pH 7.  LB agar contained LB, but with 5 g/L NaCl and 15 g/L agar (Fisher). 
 
2.2.4 Transformation into E.coli 
Transformation of an expression vector into One Shot® TOP10 chemically competent 
E.coli (Invitrogen) was carried out using the manufacturer’s rapid chemical transformation 
procedure.  This involved addition of 1-5 µl of ligation reaction to a 50 µl vial of One 
Shot® cells, followed by incubation on ice for 5 min.  The 50 µl of cells was then spread 
onto a LB agar plate containing carbenicillin that had been pre-warmed to 37°C, which 
was then incubated overnight at 37°C, 5% CO2.  Successful colonies were picked and used 
to seed LB cultures for cultivating plasmid DNA. 
 
2.2.5 Plasmid DNA extraction 
Plasmid DNA was then extracted from the culture using either a QIAprep® spin Miniprep 
Kit (Qiagen) for the 5 ml culture or a HiSpeed® Plasmid Maxiprep Kit (Qiagen) for the 350 
ml culture according to the manufacturer’s instructions. 
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2.2.6 Polymerase chain reaction (PCR) 
Successful bacterial colonies showing antibiotic resistance were picked and seeded into 0.5 
ml PCR tubes (STARLAB (UK) Ltd., Milton Keynes, UK).  The Expand High Fidelity 
PCR System (Roche) was then used according to the manufacturer’s instructions with the 
appropriate primers to amplify expected insert DNA product.  The amplification products 
were then separated by agarose gel electrophoresis (section 2.2.11) and visualised to assess 
which samples had the expected amplified product and, therefore, which colonies 
possessed the insert DNA. 
 
2.2.7 Reverse transcriptase (RT)-PCR 
RT-PCR was performed using the Qiagen® OneStep RT-PCR Kit according to the 
manufacturer’s protocol. Reactions contained: kit buffer, 400 µM dNTP mix, 0.6 µM of 
each primer, 4% kit enzyme mix (Omniscript Reverse Transcriptase, Sensiscript Reverse 
Transcriptase, and HotStarTaq DNA Polymerase) and 200 ng template RNA.  Incubations 
consisted of: 50°C for 30 min, 95°C for 15 min, 30 cycles of 94°C for 1 min, 55°C for 1 
min, and 72°C for 1 min followed by a final extension step of 72°C for 10 min.  The 
completed reactions were stored at 4°C before being analysed using agarose gel 
electrophoresis. 
 
2.2.8 RNA purification, quantification and storage 
mpkCCDcl4 cells were grown to confluency in complete cell culture media before a wash 
with PBS then treatment with trypsin/EDTA to detach the cells from their growth surface. 
The trypsin was then neutralised by the addition of complete media containing FCS and 
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cells were pelleted by centrifugation at 300 x g for 3 min. Cells were then resuspended in 
Buffer RLT (Qiagen RNeasy kit) and homogenised by passing the lysate through a 
QIAshredder spin column by centrifugation.  RNA was then extracted and purified from 
the cell lysate using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
protocol. RNA was quantified by measuring sample absorbance at 260 nm using a 
BioPhotometer spectrophotometer (Eppendorf UK Ltd., Cambridge, UK).  Purified RNA 
was stored in RNase-free water at -80°C. 
 
2.2.9 DNA isolation, quantification and storage 
mpkCCDcl4 cells prepared as described for RNA purification (section 2.2.8) were used for 
DNA isolation using TRIzol® Reagent (Invitrogen) according to the manufacturers 
instructions.  Isolated DNA was stored at -20°C in 8 mM NaOH and quantified by 




Sgk1 isoform specific primers, shown in Table 2.3, were designed to encompass unique 
isoform sequence at the first exon boundary using an online primer design tool Primer 3 
(Rozen Steve, 2000). 
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Primer Name Sequence (5’-3’) Length Function 
MmSGK1aF TTC ACT GCT CCC CTC AGT CT 20-mer Identification 
MmSGK1aR GGA CCC AGG TTG ATT TGT TG 20-mer Identification 
MmSGK1bF GCT CAG AAA AGG AGC GAG TC 20-mer Identification 
MmSGK1b+cR CCC TTT CCG ATC ACT TTC AA 20-mer Identification 
MmSGK1cF AAA GTA ACC CCA GCC TCC AC 20-mer Identification 
MmSGK1dF TGA GGC CAT GTG TCA ATC AT 20-mer Identification 
MmSGK1dR GAG GAG AGG GGT TAG CGT TC 20-mer Identification 
GAPDHF TGACATCAAGAAGGTGGTGAAG 22-mer Control 
GAPDHR TCTTACTCCTTGGAGGCCATGT 22-mer Control 
 
Table 2.3  Primers for identification of mouse Sgk1 isoforms.  Mm = Mus musculus, F 
= Forward, R = Reverse. 
 
Primers were designed for cloning of the mouse Sgk1 isoforms b, c, and d, into the pCMV-
SPORT6 expression vector, incorporating a restriction enzyme site in each primer to 
facilitate insertion of the PCR product into an expression vector (Table 2.4). 
 
Primer name Sequence (5’-3’) Length Function 






New MmSgk1cR CAAGTGTCACATTGATGCTC 20-mer Cloning 
MmSgk1cCombiF CCTTGGAAAGCTTTTATGAAACAGA 25-mer Cloning 





Table 2.4  Primers for cloning into pCMV-SPORT6. 
 
Similar primers were also designed for cloning mouse Sgk1 isoforms a, b, c, and d into 
pFLAG-CMVTM-2 (Sigma-Aldrich) and are shown in Table 2.5.  These primers were 
designed to encompass the entire ORF for each isoform whilst adding restriction sites to 
allow the in-frame insertion of the product into the expression vector. 
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Table 2.5  Primers for cloning into pFLAG-CMVTM-2. 
 
2.2.11 Agarose gel electrophoresis 
DNA samples were separated according to size by electrophoresis in 1% agarose gels.  
0.75 g DNase/RNase-free agarose (Bioline, London, UK) was mixed with 75 ml Tris-
Acetate-EDTA (TAE) buffer and heated in a microwave on full power until completely 
dissolved. TAE buffer consisted of 40 mM Tris acetate and 1 mM EDTA in water.  The 
mixture was then cooled to ~50°C before 1.25 µM ethidium bromide was added.  The 
mixture was then poured into a sealed tray and a comb suspended into the gel to form 
wells.  Once the gel had polymerised, the ends of the tray were unsealed and the comb 
removed before use. The tray was placed in an electrophoresis chamber so that it was 
immersed in TAE.  DNA samples were then mixed with the appropriate amount of 10x 
loading buffer and loaded into the wells.  5 µl of DNA size marker Hyperladder I (Bioline) 
was loaded with the DNA samples for comparison indicating sample DNA size and 
concentration.  Electrophoresis occurred over 1-2 hours at 85 V and the resulting gel was 
visualized using a FluorChem® gel imager (Cell Biosciences Inc., Santa Clara, CA, USA).  
DNA separated according to size by electrophoresis in an agarose gel was purified using a 
QIAquick Gel extraction kit (Qiagen) according to the manufacturer’s protocol. 
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2.2.12 DNA sequencing 
Sequencing of DNA samples was done by postal order to MWG (Eurofins MWG Operon, 
Ebersberg, Germany).  All sequencing results are included in the appendix. 
 
2.2.13 In vitro protein synthesis from Sgk1 isoform DNA 
Synthetic protein was generated from cloned Sgk1 isoform expression vectors using a 
TNT® SP6 Coupled Transcription/Translation System (Promega).  This system was used 
according to manufacturer’s instructions to (1) generate Sgk1 isoform mRNA using SP6 
RNA polymerase and (2) translate that mRNA into protein using rabbit reticulocyte lysate.  
A Luciferase SP6 control DNA reaction was included in the procedure as a functional 
control for the system (Figure 2.4). 
 
 
Figure 2.4  Vector map of the TNT® Luciferase SP6 control vector.  Image taken from 
(http://www.promega.com/tbs/tb126/tb126.pdf). 
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2.3 Western Blotting (Immunoblotting) 
2.3.1 Preparation, treatments and storage of protein samples 
Cells were washed once with ice cold PBS followed by 5 min incubation on ice with 
modified radio immunoprecipitation assay (RIPA) buffer. Modified RIPA buffer consisted 
of: 50 mM Tris buffer pH 7.5, 1% Nonidet P-40 (Sigma-Aldrich), 0.25% sodium 
deoxycholate (Sigma-Aldrich), 150 mM sodium chloride (Fisher), 1 mM sodium fluoride 
(Sigma-Aldrich), 5 mM Β-glycerolphosphate (Sigma-Aldrich), 1 Complete® protease 
inhibitor cocktail tablet + EDTA (Roche), 0.5 mM phenylmethylsulphonylfluoride (PMSF) 
(Sigma-Aldrich), 1 mM sodium orthovanadate (Sigma-Aldrich), and to 50 ml final volume 
with water. Modified RIPA buffer minus phosphatase inhibitors was made to the same 
recipe only without the sodium fluoride, sodium orthovanadate, and Β-glycerolphosphate. 
PMSF and sodium orthovanadate were made up and added to aliquots of modified RIPA 
buffer just before use as these components have short half-lives in solution. After 
incubation with modified RIPA buffer, cells were scraped off the growth surface using a 
cell scraper (SARSTEDT). The cell lysate was then centrifuged at 21,000 x g and 4°C for 
10 min to remove cell debris and DNA. Protein samples were stored at -80°C.  Protein 
lysates to be used as negative controls for testing the presence of phosphorylated protein 
forms (lysed using RIPA buffer minus phosphatase inhibitors) were treated with calf 
intestinal alkaline phosphatase (CIAP) (NEB). Lysates were treated with CIAP according 
to the manufacturer’s instructions. 
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2.3.2 Protein quantification 
Concentration of total protein in samples was determined using a bicinchoninic acid (BCA) 
assay (Smith et al., 1985).  A BCA™ Protein Assay Kit (Thermo Fisher Scientific, 
Cramlington, UK/Cheshire Sciences Ltd., Chester, UK) was used according to the 
manufacturer’s instructions.  A standard curve of protein concentration against absorbance 
at 562 nm was created using known concentrations (ranging from 2-0.025 mg/ml) of 
bovine serum albumin (BSA) (Sigma-Aldrich).  Samples were analysed using a 
SpectraMax 250 microplate reader and SOFTmax® Pro analysis software (Molecular 
Devices, Sunnyvale, CA, USA). 
 
2.3.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and protein transfer 
Polyacrylamide gels for electrophoresis were prepared from liquid polyacrylamide before 
being poured between glass plates that were clamped together with a 1 mm divide.  
Separating gel consisted of: 375 mM Tris pH 8.8, 10% Acrylamide/Bis 19:1 solution, 0.1% 
SDS.  Stacking gel consisted of: 125 mM Tris pH 6.8, 4% Acrylamide/Bis 19:1 solution, 
0.1% SDS.  Stacking gel was laid on top of the separating gel and had a comb inlaid to 
form wells.  Protein samples were prepared to contain equal amounts of total protein and 
SDS sample buffer before being incubated at 95°C for 5 min then loaded into the gel wells.  
In each gel were lanes reserved for prestained and/or biotinylated protein standards. SDS 
sample buffer consisted of: 50 mM Tris HCl pH 6.8, 2% SDS, 6% glycerol, 0.02% 
bromophenol blue, and 1% β-mercaptoethanol. 
Gels were immersed in SDS-PAGE running buffer which is: 25 mM Tris Base, 192 mM 
glycine, 3.5 mM SDS in water.  Electrophoresis occurred over 1-2 hours running at 100 V 
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increasing to 180 V when the loading dye had entered the separating gel.  When the protein 
samples had run far enough through the gel (assessed using the prestained protein 
standards) the protein was transferred to a nitrocellulose membrane (Fisher).  The gel was 
placed in a sandwich between blotting paper against the nitrocellulose membrane and 
immersed in transfer buffer.  Transfer buffer consists of: 25 mM Tris Base, 192 mM 
glycine, 0.35 mM SDS, and 20% methanol in water.  Transfer occurred over 1 hour at 100 
V incubated at 4°C.  The protein-bound membrane was then removed from the sandwich 
and stored at 4°C in Tris-buffered saline with Tween20 (TBS/T), which consisted of 20 
mM Tris Base, 137 mM sodium chloride, and 0.1% Tween20 in water. 
 
2.3.4 Membrane immunostaining 
Membranes were blocked by incubation in 4% milk TBS/T with mild agitation overnight 
at 4°C.  Primary antibody was then incubated on the membrane at the appropriate dilution, 
as shown in Table 2.6, in TBS/T for 2 hours at room temperature or overnight at 4°C, 
inside a tube with constant rolling.  After primary antibody incubation the membrane was 
washed three times with TBS/T before incubation with the secondary antibody.  Secondary 




Antibody Name Type Epitope Dilution 
Anti-SGK (Sigma-Aldrich) Polyclonal IgG vkeaaeaflgfsyapptdsfl 1:2000 
Anti-DDDDK tag (Abcam 
plc, Cambridge, UK) 
Polyclonal IgG xxxDDDDK 1:1000 
Anti-DYKDDDK 
(Chemicon (Millipore), 









TSC22D3 (GILZ) 1:400 
Anti-SGK1 (phospho S422) 
(Abcam) 
Polyclonal IgG GFSPYA 1:500 
Anti-p-SGK (Ser 422) 
(Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA) 
Polyclonal p-SGK (Ser 422) 1:500 
Anti-p-SGK (Thr 256) 
(Santa Cruz) 
Polyclonal p-SGK (Thr 256) 1:500 
Anti-SGK1B 3259 
(Cambridge BioScience 













Rabbit IgG 1:5000 




Mouse IgG 1:1000 
Biotinylated anti-Rabbit 




Rabbit IgG 1:500 
Anti-GAPDH (14C10) (Cell 
Signaling Technology, Inc., 
Danvers, MA, USA) 
Monoclonal IgG GAPDH 1:10000 
 
Table 2.6  Details of antibodies used in Western blotting. 
 
2.3.5 Visualisation 
To visualise immunostained protein, membranes were first washed for 5 min three times 
with TBS/T.  For biotinylated secondary antibodies an Avidin-Biotin Complex solution 
(VECTASTAIN (Vector Laboratories)) was prepared according to the manufacturer’s 
instructions and incubated on the membrane for 30 min.  After a further three washes with 
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TBS/T, the membrane was stained for 5 min with a chemiluminescence solution (ECL 
Plus™ Western Blotting Detection Reagent (GE Healthcare Life Sciences, Little Chalfont, 
Buckinghamshire, UK)) prepared just before use according to the manufacturer’s 
instructions.  The membranes were then imaged using a FLA-3000 fluorescent image 
analyser (Fujifilm UK Ltd., Bedford, UK). 
 
2.3.6 Membrane stripping 
To strip antibodies from the nitrocellulose in order that staining of the sample membrane 
by other antibodies could be performed, stripping buffer consisting of the following was 
used: 200 mM glycine (Fisher), 3.5 mM SDS (Fisher), 1% Tween 20 in H2O with pH 
adjusted to 2.2.  Nitrocellulose was immersed in stripping buffer for two sequential 10 min 
incubations, before two 5 min washes in TBS/T, with mild agitation, and at room 
temperature.  Membranes were then re-blocked ready for re-probing. 
 
2.3.7 Data analysis 
Western blot images were analysed using AlphaEase®FC 5.0 Software (Cell Biosciences).  
For quantification of band densities, bands of interest and a reference background area for 
each were manually selected and from these, an integrated density value (IDV) was 
generated for each band based on the size of the selection areas, average pixel intensities 
within those areas, and correction for intensity of the background.  Predicted molecular 
weights for bands of interest were also generated using this software, by comparison with 
bands of known molecular weight in size marker lanes.  Graphs and statistical analyses of 
band IDVs normalised to GAPDH were done using Microsoft® Office Excel 2003 or 
GraphPad Prism® 4.0. 
 51
2.4 Immunoprecipitation 
Immunoprecipitation (IP) of transfected FLAG-tagged SGK1 isoforms or GILZ was 
performed with anti-FLAG (Abcam/Chemicon) and anti-GILZ (Abnova) antibodies (Table 
2.6).  Transfected cells were lysed for IP as described by Soundararajan et al. (2005) 
(Soundararajan et al., 2005).  Cell lysis buffer consisted of: 50 mM HEPES, 150 mM 
NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, 1% Triton X-100.  Antibody was 
added to cell lysates diluted 1:500 and incubated with mild agitation overnight at 4°C.  
Protein G Sepharose beads (Sigma-Aldrich) were added to the cell lysate and antibody mix 
(100 µl of bead suspension per 400 µg of total protein) and incubated with mild agitation 
overnight at 4°C for both the pre-clear and precipitation stages.  After 
immunoprecipitation, mixes were centrifuged to pellet the beads and supernatants collected 
for analysis by Western blotting.  Beads were washed four times to remove non-
immunoprecipitated residue using 50 mM Tris-HCl pH 7.4, 150 mM NaCl wash buffer.  
For analysis by Western blotting, beads were boiled at 95°C with SDS-sample buffer for 5 
min. 
Crosslinked IP was performed using a Pierce® Crosslink IP kit (Thermo Scientific) 
according to manufacturer’s instructions.  This kit uses Disuccinimidyl suberate (DSS) to 
crosslink the antibody to the agarose beads to prevent antibody fragments contaminating 
the immunoprecipitation product.  The kits standard protocol was followed, but using 2 µg 




2.5.1 Measurement of transepithelial resistance and potential difference 
To measure the electrical resistance and potential difference of mpkCCDcl4 cells grown on 
Transwell® membranes, an EVOMX meter and STX2 electrodes (World Precision 
Instruments UK, Stevenage, UK) were used (Bens et al., 1999).  This equipment uses pairs 
of silver and silver/silver chloride electrodes and two different recording modes to 
measure: (1) transepithelial resistance of the membrane and (2) potential difference across 
the membrane.  Transepithelial resistance is measured by the EVOMeter by application of 
an AC current through the membrane.  Prior to use, electrodes were sterilised by 
immersion in 70% ethanol then pre-conditioned by immersion in mpkCCDcl4 starvation 
medium for 1 hour.  When taking readings from each well of a 12-well plate, the electrodes 
were positioned at the same point in each well to reduce error. 
Resistance readings were taken every 2 days from seeding of mpkCCDcl4 cells onto 
Transwell® membranes to assess the health and stability of the monolayer.  For equivalent 
short circuit current experiments, resistance and potential difference readings were taken 




Hormones and drugs or their respective vehicle solutions were added to cells grown on 
Transwell membranes, diluted in starvation medium to 100 x final concentration, allowing 
for a 1:100 final dilution in the culture medium.  Cells were allowed to stabilise for 1 hour 
after any addition to the culture medium. 
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2.5.3 Data analysis 
Resistance and potential difference measurements were entered into Microsoft® Office 
Excel 2003 and used to calculate the equivalent short circuit current according to Ohm’s 
Law:  I (current (amperes)) = V (potential difference (volts)) / R (resistance (ohms)).  
Values were then converted to ohms-centimetre squared (Ωcm2), millivolts per centimetre 
squared (mV/cm2) and microamperes per centimetre squared (µA/cm2) before being 
transferred to GraphPad Prism® 4.0 to generate graphs and perform statistical analyses. 
 
2.6 Immunofluorescence 
2.6.1 Human renal tissue collection and preparation 
Human renal tissue was collected, prepared, and supplied to this investigation by Dr 
Shabbir Moochala (Institute for Cell and Molecular Biosciences, Newcastle University).  
Tissue was collected from the normal pole of nephrectomised specimens at the Freeman 
Hospital, Newcastle upon Tyne. Ethical approval was obtained from the Sunderland Local 
Research Ethics Committee. Kidney tissue was obtained after informed consent from 
patients undergoing nephrectomy for renal cell carcinoma subject to the following 
exclusion criteria: serum creatinine > 140 μmol/l, or any evidence of renal scarring. 
Tissue was immediately removed to a renal preservation solution (Ahmad et al., 2006) at 4 
°C and transported to the laboratory on ice.  The solution consisted of: 140 mM sucrose, 
42.3 mM Na2HPO4, and 26.7 mM NaH2PO4 in distilled water.  This was pH corrected to 
7.4, then autoclaved, aliquoted into sterile containers, and stored at 4 °C until use. 
Human tissue on ice was cut into blocks of 5 mm x 5 mm in a Class II ventilation hood 
before being embedded, as a small volume of tissue enabled quicker and more even 
 54
freezing.  Tissue blocks were embedded in OCT embedding medium (RA Lamb Ltd., 
Eastbourne, UK/Thermo Fisher Scientific) and then snap-frozen, attached to a cork 
mounting block, by immersion in liquid nitrogen-chilled isopentane (2-methylbutane).  
Once frozen, tissue blocks were stored in a sealed container at -80 °C. 
 
2.6.2 Mouse renal tissue collection and preparation 
Normal mouse renal tissue was supplied by Newcastle University Comparative Biology 
Centre and was immediately immersed in DMEM/HAM’s F12 1:1 vol/vol at 4 °C to 
preserve the tissue for transportation to the laboratory on ice.  As with the human tissue 
preparation, mouse tissue was cut into blocks of 5 mm x 5 mm before being embedded.  
Tissue blocks were embedded in OCT embedding medium (RA Lamb/Thermo Fisher 
Scientific) and then snap-frozen, attached to a cork mounting block, by immersion in liquid 
nitrogen-chilled isopentane (2-methylbutane).  Once frozen, tissue blocks were stored in a 
sealed container at -80°C. 
 
2.6.3 Tissue sectioning 
Blocks of embedded tissue were removed from storage and allowed to acclimatise in a 
Cryostat chilled to -20°C before tissue sections of 6 µm thickness were cut.  Cut sections 
were immediately applied to Superfrost Plus microscope slides (VWR International Ltd., 
Leighton Buzzard, UK) or to standard Superfrost microscope slides (Thermo Fisher 
Scientific) that had been pre-coated with 3-aminopropyltriethoxysilane (APTES) (Sigma-




2.6.4 Preparation of tissue and cells for immunofluorescence studies 
Tissue sections attached to slides were ringed with a hydrophobic pen before being fixed in 
cytoskeletal fixative solution for 10 min.  Cytoskeletal fixative consisted of: 4% 
paraformaldehyde (Sigma-Aldrich), 100 mM PIPES pH 6.8 (Sigma-Aldrich), 2 mM EGTA 
(Sigma-Aldrich) and 2 mM MgCl2 in H2O.  Sections were then washed with 150 mM Tris 
HCl to quench fixative before permeabilisation of tissue using 0.2% Triton X100 for 10 
min.  Sections were washed with Phosphate-buffered saline with Tween20 (PBS/T) three 
times and blocked with 3% horse serum for 1 hour at room temperature.  PBS/T consisted 
of: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, and 0.05% Tween20 
in water.  Sections were then washed another three times with PBS/T before treatment with 
primary antibody (Table 2.7) at the appropriate dilution in block solution for 2 hours at 
room temperature or overnight at 4°C.  After primary antibody incubation, sections were 
washed and then blocked again, as before, by incubation with 3% secondary antibody host 
serum for 1 hour, with mild agitation, and at room temperature.  Secondary antibody 
incubation was under the same conditions as for primary.  Finally, sections were washed 
three times in PBS/T and once in ultrapure H2O before coverslips were affixed over the 
sections using fluorescence mounting medium (Dako UK Ltd., Ely, UK).  Slides were kept 
in the dark and at room temperature until mounting medium was set, after which, slides 
were stored in the dark at 4°C. 
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Antibody Name Type Epitope Dilution 
Anti-DYKDDDK 
(Chemicon) 
Monoclonal IgG DYKDDDK 1:1000 
Anti-AQP2 (C-17) 
(Santa Cruz) 






Anti-γ tubulin (Abcam) Monoclonal IgG1 γ tubulin 38-53 1:200 
Anti-acetylated α tubulin 
(Sigma-Aldrich) 





Monoclonal IgG1 k Human ZO-1 334-364. 1:200 
Anti-Calnexin (H-70) 
(Santa Cruz) 
Polyclonal Human Calnexin 1-70. 1:100 
 
Table 2.7  Primary antibodies used in immunofluoresence studies. 
 
Cells grown on coverslips were treated in exactly the same way as tissue, except that, after 
staining, they were attached face-down onto Superfrost microscopy slides (Thermo 
Scientific).  In some experiments, the actin cytoskeleton of cells was stained using Alexa 
Fluor 633 Phalloidin (Molecular Probes, Invitrogen) at a concentration of 1:500.  
Secondary antibodies for all experiments were from Molecular Probes, Invitrogen and 
were used at a concentration of 1:300 for 2 hours.  For tissue staining, secondary 
antibodies raised in donkey were used, whereas for cells, secondary antibodies raised in 
goat or rabbit were used.  Nuclei were stained by using Hoechst 33258 at a concentration 
of 1:1000 for 10 min.  The following fluorophores and their representative colours were 
used:  Hoechst (blue), Alexa Fluor 488 (green), Oregon Green 488 (green) Alexa Fluor 568 




Slides were imaged using either a Leica TCS SP2 UV Upright Confocal System or a Zeiss 
LSM 510 META laser scanning confocal microscope.  The lenses used for each system 
were a 63x HCX PL APO oil immersion lens and a Plan-Neofluar 40x/1.3 Oil Ph3 lens, 
respectively.  Images where nuclei are shown were taken with the Leica microscope and 
consist of collapsed Z-stacks.  Images that are two-channel only were taken using the Zeiss 
microscope and are single Z-sections.  Images were collected sequentially to avoid 
emission signal bleed-through.  For multiple slides from a single experiment channel 
settings were kept the same except for slight alterations of the gain and offset to reduce the 
appearance of non-specific staining.  Z-section images were captured at ~1 µm intervals.  
For each experiment, positive signals were verified by comparison with controls. 
 
2.7 Statistical analyses 
Statistical analyses were performed using GraphPad Prism® 4.0.  All data is presented as 
mean values ± standard error of the mean (sem). Statistical differences among different 
groups were determined using one-way or two-way analysis of variance (ANOVA) with 
Tukey’s Multiple Comparison or Bonferroni Multiple Comparison posttests, respectively.  
P values of ≤0.05 were considered to be statistically significant. 
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Chapter 3 - Identification of Multiple Isoforms of Mouse Sgk1 
3.1 Introduction 
Hypertension of unknown cause (essential hypertension) affects a significant proportion of 
the population (Beevers et al., 2001).  Salt imbalance in the body, as a result of 
dysregulated sodium reabsorption in the aldosterone-sensitive distal nephron (ASDN), is a 
known cause of hypertension (Meneton et al., 2005).  Regulation of epithelial sodium 
channel (ENaC) activity in the ASDN is a major determinant of renal Na+ reabsorption 
and, consequently, overall body fluid homeostasis and blood pressure (Butterworth, 2010; 
Jin et al., 2010).  Historically, a single isoform of SGK1 was identified as a key mediator 
of aldosterone-stimulated sodium transport via its regulation of ENaC (Chen et al., 1999).  
The importance of ENaC and SGK1 in sodium transport has been shown by their roles in 
various disease states in addition to hypertension, such as Liddle’s syndrome, diabetes, and 
cystic fibrosis (Berdiev et al., 2009; Lang et al., 2009b; Lu et al., 2007) as reviewed in 
chapter 1.  This has led to both proteins becoming key pharmacological targets.  Research, 
thus far, is based on an incomplete knowledge of the identity, regulation, and roles of 
SGK1 and its relation to ENaC.  Over the past 3 years, successive studies have identified 
additional isoforms of SGK1, some of which have been shown to display specificity in 
their regulation of ENaC.  Since the start of the present study, two publications appeared 
which described the expression of isoforms of human SGK1.  A study by Simon et al. 
(2007) into sequence variations in SGK1 transcripts has described two novel human SGK1 
isoforms, in addition to the original SGK1, arising from alternative initiation of 
transcription and splicing.  In a second study around the same time, a study by Hall (2007) 
on SGK1 signalling in skin identified the same two novel human SGK1 isoforms as well as 
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two additional novel isoforms, which were collectively named SGK1B, SGK1C, SGK1D, 
and SGK1F.  The work described in this thesis was thus initiated based on the findings of 
Simon et al. (2007) and Hall (2007), with the aim of examining the role of SGK1 isoforms 
in regulating ENaC in renal cortical collecting duct (CCD) cells.  Through differences in 
their expression, regulation, subcellular distribution, degradation, kinase activity, or 
substrate specificity, the SGK1 isoforms may differ greatly in their physiological 
consequences for renal sodium reabsorption.  The approach to identify and investigate the 
regulated expression of multiple isoforms of mouse Sgk1 in the present study uses the 
mpkCCDcl4 mouse CCD model cell line as it displays aldosterone-sensitive, SGK1-
regulated, and ENaC-mediated sodium transport (Flores et al., 2005; Bens et al., 1999), 




3.2.1 Identification and comparisons of mouse Sgk1 variant sequences 
Gene homology between the human SGK1 and the mouse Sgk1 gene suggests that the 
mouse Sgk1 gene may also produce multiple isoforms.  To investigate this possibility, 
mouse Expressed Sequence Tags (ESTs) from the EST database, dbEST (Boguski et al., 
1993), were compared to the human SGK1 splice variant sequences before being 
considered as potentially encoding isoforms of Sgk1.  Putative mouse Sgk1 splice variant 
EST sequences were then entered into the Spidey mRNA-to-genomic alignment program 
(Wheelan et al., 2001) and compared to the NCBI Mus musculus genome sequence around 
the Sgk1 locus on chromosome 10 A3.  From these searches, four putative mouse isoforms 
were identified.  These mouse isoforms were then named according to their equivalent 
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human isoforms as Sgk1a, b, c, and d.  Table 3.1 shows the differences in N-terminal 





Unique N-terminal coding nucleotide 
sequence 














117 of 1338 











354 of 1575 
 
Table 3.1  Sgk1 isoform nucleotide data. 
 
3.2.2 Features of the mouse Sgk1 variant sequences 
Genomic alignment of the variant sequences revealed unique alternative exons 1-5, whose 
addition to the Sgk1 locus expanded its size from 5 to 120 kbp (Figure 3.1).  Exons 7-17 
are conserved between all isoforms, whereas exons 1-6 are isoform-specific.  Exons 1-3 
encode the unique N-terminus of Sgk1d (the longest Sgk1 isoform), whereas exons 4, 5, 
and 6 encode the unique N-termini of Sgk1c, b, and a, respectively.  The increase in size of 
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the Sgk1 locus, from 5 to 120 kbp, meant an expansion of genetic sequence that could 
contain promoter regions or regulatory binding sites.  Also, because unique exons were 
attributed to each Sgk1 isoform, any promoter and regulatory domains may be isoform-
specific.  To test this hypothesis the genomic sequence 5’ of each isoforms primary exons 
was searched for common promoter element binding sites.  Different transcription factor 
binding sites were found in close proximity to the Sgk1 isoforms primary exons.  Sgk1a 
and c had potential TATA box binding sites (TATAAA) at -44 bp and -22 bp positions, 
respectively, whereas Sgk1b and d were closest to potential E-box binding sites, CATTTG 
and CAGCTG at -3 bp and -19 bp, respectively. 
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Figure 3.1  The mouse Sgk1 locus, showing the possible alternative splicing and the 
resulting mRNAs.  A depicts the 120 kbp mouse Sgk1 locus.  Genomic sequence is 
represented by a black horizontal line, onto which exons are marked by coloured (isoform 
specific) or black (conserved) bars.  Untranslated regions (UTRs) are shown as colourless 
sections of the exon bars.  Where the genomic sequence is shortened, between exons 2, 3 
and 4, the actual intron sizes are given, above, in italics.  Drawn below the locus are the 
alternative splicing variations for each isoforms unique exons showing how each isoform 
arises.  B shows the different Sgk1 isoform mRNAs, showing their unique and common 
exons (UTRs are not shown). 
 
3.2.3 Predicted protein products for the mouse Sgk1 variants 
To investigate the proteins encoded by the four mouse Sgk1 splice variants described in 
section 3.2.1, their nucleotide sequences were analysed using the sequence manipulation 
suite open reading frame (ORF) finder (http://www.bioinformatics.org/sms/) (Stothard, 
2000).  This showed all the longest ORF sequences encoded by each variant mRNA, 
allowing the full-length amino acid sequences to be determined.  The amino acid 
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sequences were then entered into the sequence manipulation suite protein molecular weight 
calculator giving a predicted molecular weight for each full-length Sgk1 isoform protein 
(Stothard, 2000).  However, Arteaga et al. (2007) showed that mouse Sgk1a is 
endogenously expressed as four, progressively shorter, isoforms resulting from alternative 
initiation of translation at alternative, in-frame, downstream methionines (Arteaga et al., 
2007), which suggested that Sgk1b, c, and d may also be expressed as multiple alternative 
initiation of translation products (AITPs).  The amino acid sequences of the unique N-
termini and common region of the Sgk1 isoforms were searched for alternative start 
methionines followed by prediction of the molecular weights of the resulting isoforms 
(Table 3.2).  Isoform-specific AITPs are named by a delta symbol (Δ) followed by the 
number of amino acids missing from the full-length isoform protein and then the name of 
the isoform (e.g. Δ16Sgk1a).  Common AITPs are named by a delta symbol (Δ) followed 
by the number of amino acids missing from the common sequence then ‘Sgk1’ (e.g. 
Δ2Sgk1).  The Sgk1 isoforms identified previously by Arteaga et al. (2007) had molecular 
weights of 49, 47, 45, and 42 kDa, corresponding to isoforms Sgk1a, Δ16Sgk1a, Δ19Sgk1a 
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Table 3.2  Sgk1 isoform protein data.  * indicates where unique N-termini sequence and 
common sequence attach. 
 
The SGK1 protein that, prior to the publications describing other isoforms by Simon et al. 
(2007) and Arteaga et al. (2007), was thought to be the sole isoform of SGK1 is equivalent 
to SGK1A (Webster et al., 1993b).  A specific six-amino-acid motif (GMVAIL) that was 
identified in human SGK1A is also present in mouse Sgk1a.  A Phox homology (PX) 
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domain identified in the N-terminal region of human SGK1D is conserved in mouse 
Sgk1d, identified by SMART and Pfam database searches (Hall, 2007).  The human SGK1 
PDZ binding motif (DSFL) present at its C-terminal end is also conserved in the mouse 
isoforms.  The phosphorylation sites reported for human SGK1 at Serine 78 (Hayashi et 
al., 2001), Threonine 256 (Kobayashi and Cohen, 1999), Threonine 369 (Perrotti et al., 
2001), Serine 377 (Lizcano et al., 2002), and Serine 422 (Kobayashi and Cohen, 1999) are 
also all conserved in mouse Sgk1 (numbers reflect amino acid positions in SGK1A).  The 
distribution of some of these domains on the Sgk1 isoforms is shown in Figure 3.2. 
 
 
Figure 3.2  Full-length mouse Sgk1 isoform proteins. 
 
3.2.4 Cloning of the mouse Sgk1 isoforms 
In order to help identify and investigate expression of the mouse Sgk1 isoforms using 
molecular biology techniques such as transient transfection, mouse Sgk1 isoform cDNAs 
were obtained or cloned in expression vectors.  Mouse Sgk1a was purchased from 
Geneservice (www.geneservice.co.uk) cloned in the pCMV-SPORT6 expression vector 
between the SalI (5’) and NotI (3’) restriction sites in its multiple cloning site (MCS) 
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(Figure 3.3).  This expression vector contains several useful features for molecular biology 
including: an ampicillin resistance gene appropriate for its selective generation in bacteria; 
a powerful cytomegalovirus (CMV) promoter upstream of its MCS for enhanced 
transcription of inserted DNA; T7 and SP6 promoters either side of its MCS, suitable for 
artificial generation of mRNA.  Based on its favourable characteristics, the remaining Sgk1 
isoforms were also cloned into pCMV-SPORT6.  Sgk1b was cloned into pCMV-SPORT6 
through replacement of the N-terminus of Sgk1a in pCMV-SPORT6 with that of Sgk1b.  
The N-terminus of Sgk1b was amplified from whole mpkCCDcl4 cell RNA by RT-PCR 
using primers that introduced a SalI restriction site at the 5’ end and a PacI restriction site 
at the 3’ end of the product.  The Sgk1b RT-PCR product and the Sgk1a plasmid were then 
digested with SalI and PacI to produce fragments that had corresponding 2-4 base 
overhangs.  The Sgk1b N-terminus fragment was then ligated into the pCMV-SPORT6 
fragment in place of the Sgk1a N-terminus to create complete Sgk1b in pCMV-SPORT6.  
Due to its unavailability from Geneservice and difficulties in its production by RT-PCR, 
mouse Sgk1c was generated by combinatorial PCR, as described in section 2.2.1.  The 
Sgk1c PCR product was cloned into pCMV-SPORT6 by the same process using the SalI 
and PacI restriction sites as described for Sgk1b.  Mouse Sgk1d was also obtained from 
Geneservice and was sub-cloned from its original vector (pYX-Asc) into pCMV-SPORT6, 
by digestion using Not1 and EcoR1 restriction enzymes.  The amino acid sequence of each 
clone was confirmed by sequencing carried out by Eurofins MWG Operon 
(http://www.eurofinsdna.com/).  Evidence that the cloned Sgk1 vectors were able to code 




Figure 3.3  The pCMV-SPORT6 vector map and multiple cloning site sequence.  
Mouse Sgk1a was obtained in this vector, whilst Sgk1b, c, and d were cloned into this 
vector using RT-PCR, combinatorial PCR and sub-cloning, respectively. 
 
In order to distinguish overexpressed Sgk1 isoform protein from endogenous protein, the 
mouse Sgk1 isoforms were also cloned into the pCMV-FLAG2 vector (Figure 2.3).  This 
cloning was carried out as described in section 2.2.1.  When transiently transfected into 
cells, these clones produced overexpressed FLAG-tagged Sgk1 isoforms, which could then 
be detected using FLAG-specific antibodies.  The FLAG-tagged Sgk1 isoforms could also 
be used with other techniques such as co-immunoprecipitation and immunofluorescence. 
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3.2.5 Multiple mouse Sgk1 isoforms are expressed in mpkCCDcl4 cells 
To determine which mouse Sgk1 isoforms were being expressed in mpkCCDcl4 cells, 
isoform-specific primers were designed (Table 2.3) and, together with RT-PCR, were used 
to amplify specific cDNA products from purified mpkCCDcl4 cell RNA.  Data 
demonstrated the expression of all four mouse Sgk1 mRNAs was detectable in mpkCCDcl4 
cells (Figure 3.4).  Sequencing analysis then confirmed the Sgk1 isoform identities of the 
products (see appendix). 
 
 
Figure 3.4  mpkCCDcl4 cells express all four isoform-specific Sgk1 variant mRNAs.  
RNA was purified from mpkCCDcl4 cells that were grown on plastic for 24 hours in 
growth medium using an RNeasy kit.  Specific mouse isoform cDNAs were amplified 
using the OneStep RT-PCR kit in reactions containing 400 ng of the purified RNA and 
Sgk1 isoform specific primers (Table 2.3).  Reaction products were size separated via 
electrophoresis and visualised with ethidium bromide by UV imaging.  No RNA controls 
showed no amplified product. 
 
To verify that the expression of isoform RNA was the same in both mpkCCDcl4 cells and 
native mouse kidney tissue, the same RT-PCR was performed using RNA purified from 
whole mouse kidneys.  Kidneys were obtained from three different mice and results 




Figure 3.5  Native mouse kidney tissue expresses specific Sgk1a, b, c, and d variant 
mRNAs.  RNA was purified from 3 whole mouse kidneys from different mice using 
TRIzol reagent (Invitrogen) according to the manufacturer’s instructions.  Specific mouse 
isoform and GAPDH cDNAs were amplified from the tissue RNA and imaged using the 
procedure described in Figure 3.4.  No RNA controls showed no amplified product. 
 
3.2.6 Aldosterone stimulates endogenous expression of multiple Sgk1 isoforms 
in mpkCCDcl4 cells 
Although results from the present study showed that multiple mouse Sgk1 variant mRNAs 
are expressed in mpkCCDcl4 cells and native mouse kidney tissue (section 3.2.5), the 
translation and endogenous expression of multiple mouse Sgk1 isoforms required further 
investigation.  Previous studies in mpkCCDcl4 cells have shown that aldosterone treatment 
caused an increase in endogenous Sgk1 expression levels (Wang et al., 2008; Flores et al., 
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2005).  The effect of different concentrations of aldosterone on Sgk1 expression levels in 
serum and hormone-starved mpkCCDcl4 cells was therefore investigated.  Cells were 
starved for 24 hours in starvation medium before exposure to different aldosterone 
concentrations ranging between 0.3-300 nM, or vehicle control, for a further 24 hours and 
prior to lysis in RIPA buffer. 
Western blotting detected three Sgk1 protein bands which, although poorly resolved, were 
of the correct approximate size to correspond to the predicted mouse Sgk1 isoforms Sgk1b 
(51 kDa), Sgk1c (48 kDa), and Sgk1d (60 kDa) (Figure 3.6A).  Due to the poor resolution 
Sgk1a could not be specifically identified, but probably overlapped with Sgk1b.  
Regarding the Sgk1 protein bands, very little expression of Sgk1b/a and Sgk1c was 
detected in serum and hormone-starved cells, but surprisingly Sgk1d was clearly detected.  
Furthermore, Sgk1b/a and Sgk1c were only detected following treatment of cells with 
between 0.3-100 nM aldosterone (Figure 3.6A). 
After the detection of Sgk1 protein bands, the Western blot was stripped and reprobed for 
GAPDH expression as a control for equal protein loading.  The images of the Sgk1 and 
GAPDH Western blots were then analysed by densitometry to compare the densities of the 
Sgk1 bands between treatments.  The results of the densitometric analysis indicated that in 
starved cells Sgk1d was expressed at a high basal level, which appeared not to change in 
response to 0.3-1 nM aldosterone, but 3 nM aldosterone did increase expression (~1.75-
fold) (Figure 3.6B).  Increasing the concentration of aldosterone from 0 up to 3 nM caused 
a dose-dependent increase in expression of Sgk1b/a and Sgk1c to a peak of 2.25-fold basal 
Sgk1d expression at 3 nM aldosterone.  Increasing aldosterone concentrations from 3-300 
nM caused a dose-dependent decrease in expression of Sgk1b/a, c, and d, reaching 
starvation levels or below at 100 nM for Sgk1d and 300 nM for Sgk1b/a and c.  These data 
suggest that expression of Sgk1d in renal epithelial cells was at a higher basal level than 
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Sgk1b and c, but was less sensitive to aldosterone.  In contrast, Sgk1 isoforms b/a and c 




Figure 3.6  Aldosterone stimulates endogenous Sgk1 protein expression in mpkCCDcl4 
cells in a dose-dependent manner.  A shows Sgk1 protein expression in cells that were 
starved for 24 hours then treated for 24 hours to a range of concentrations of aldosterone.  
Cells grown on plastic were starved for 24 hours before being treated for 24 hours with 
vehicle or 0.3-300 nM aldosterone.  After treatment, cells were lysed and Sgk1 expression 
analysed by Western blotting using a SGK1 antibody.  Arrows indicate the Sgk1 bands and 
corresponding sizes used for quantification.  Due to poor resolution only single bands are 
present for Sgk1d and Sgk1a&b combined.  B shows the mean Sgk1 protein band density 
as a ratio versus GAPDH for the untreated and aldosterone treated cells from two 
experiments.  Results are representative of two separate experiments. 
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Based on the results presented in Figure 3.6, together with previous studies describing 
normal physiological plasma aldosterone concentration (Gonzalez-Rodriguez et al., 2007; 
Hollenberg et al., 2004) and aldosterone-stimulated changes in sodium transport by 
mpkCCDcl4 cells (Bens et al., 1999), 10 nM aldosterone was therefore employed as a 
standard treatment for further study.  Previous studies using mpkCCDcl4 cells have shown 
that aldosterone treatment caused a time-dependent increase in sodium transport (Bens et 
al., 1999).  Therefore, the effect of aldosterone treatment on starved mpkCCDcl4 cell 
expression of Sgk1 isoforms over a similar time period was investigated.  Cells grown on 
cell-culture plastic were serum and hormone-starved for 24 hours in starvation medium 
before being treated with 10 nM aldosterone.  At different time points, cells were lysed and 
processed for Western blotting to detect Sgk1 protein expression. 
Figure 3.7A shows that 10 nM aldosterone increased expression of multiple Sgk1 
immunoreactive protein bands of the appropriate sizes corresponding to isoforms a (49 
kDa), b (51 kDa), c (48 kDa) and d (60 kDa).  An additional Sgk1 band was present that 
was the correct size corresponding to the Δ31Sgk1d isoform (~56 kDa).  As was seen in 
Figure 3.6, a protein band for Sgk1d was detected in serum and hormone-starved cells, but 
the other isoforms were not.  However, in the presence of 10 nM aldosterone, detection of 
Sgk1a, b, and c were visible after 1 hour and intensity increased after 4 and up to 24 hours. 
Densitometric analysis of aldosterone-induced Sgk1 isoform bands indicated that 
expression of Sgk1a, b, and c in starved cells was gradually increased ~25-fold in a time-
dependent manner over 6 hours (Figure3.7C).  Expression of Sgk1d and Δ31Sgk1d was 
~5-fold higher than the other Sgk1 isoforms in starved cells and aldosterone treatment only 
significantly increased the 60 kDa Sgk1d band after 6 hours of exposure, by ~2.5-fold.  In 
contrast, there was a significant increase in the expression of Sgk1a, b, and c bands by 4 
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hours of aldosterone treatment.  From 6 hours up to 24 hours exposure to aldosterone, no 




Figure 3.7  Aldosterone stimulates expression of multiple endogenous Sgk1 proteins 
in mpkCCDcl4 cells in a time-dependent manner.  A shows Sgk1 protein expression in 
cells that were starved for 24 hours then treated with 10 nM aldosterone.  Cells that were 
untreated or treated for 1, 4, 6, 12, and 24 hours were lysed and analysed by Western 
blotting using a SGK1-specific antibody.  B shows the Sgk1 protein band density as a ratio 
versus GAPDH for the Western blot shown in A.  C shows summary data from 3 
independent experiments.  Because of variation in protein density between different 
experiments the summary data is expressed as a percentage of the 24 h time point 
Sgk1/GAPDH band density ratio for each individual isoform (24 h time point designated 
as 100 %).  Values are means ± sem and are significantly different to 0 hours (P = <0.05) 
from 6 hours for 60 kDa Sgk1d and from 4 hours for 51 kDa Sgk1b, 49 kDa Sgk1a, and 48 
kDa Sgk1c.  However, there was no significant change in the 56 kDa Sgk1d band over 24 
hours. 
 
3.2.7 Co-migration of overexpressed Sgk1 isoforms with endogenous Sgk1 
proteins 
The estimated sizes of the aldosterone-induced Sgk1 bands could only be used to suggest 
their corresponding Sgk1 isoform identities.  To better identify the aldosterone-induced 
Sgk1 bands, cloned Sgk1 isoforms were overexpressed in mpkCCDcl4 cells and lysates 
compared to endogenous Sgk1 proteins in aldosterone plus insulin-treated mpkCCDcl4 cell 
lysates by Western blotting.  Insulin was added to aldosterone treatment of cells in order to 
try and maximise detection of Sgk1. 
Aldosterone plus insulin-responsive bands of estimated sizes 51, 49, and 48 kDa, co-
migrated with intense overexpressed Sgk1 isoforms (Figure 3.8).  In addition to this, a 60 
kDa endogenous Sgk1 band was detected corresponding to and co-migrating with Sgk1d.  
It is clear from Figure 3.8 that there were a number of additional lower molecular weight 
Sgk1 immunoreactive bands visible below the most intense bands.  These additional bands 
have not been formally identified, but could be endogenous Sgk1 isoforms resulting from 
alternative translational start sites, such as those described by Arteaga et al. (2007).  The 
shortened isoforms that resulted from translation initiation at alternative start methionines 
are described in section 3.2.3.  Other possible explanations for additional bands include the 
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presence of phosphorylated, partially degraded, ubiquitinated or post-translationally 
modified forms of Sgk1.  The overexpression of each individual isoform may also have 
altered the expression levels of the endogenous isoforms causing induction of Sgk1 bands 
of other predicted sizes.  Nonetheless, it is clear from Figure 3.8 that A+I treatment of 
mpkCCDcl4 cells induced the expression of bands which co-migrate with exogenously 
expressed Sgk1a, b, c, and basally expressed 1d. 
 
 
Figure 3.8  Aldosterone plus insulin-stimulated endogenous Sgk1 proteins co-migrate 
with overexpressed Sgk1 isoforms.  mpkCCDcl4 cells grown on plastic were incubated 
for 24 hours in starvation medium before being exposed to A+I for 24 hours, then lysed.  
Other mpkCCDcl4 cells were transfected with Sgk1 isoforms, empty vector control 
(Vector), or no DNA (Untran) and incubated for 24 hours to allow plasmid protein 
expression before being lysed.  Arrows with estimated sizes indicate full-length Sgk1 
isoforms.  Arrows without sizes in the Ctrl lane indicate other endogenous immunoreactive 
Sgk1 isoform bands.  Arrows without sizes in the overexpressed lanes indicate Sgk1 
isoform bands induced by the transfection.  Results are representative of five separate 
experiments. 
 
3.2.8 Co-migration of overexpressed Sgk1 isoform proteins with synthesised 
Sgk1 isoform proteins 
In order to further improve identification of the multiple Sgk1 protein bands detected in 
overexpression lysates by Western blotting, Sgk1 plasmid protein was synthesised in vitro 
for comparison.  This also allowed detection of the Sgk1 isoform Western blot bands 
specifically produced by the individual Sgk1 splice variant mRNAs.  Whole TNT kit 
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reaction was added to SDS sample buffer and boiled according to the standard preparation 
of Western blotting samples described in section 2.3.4.  The synthesised protein samples 
were run alongside samples of mpkCCDcl4 cell lysate transfected with Sgk1 isoforms in a 
Western blot (Figure 3.9). 
Multiple intense Sgk1 protein bands were detected for synthesised Sgk1a of estimated 
sizes; 49, 45, and 42 kDa, which corresponded to Sgk1a, Δ7Sgk1, and Δ34Sgk1, 
respectively (Figure 3.9).  For synthesised Sgk1b, two intense Sgk1 protein bands were 
detected of estimated sizes; 58 and 51 kDa, of which the 58 kDa isoform was unidentified, 
whilst the 51 kDa isoform was Sgk1b (Figure 3.9).  Synthesised Sgk1c produced intense 
bands of estimated sizes 48, 45, and 42 kDa, which corresponded to Sgk1c, Δ7Sgk1, and 
Δ34Sgk1, respectively (Figure 3.9).  Synthesised Sgk1d produced a single intense band of 
60 kDa, the correct size corresponding to Sgk1d (Figure 3.9).  The equivalent 
overexpressed full-length Sgk1 plasmid protein bands from transfected mpkCCDcl4 cells 




Figure 3.9  Synthesised and overexpressed Sgk1 isoforms show similar protein 
products.  mpkCCDcl4 cells grown on plastic were transfected with Sgk1 isoforms, empty 
vector control (Vector), or no DNA control (Untran), grown for 24 hours to allow plasmid 
protein expression, then lysed.  Sgk1 isoform plasmid protein, empty vector control protein 
(Vector), or no DNA control protein (No DNA) was synthesised in vitro in reactions with 
reticulocyte lysate using a TNT kit.  Reactions product and lysates were analysed for Sgk1 
protein by Western blotting using anti-SGK1 antibody.  Arrows indicate strongly detected 
Sgk1 protein bands.  Representative of two separate experiments. 
 
3.2.9 Detection of multiple phosphorylated Sgk1 isoforms 
To mediate any effects on the cell, Sgk1 must first be activated by phosphorylation at one 
or more of the sites described in section 3.2.3.  Therefore, changes in total Sgk1 protein 
levels can only suggest possible changes in the level of Sgk1 activity.  To gain a better 
understanding of the levels of active Sgk1 in mpkCCDcl4 cells, and how aldosterone and 
insulin treatments affect phosphorylated Sgk1 protein levels, cell lysates were analysed by 
Western blotting using phosphorylated Sgk1-specific antibodies.  Insulin was used because 
it has been shown to activate SGK1 via the PI3K pathway and 3-phosphoinositide 
dependent protein kinase-1 (PDPK1) (Wang et al., 2001).  Antibodies that targeted 
phosphorylated Sgk1 at either threonine 256 or serine 422 were used for these experiments.  
Despite many attempts to detect endogenous phospho-Sgk1 protein in aldosterone and 
insulin stimulated mpkCCDcl4 cells, none were successful.  Even combining 
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overexpression of Sgk1 isoforms with insulin treatment in mpkCCDcl4 cells did not lead to 
detectable phosphorylated Sgk1 (Figure 3.10). 
 
 
Figure 3.10  No detected expression of phosphorylated Sgk1 isoform protein in 
insulin-treated mpkCCDcl4 cells.  Cells grown on plastic were transfected with Sgk1 
isoforms, empty vector control (Vector), or no DNA (Untran) and incubated for 24 hours 
to allow plasmid protein expression.  Cells were then given 1 µM insulin in grown medium 
for 24 hours to stimulate Sgk1 phosphorylation before cells were lysed.  Cells lysates were 
analysed for total and phosphorylated Sgk1 protein by Western blotting using anti-SGK1 
and anti-p-SGK1 (Ser 422) antibodies.  A positive control lysate of HEK293T cells that 
were co-transfected with SGK1C and PDPK1 was included (Control) to verify functioning 
of the Abcam antibody.  Arrows indicate detected SGK1 immunoreactive bands.  
Representative of four separate experiments. 
 
The only experiment that detected phosphorylated Sgk1 isoforms used transfected 
HEK293T cells, which overexpress protein at very high amounts compared to the 
mpkCCDcl4 cells.  These cells were transfected with a combination of Sgk1 isoforms and 
human PDPK1 to ensure high expression levels of both Sgk1 and the activating kinase 
PDPK1.  The human SGK1 isoforms were also included, in order to compare 
phosphorylation profiles with the mouse Sgk1 isoforms.  SGK1 isoform expression was 
verified using anti-SGK1 antibody.  Results showed that a single band of phosphorylated 
human SGK1B and multiple bands of phosphorylated human and mouse SGK1C were 
detected under these conditions, as shown in Figure 3.11 and Figure 3.12, respectively.  




Figure 3.11  Detection of phosphorylated SGK1 protein in HEK293T cells co-
transfected with SGK1B and PDPK1.  Cells grown on plastic were co-transfected with 
mouse Sgk1b plus PDPK1 (Sgk1b+PDPK1), human SGK1B plus PDPK1 
(SGK1B+PDPK1), empty vector plus PDPK1 (Vector+PDPK1), or no DNA (Untran).  
After 24 hours growth to allow plasmid protein expression, cells were lysed and cell 
lysates analysed for total SGK1 and phosphorylated SGK1 protein expression by Western 
blotting using anti-SGK1 and anti-p-SGK (Thr 256) antibodies.  Arrows indicate detected 
SGK1 immunoreactive bands. 
 
 
Figure 3.12  Detection of phosphorylated SGK1 protein in HEK293T cells co-
transfected with SGK1C and PDPK1.  Cells grown on plastic were co-transfected with 
mouse Sgk1c plus PDPK1 (Sgk1c+PDPK1), human SGK1C plus PDPK1 
(SGK1C+PDPK1), empty vector plus PDPK1 (Vector+PDPK1), or no DNA (Untran).  
After 24 hours growth to allow plasmid protein expression, cells were lysed and cell 
lysates analysed for total SGK1 and phosphorylated SGK1 protein expression by Western 
blotting using anti-SGK1 and anti-p-SGK (Thr 256) antibodies.  Arrows indicate detected 
SGK1 immunoreactive bands. Representative of two separate experiments. 
 
3.2.10 Sensitivity of aldosterone-stimulated Sgk1 isoforms to LY294002 
Previous studies have shown that inhibition of phosphoinositide 3-kinase (PI3K) abrogates 
aldosterone-induced Sgk1 expression and ENaC-mediated sodium transport (Shane et al., 
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2006; Flores et al., 2005).  Therefore, to investigate which aldosterone-induced Sgk1 
isoforms are dependent on PI3K, mpkCCDcl4 cells were treated with LY294002 to inhibit 
PI3K and then treated with aldosterone before being examined for Sgk1 isoform 
expression by Western blotting.  Cells grown on plastic were starved for 24 hours before 
being exposed to 10 µM LY294002 or vehicle control for 30 mins followed by addition of 
a range of aldosterone concentrations or vehicle control for an additional 24 hours.  Figure 
3.13 shows that LY294002 (LY) caused a decrease in expression of all isoforms, but 
particularly in the Sgk1b and c expression induced by aldosterone.  Basal expression of 
Sgk1d in starved cells was ~4-fold higher that the other isoforms in both untreated and 
LY294002 treated cells.  However, Sgk1d expression in starved cells and cells treated with 




Figure 3.13  LY294002 reduces aldosterone-stimulated expression of Sgk1a, b, and c.  
A and B show additional data from the experiment described in Figure 3.6.  mpkCCDcl4 
cells were treated with a range of concentrations of aldosterone in the absence or presence 
of 10 µM LY294002.  Lysates were analysed for Sgk1 expression by Western blotting 
using a SGK1 antibody.  Arrows indicate the Sgk1 bands and corresponding sizes used for 
quantification.  Due to poor resolution only a single band is present for Sgk1d and 
Sgk1a&b combined.  B shows the mean Sgk1 protein band density as a ratio versus 
GAPDH for the untreated and aldosterone treated cells from two experiments.  Results are 
representative of two separate experiments. 
 
Additionally, insulin has been shown to increase phosphorylated Sgk1 and ion transport in 
mpkCCDcl4 cells in a PI3K-dependent manner (Wang et al., 2008).  Therefore, to 
investigate if any of the Sgk1 bands were induced by insulin (and were therefore due to 
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phosphorylated Sgk1), treatments of 1 µM insulin and combined 10 nM aldosterone plus 1 
µM insulin were included. 
Western blotting showed that aldosterone and aldosterone plus insulin, but not insulin 
alone, increased expression of Sgk1a, b, and c, whereas Sgk1d was expressed at a high 
level regardless of treatment (Figure 3.14).  LY294002 reduced the aldosterone plus 
insulin-stimulated expression of Sgk1a, b, and c, but did not affect Sgk1d expression.  
These results therefore suggest that Sgk1a, b, and c are expressed at low levels in 
unstimulated cells and are upregulated by aldosterone and insulin, but Sgk1d is expressed 





Figure 3.14  Aldosterone plus insulin-stimulated expression of endogenous Sgk1 is 
partially sensitive to LY294002.  A shows a Western blot comparing the expression of 
Sgk1 in insulin, aldosterone, aldosterone plus insulin, and LY294002 treated mpkCCDcl4 
cells including cells that were transfected with Sgk1 isoforms to show co-migration.  The 
endogenous Sgk1 protein bands, detected using anti-SGK1 antibody, corresponding to the 
different Sgk1 isoforms, are indicated by arrows.  Sgk1 immunoreactive bands in the 
overexpressed Sgk1 isoform cells are also indicated by arrows.  B shows the quantification 
of the endogenous Sgk1 protein bands as a density ratio versus GAPDH. 
 
3.2.11 Detection of overexpressed mouse Sgk1 isoforms with human SGK1 
isoform-specific antisera 
To address the need to detect and identify specific SGK1 isoforms in Western blotting and 
other applications, human SGK1 isoform-specific antisera were generated in collaboration 
with Cambridge BioScience Ltd, Cambridge, UK (Table 2.6).  However, to use these 
antibodies to detect the mouse Sgk1 isoforms first required testing their specificity and 
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sensitivity with this different species.  To address this, the isoform-specific antibodies were 
individually assessed for their ability to specifically detect overexpressed human SGK1 
isoforms and mouse Sgk1 isoforms in lysate of transfected HEK293T and mpkCCDcl4 
cells. 
Six peptides were used in generation of the antibodies, four corresponding to amino acid 
sequence within the unique N-termini of SGK1A, B, C and F and two from within the 
longer N-terminus of SGK1D.  Two rabbits were immunized per peptide, giving two 
antibody purifications for each isoform.  Purified antibodies were initially tested for their 
ability to detect overexpressed human SGK1 isoforms in transfected HEK293T cell lysate 
by Western blotting.  In addition to each isoform-specific antibody, anti-SGK1 antibody 
and peptide-blocked isoform-specific antibody were used as positive and negative controls, 
respectively. 
The only isoform-specific antibodies that were found to specifically detect their target 
overexpressed human SGK1 isoforms were anti-SGK1B 3259 and anti-SGK1D 3253.  
Anti-SGK1B 3259 detected a single band in SGK1B transfected cell lysate of estimated 
size 51 kDa that co-migrated with the corresponding anti-SGK1-detected band and was 
removed by peptide-blocking (Figure 3.15).  Similarly, anti-SGK1D 3253 also detected a 
single band in SGK1D transfected cell lysate of estimated size 60 kDa that co-migrated 





Figure 3.15  Pre-incubation with target peptide blocked anti-SGK1B 3259 detection 
of overexpressed human SGK1B in lysate of transfected HEK293T cells.  HEK293T 
cells grown on plastic were transfected with SGK1B or control plasmid, grown for 24 
hours to allow plasmid protein expression, then lysed.  Lysates were co-analysed by 
Western blotting using anti-SGK1 antibody, anti-SGK1B 3259 antibody, and peptide-
blocked anti-SGK1B 3259 antibody.  Arrows indicate SGK1B bands in both the SGK1 and 
SGK1B-specific blots that was absent on the peptide-blocked blot. 
 
 
Figure 3.16  Pre-incubation with target peptide blocked anti-SGK1D 3253 detection 
of overexpressed human SGK1D in lysate of transfected HEK293T cells.  HEK293T 
cells grown on plastic were transfected with SGK1D or control plasmid, grown for 24 
hours to allow plasmid protein expression, then lysed.  Lysates were co-analysed by 
Western blotting using anti-SGK1 antibody, anti-SGK1D 3253 antibody, and peptide-
blocked anti-SGK1D 3253 antibody.  Arrows indicate SGK1D bands in both the SGK1 
and SGK1D-specific blots that was absent on the peptide-blocked blot. 
 
Once an isoform-specific antibody had been verified against human SGK1 isoforms, it was 
then tested on overexpressed mouse Sgk1 isoforms from transfected mpkCCDcl4 cell 
lysate.  To ensure antibodies remained specific in the detection of their target isoform, 
despite the presence of other overexpressed isoforms, antibodies were tested in the 
presence of overexpressed Sgk1a, b, c, and d.  This testing showed that both anti-SGK1B 
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3259 (Figure 3.17) and anti-SGK1D 3253 (Figure 3.18) successfully detected mouse 
Sgk1b and Sgk1d, respectively. 
 
 
Figure 3.17  Anti-SGK1B 3259 antibody specifically detected overexpressed mouse 
Sgk1b in transfected mpkCCDcl4 cells.  mpkCCDcl4 cells grown on plastic were 
transfected with Sgk1 isoforms, grown for 24 hours to allow plasmid protein expression, 
then lysed.  Lysates were co-analysed by Western blotting using anti-SGK1 antibody to 
confirm Sgk1 expression and anti-SGK1B 3259 antibody.  Arrows indicate Sgk1b bands in 
both the SGK1 and SGK1B-specific blots. 
 
 
Figure 3.18  Anti-SGK1D 3253 antibody specifically detected overexpressed mouse 
Sgk1d in transfected mpkCCDcl4 cells.  mpkCCDcl4 cells grown on plastic were 
transfected with Sgk1 isoforms, grown for 24 hours to allow plasmid protein expression, 
then lysed.  Lysates were co-analysed by Western blotting using anti-SGK1 antibody to 
confirm Sgk1 expression and anti-SGK1D 3253 antibody.  Arrows indicate Sgk1d bands in 




3.3.1 Identification and features of mouse Sgk1 isoforms 
Results from the present study show that four different splice variants of mouse Sgk1 are 
expressed in kidney and produce multiple mouse Sgk1 isoforms named Sgk1a, Sgk1b, 
Sgk1c, and Sgk1d.  Conserved amino acid sequence between the mouse Sgk1 isoforms 
meant that all four isoforms contain a serine/threonine kinase domain, a C-terminal PDZ-
binding motif (DSFL), and multiple phosphorylation sites.  However, each Sgk1 isoform 
has a unique N-terminus creating some isoform-specific domains.  For example, mouse 
Sgk1a contains an ubiquitin tagging domain (GMVAIL) and mouse Sgk1d contains a Phox 
homology (PX) domain. 
The domains of the different Sgk1 isoforms could confer pan or isoform-specific roles.  
The C-terminal PDZ-binding motif (DSFL) is involved in phosphorylation of SGK1, as it 
is where the Na+/H+ exchanger regulatory factor 2 (NHERF2) binds to recruit PDPK1 to 
SGK1, inducing phosphorylation at threonine 256 (Chun et al., 2002).  The 
phosphorylation and activity profiles of the different Sgk1 isoforms are yet to be 
determined, but future work on this could lead to identification of a predominantly active 
isoform.  Although conserved phosphorylation sites between the isoforms suggest that all 
four isoforms may be activated by similar routes  Mouse Sgk1 displays conserved 
phosphorylation sites at serine 78, threonine 256, threonine 369, serine 377, and serine 422 
(Kobayashi and Cohen, 1999).  Serine 78 is phosphorylated by big mitogen-activated 
kinase 1 (BMK1) in a pathway regulating cell proliferation (Hayashi et al., 2001).  As 
mentioned earlier, threonine 256 of Sgk1 is phosphorylated by PDPK1 (Kobayashi and 
Cohen, 1999).  Threonine 369 is phosphorylated by protein kinase A (PKA) as part of 
cAMP-mediated effects of vasopressin (Perrotti et al., 2001).  Serine 377 is phosphorylated 
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by NIMA (never in mitosis, gene A)-related kinase-6 (NEK6) (Lizcano et al., 2002).  
Serine 422 is phosphorylated by mechanistic target of rapamycin (mTOR) complex 2 
(mTORC2) (Lu et al., 2010). 
Of the Sgk1 isoform-specific domains, the GMVAIL motif of Sgk1a is a site of ubiquitin 
tagging of SGK1, signalling it for degradation by the 26S proteasome and is probably the 
site ubiquitinated by phosphorylated Nedd4-2 as part the negative feedback regulation of 
Sgk1 (Bogusz et al., 2006).  However, the GMVAIL motif is only present in Sgk1a and 
none of the other SGK1 isoforms, suggesting that SGK1A may be the only isoform subject 
to negative feedback regulation by ubiquitination (Zhou and Snyder, 2005).  Another Sgk1 
isoform-specific domain, the PX domain of Sgk1d, is involved in targeted binding to 
phosphoinositides, suggesting that Sgk1d may have a role particularly linked to PI3K, 
ENaC or other plasma membrane proteins (Ellson et al., 2002; Wishart et al., 2001).  The 
potential interactions of the PX domain of Sgk1d are discussed further in section 5.3.2. 
The mouse Sgk1 isoforms share considerable sequence identity to their human equivalents 
and many features are conserved, which was expected considering the similar roles of 
Sgk1 described for both humans and mice.  The mouse Sgk1 locus at chromosome position 
10 A3 was extended from ~5 to ~120 kbp due to the addition of the alternative splice 
variant exons.  This is highly similar to the human SGK1 locus at chromosome position 
6q23, which was expanded from ~5 to ~150 kbp by the addition of splice variant exons.  
The main SGK1 splice variant responsible for the locus extension in both humans and mice 
is SGK1D, as it has 3 unique exons compared to 1 unique exon for each of the other 
isoforms.  As the isoforms were named according to their proximity to the original locus, 
the exons of SGK1D stretch the furthest upstream (5’) in both humans and mice.  The next 
closest in proximity are the unique exons of SGK1C, SGK1B, and SGK1A, respectively.  
Interestingly, human SGK1F is the exception to the naming rule because it is produced by 
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a combination of the exon and intron sequence immediately upstream of the common 
human SGK1 exons, however, there is no mouse Sgk1 isoform equivalent to human 
SGK1F. 
The discovery of mouse Sgk1 isoforms, in addition to the human SGK1 isoforms, renders 
much of the current research on mouse Sgk1 as too limited, but enables future 
investigation into the roles of these isoforms and of the evolution of SGK1 and its 
conservation and possible roles in other species.  Regarding this project, the profiling of 
Sgk1 isoforms expression in mouse allowed further investigation into their roles in renal 
sodium transport. 
 
3.3.3 Cloning of the mouse Sgk1 isoforms 
Sgk1a and Sgk1d were purchased from Geneservice in the pCMV-SPORT6 and pYX-Asc 
expression vectors, respectively.  Sgk1 isoforms b, c, and d were cloned into the pCMV-
SPORT6 vector by RT-PCR, combinatorial PCR, and sub-cloning, respectively.  Once 
cloned, sequencing was used to confirm the identity and accuracy of the products.  The 
cloning of Sgk1b and Sgk1d into pCMV-SPORT6 was carried out without any problems.  
However, the initial approach to clone Sgk1c following the same procedure as for Sgk1b 
failed for unknown reasons.  This led to the use of combinatorial PCR to clone Sgk1c from 
mouse genomic DNA isolated from mpkCCDcl4 cells. 
Future cloning of the mouse Sgk1 could add alternative epitope or fluorescent tags to the 
isoforms.  The data in this chapter also provides insight for future studies into the promoter 
regions for each isoform.  Additional cloning could include the 5’ and 3’ untranslated 
regions in order to study their regulatory properties for each isoform.  Cloning of the 
mouse Sgk1 isoforms enabled size comparison of overexpressed with endogenous proteins 
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to reinforce their identification.  These vectors were also used to aid detection of 
phosphorylated Sgk1 isoforms and in verification of isoform specific antibodies. 
 
3.3.4 Identification of multiple aldosterone-stimulated endogenous Sgk1 
isoforms in mpkCCDcl4 cells 
Aldosterone treatment of starved mpkCCDcl4 cells stimulated expression of Sgk1a, b, and c 
in a time-dependent manner, whereas Sgk1d showed little induction by aldosterone, but 
was expressed at a much higher basal level.  These data therefore suggest that Sgk1a, b, c, 
and d are differentially regulated by aldosterone in mouse cortical collecting duct cells.  At 
concentrations above 30 nM, aldosterone had a detrimental effect on Sgk1 expression, 
possibly due to off-target effects that would occur at this concentration.  The high 
concentrations of aldosterone are much greater than cells would experience physiologically 
and this may be having a detrimental effect on expression of Sgk1. 
The results described in this study are supported by Flores et al. (2005), which showed that 
three Sgk1 bands of estimated sizes; 49, 47, and 45 kDa become detectable after 1 hour of 
1 µM aldosterone treatment and increase in density, in a time-dependent manner, peaking 
at 3 hours, before decreasing slightly at 6 hours.  Similar results have also been reported by 
Gonzalez-Rodriguez et al. (2007).  This work showed multiple endogenous Sgk1 bands in 
mCCDcl1 cells that were maximally induced by combined aldosterone plus insulin or IGF-1 
(Gonzalez-Rodriguez et al., 2007).  Three aldosterone-induced Sgk1 bands of estimated 
sizes; 49, 51, 53 kDa were not removed by lambda phosphatase treatment. 
The high basal expression of Sgk1d that was found in mpkCCDcl4 cells (Figure 3.7) may, 
in part, be explained by the findings in Raikwar et al. (2008), which showed that human 
SGK1D had a much longer half-life than SGK1A in HEK293 cells (t1/2 = SGK1A: 16 min, 
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SGK1D: 119 min), but, despite this, latent Sgk1d would still be degraded after 24 hours of 
starvation.  The data from Raikwar et al. (2008) and the limited sensitivity of Sgk1d to 
aldosterone treatment also suggest that Sgk1d is regulated differently to the other Sgk1 
isoforms.  The differential regulation of expression of multiple Sgk1 isoforms by 
aldosterone highlights the need to re-evaluate the existing model of regulation of ENaC in 
principal cells. 
 
3.3.5 Co-migration of overexpressed Sgk1 isoform proteins with endogenous 
and synthesised Sgk1 isoform proteins 
Three aldosterone-induced Sgk1 bands of estimated sizes; 51, 49, and 48 kDa, co-migrated 
with overexpressed Sgk1 isoform bands corresponding to the full-length isoforms.  An 
endogenous Sgk1 band at 60 kDa also co-migrated with the overexpressed Sgk1 band 
corresponding to full-length Sgk1d.  Additional Sgk1 bands were detected in 
overexpressed isoform lanes that corresponded to smaller Sgk1 isoforms, but although 
some of these co-migrated with endogenous bands, the bands did not appear to be induced 
by aldosterone.  To improve identification of which Sgk1 bands originated from which 
Sgk1 variant mRNA, synthesised Sgk1 isoform plasmid protein was also analysed for co-
migration.  An unexpected Sgk1 band was detected in the synthesised Sgk1b protein lane 
that was estimated to be 56 kDa in size.  This 56 kDa band was unexpected as none of the 
isoforms of Sgk1b are predicted to be above 51 kDa in size.  The in vitro synthesis of the 
protein removes post-translational modification and other Sgk1 isoforms as possible 
origins of the 56 kDa, suggesting an error in cloning.  However, cloning was confirmed by 
plasmid nucleotide sequencing, leaving the identity of the 56 kDa band unknown. 
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3.3.6 Detection of phosphorylated Sgk1 isoforms 
Only overexpressed human SGK1B and C and mouse Sgk1c were detected when 
overexpressed with PDPK1 in HEK293T cells using phospho-specific Sgk1 antibodies.  
Attempts to stimulate phosphorylated endogenous or overexpressed Sgk1 in mpkCCDcl4 
cells were unsuccessful despite using phosphatase inhibitors, insulin treatment and co-
transfection with PDPK1.  Transfected HEK293T cells overexpress protein at a much 
higher level than mpkCCDcl4 cells, enabling the weakly-detecting phospho-specific 
antibodies to detect their target.  Not being able to detect all isoforms phosphorylated at 
threonine 256 suggests there may be differential regulation of phosphorylation between the 
isoforms.  No detectable phosphorylation at threonine 256 may have occurred as a result of 
different phosphorylation thresholds at the different conserved phosphorylation sites.  
Also, different activators of Sgk1 such as mTOR may be involved in Sgk1 phosphorylation 
(Garcia-Martinez et al., 2008; Hong et al., 2008). 
Future experiments could use constitutively active/inactive mutants of Sgk1 isoforms to 
investigate effects of SGK1 phosphorylation on regulation of ENaC.  Simple methods to 
increase the likelihood of detecting phosphorylated SGK1 include: using Ac-Leu-Leu-Nle-
CHO (ALLN) to inhibit the proteasome and decrease endogenous SGK1 degradation, or 
using a greater concentration of sample protein in the Western blotting, or 
immunoprecipitating total or phosphorylated SGK1 before detection. 
 
3.3.7 Sensitivity of aldosterone-stimulated Sgk1 isoforms to LY294002 
LY294002 partially inhibited aldosterone + insulin induction of Sgk1 bands of estimated 
sizes; 51, 49, and 48 kDa, corresponding to Sgk1b, a, and c, respectively.  These data 
therefore imply that PI3K has a role in regulating the expression levels of Sgk1a, b, and c 
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in mpkCCDcl4 cells.  Interestingly, just as Sgk1d was shown to be unresponsive to 
aldosterone, Sgk1d expression was unchanged after exposure of cells to LY294002.  The 
present results are supported by the findings of Flores et al. (2005), which showed that 
aldosterone-induced Sgk1 bands of estimated sizes; 49, 47, and 45 kDa were reduced by 
exposure of the mpkCCDcl4 cells to 30 min of 50 µM LY294002 (Flores et al., 2005).  
Also, Gonzalez-Rodriguez et al. (2007) showed that aldosterone-induced Sgk1 bands of 
estimated sizes; 49, 51, 53 kDa were reduced, but not removed by treatment with 50 µM 
LY294002 (Gonzalez-Rodriguez et al., 2007).  These results suggest that Sgk1 induction 
by aldosterone, with or without insulin, is partially dependent on PI3K and mTOR, a 
conclusion that is not explained by the current model of Sgk1 stimulation.  Further work is 
needed to resolve the roles of PI3K and mTOR in the regulation of expression of Sgk1 in 
CCD cells. 
 
3.3.8 Detection of overexpressed isoforms with isoform-specific antisera 
Although isoform-specific antibodies were created for each of the human SGK1 isoforms 
(A-F), the SGK1B 3259 and SGK1D 3253 antibodies were the only ones found to be 
specific for their equivalent mouse Sgk1 isoform targets.  The specificity of these 
antibodies to their target isoform against overexpressed protein further verifies the identity 
of Sgk1 isoforms b and d.  These isoform-specific antibodies provide a method of 
specifically detecting expression of SGK1B and SGK1D in cell lysate by Western blotting.  
Also, these antibodies were later used in immunofluorescence studies of Sgk1 expression 
in native renal tissue.  These antibodies could be used in future studies to show localisation 




 Mouse Sgk1 is expressed as multiple isoforms similar to human SGK1. 
 Four distinct Sgk1 isoforms identified in mouse were named Sgk1a, Sgk1b, Sgk1c, 
and Sgk1d according to their similarity to human SGK1 isoforms. 
 mpkCCDcl4 cells and mouse renal tissue express mRNA for Sgk1 isoforms a, b, c 
and d. 
 mpkCCDcl4 cells endogenously express multiple Sgk1 proteins of comparable 
molecular weights to the predicted proteins of Sgk1a, b, c, and d. 
 Endogenously expressed and exogenously expressed Sgk1 isoforms co-migrate in 
Western blotting. 
 Endogenous Sgk1 isoforms are induced by aldosterone. 
 Phosphorylated human SGK1 isoform B and C and mouse Sgk1 isoform c are 
detectable when overexpressed with PDPK1 by Western blotting using phospho-
threonine 256-specific antibody. 
 Aldosterone stimulation of Sgk isoforms is sensitive to LY294002. 
 Sgk1 isoforms b and d are detectable by Western blotting using isoform-specific 
antibodies. 
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Chapter 4 - Electrophysiological Studies of the Regulation of 
Sodium Transport 
4.1 Introduction 
The principal cells of the cortical collecting duct in the kidney mediate hormone-regulated 
sodium reabsorption required for the essential maintenance of salt homeostasis.  
Aldosterone acts on principal cells to regulate sodium reabsorption by increasing the 
synthesis and activities of the epithelial sodium channel (ENaC), the basolateral Na+/K+-
ATPase, and K+ channels (Ring et al., 2007b; Liang et al., 2006; Flores et al., 2005; Huang 
et al., 2004; Summa et al., 2004).  Aldosterone diffuses into the cell cytosol and binds to 
the mineralocorticoid receptor (MR) creating a hormone-receptor complex.  This complex 
then translocates from the cytosol to the nucleus where it induces transcription of various 
genes, including SGK1 (Verrey et al., 2007).  SGK1 itself requires activation to mediate 
the effects of aldosterone.  This occurs by phosphorylation at positions threonine 256 and 
serine 422, which is mediated by 3-phosphoinositide-dependent protein kinase 1 (PDPK1) 
and mechanistic target of rapamycin complex 2 (mTORC2), respectively (Lu et al., 2010; 
Park et al., 1999).  The activities of PDPK1 and mTORC2 are regulated by the 
phosphoinositide 3-kinase (PI3K) pathway, which is activated by insulin, amongst other 
agonists (Wang et al., 2001; Park et al., 1999).  Activated SGK1 binds, phosphorylates and 
thus inactivates Nedd4-2, which would otherwise signal ENaC for internalisation and 
degradation via ubiquitination (Snyder et al., 2002; Staub et al., 2000).  This increases the 
number of ENaC at the apical membrane thus increasing sodium transport (McCormick et 
al., 2005; Debonneville et al., 2001).  There are early and late phases to aldosterone-
stimulated sodium transport in the CCD, which begin after ~30 min and ~2 hours of 
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treatment, respectively (Verrey et al., 2000).  The early phase is attributed to increased 
ENaC activity and redistribution of intracellular ENaC to the apical membrane, whereas 
the late phase is attributed to stimulated ENaC production to gradually increase channel 
number in the apical membrane (Butterworth, 2010).  An additional level of regulation of 
ENaC occurs through proteolysis of the alpha and gamma subunits of channels present in 
the apical membrane, which increases channel activity (Kleyman et al., 2009). 
In the previous chapter, four different mouse Sgk1 isoforms were shown to be 
differentially induced by aldosterone and insulin treatment in renal epithelial cells.  The 
aim of this chapter was to investigate how manipulation of Sgk1 expression and signalling 
affects ENaC-mediated transepithelial Na+ transport by mpkCCDcl4 cells.  For these 
studies, aldosterone and insulin were used as physiological stimulants of Na+ transport.  In 
order to determine the ENaC-mediated transepithelial current I have used amiloride to 
selectively block ENaC.  Amiloride blocks ENaC with a Ki of ~100 nM, therefore, 1 µM 
amiloride was used in an attempt to completely block ENaC without inhibiting other ion 
channels such as the cyclic nucleotide-gated channel A3 (CNG-A3), which amiloride 
blocks with a Ki of ~50 µM (Novaira et al., 2004; Rossier, 2003). 
Transepithelial short-circuit current (Isc) is a measure of the charge flow per time 
associated with ion transport across an epithelial cell monolayer (Li et al., 2004).  This 
transepithelial flow of charge is dependent on two factors: resistance of the cell monolayer; 
and transepithelial potential difference.  Resistance of epithelia is determined by the 
polarity of the cells and the permeability of the tight-junctions between adjacent cells.  
Transepithelial potential difference is equivalent to the voltage generated by the net 
movement of ions across a monolayer.  Monolayers of mpkCCDcl4 cells were tested under 
open-circuit conditions (where transepithelial voltage (Vte) is not clamped) using an 
epithelial volt and ohmmeter (EVOMeter) (World Precision Instruments, Sarasota, FL, 
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USA) to measure the transepithelial resistance (Rte) and Vte.  From these two values, the 
equivalent Isc (Ieq) can be calculated using the following equation that is based on Ohm’s 
Law: Ieq = Vte/Rte.  Ieq represents a measure of actual transepithelial flow of ions across the 
cell monolayer, a positive value corresponding to a net movement of positively charged 
ions apically to basolaterally (epithelial absorption) or negatively charged ions 
basolaterally to apically (epithelial secretion) (for negative values this net flow would be 
vice versa for each ion). 
 
4.2 Results 
4.2.1 Aldosterone and insulin stimulate ENaC-mediated sodium transport 
In chapter 3, Western blotting results demonstrated that 24 hours treatment of serum-
starved mpkCCDcl4 cells with 3-30 nM aldosterone gave a maximal induction of Sgk1 
isoforms (Figure 3.6).  Results also showed that 10 nM aldosterone induced Sgk1a, b, c, 
and d expression in a time-dependent manner that was detectable at 1 hour and maximal at 
6 hours (Figure 3.7).  Bens et al. (1999) have shown previously that 10 nM aldosterone 
induced ENaC-mediated transepithelial sodium transport in mpkCCDcl4 cells in a similar 
time-dependent manner.  These studies indicated that 10 nM aldosterone gave a time-
dependent increase in Ieq, from a basal level of ~10 µA/cm2, that was significantly above 
control from 2 hours and maximal (4-fold) at 6 hours. 
To investigate if the changes in Sgk1 isoform expression were linked to increases in Na+ 
transport required a reliable assay to measure Ieq.  To this end, the EVOMeter 
electrophysiology assay and mpkCCDcl4 cell growth conditions described by Bens et al. 
(1999) were employed.  In order to ensure the maximum Ieq response of the mpkCCDcl4 
cells to aldosterone treatment, 1 µM insulin was also included in the treatment assay.  
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Insulin is known to activate a pathway that leads to the phosphorylation and activation of 
SGK1 and was shown previously to produce a maximal Ieq response when combined with 
another mineralocorticoid, dexamethasone (Wang et al., 2001). 
Aldosterone plus insulin treatment of serum and hormone-starved mpkCCDcl4 cells 
stimulated time-dependent changes in Rte, Vte and calculated Ieq as well as the calculated 
amiloride-sensitive Ieq at 6 hours (Figure 4.1).  Transepithelial resistance (Rte) had 
immediately dropped after 1 hour of treatment for both control and aldosterone plus insulin 
(A+I) treated cells (Figure 4.1A).  The initial Rte of ~3400 ± 200 Ωcm2 had dropped by 
~1000 Ωcm2 for control cells and by ~1500 Ωcm2 for A+I treated cells following 1 hour of 
treatment.  After 1 hour, the reduction in Rte gradually slowed, but the ~500 Ωcm2 
difference between the control and A+I treated cells was maintained (Figure 4.1A).  
Control cell Rte continued to decrease, reaching ~1500 ± 100 Ωcm2 at 6 hours, whereas 
A+I treated cells stabilised at ~1000 ± 100 Ωcm2 at 4 hours, which was maintained up to 6 
hours.  After 6 hours, cells were exposed to 1 µM amiloride to selectively block ENaC.  
This resulted in an increase in resistance of ~300 Ωcm2 for control cells and ~400 Ωcm2 
for A+I treated cells from 6 to 6.5 hours (Figure 4.1A).  The large initial drop in Rte is 
probably due to a reaction of the cells to the addition of treatment solutions and to the short 
removal of the cells from a 37°C, 5% CO2 atmosphere for EVOM measurement. 
Transepithelial potential difference (Vte), which had a basal value of ~85 ± 3 mV at 0 
hours, also showed a large initial decrease of ~30 mV by 1 hour (Figure 4.1B).  As with 
the Rte, the decrease slowed after 1 hour and stabilised at ~50 mV for A+I treated cells and 
~25 mV for control cells after 3 hours.  Amiloride treatment after 6 hours caused the 
potential difference to drop to ~11 ± 2 mV for control cells and to ~35 ± 4 mV for A+I 
treated cells. 
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Polarised mpkCCDcl4 cells exhibited a basal level of net ion absorption giving an Ieq of 
26.0 ± 2.2 µA/cm2 (Figure 4.1C).  Aldosterone plus insulin stimulated significant Ieq above 
control cells at 1 hour, which continued to increase in a time-dependent manner up to 6 
hours.  This response paralleled the aldosterone-induced time-dependent increase in Sgk1 
expression shown in Figure 3.7.  After 6 hours, aldosterone plus insulin Ieq had increased in 
a time-dependent manner to 50.9 ± 3.8 µA/cm2, 2.5-fold above the control Ieq of 19.0 ± 2.0 
µA/cm2.  Treatment with 1 µM amiloride removed the majority of the Ieq for both vehicle 
and A+I treated cells, which was expected, as the majority of ion transport by these cells 
occurs via ENaC (Bens et al., 1999).  Ieq in vehicle treated cells was reduced to 5.2 ± 0.8 
µA/cm2, whereas Ieq in A+I treated cells was reduced to 23.7 ± 2.4 µA/cm2, a reduction of 
just over half for the A+I treated cells.  This suggests that there was a significant amount of 
current that was not due to functional ENaC.  However, the identity of this amiloride-
insensitive Ieq was not investigated further. 
Calculation of the amiloride-sensitive equivalent short circuit current allowed comparison 
of the treatment effects on ENaC-mediated sodium transport.  At 6 hours, control cells 
displayed around half the amiloride-sensitive Ieq compared to A+I treated cells (Control: 
13.3 ± 1.6 µA/cm2; A+I: 27.2 ± 1.9 µA/cm2, P = <0.001) (Figure 4.1D).  This indicated 
that A+I treatment significantly stimulated ENaC-mediated sodium transport, but also that 




Figure 4.1  Effect of aldosterone plus insulin on electrophysiology measurements of 
ion transport in mpkCCDcl4 cells.  A and B show parallel electrophysiology 
measurements of transepithelial resistance (Rte) and transepithelial potential difference (Vte) 
over 6.5 hours of treatment of mpkCCDcl4 monolayers.  Cells which had been pre-starved 
for 24 hours were then exposed to 10 nM aldosterone plus 1 µM insulin (closed circles) or 
vehicle (open circles).  C shows the equivalent short circuit current (Ieq) calculated from 
the Rte and Vte values.  D shows the amiloride-sensitive Ieq, calculated from the difference 
in Ieq before and 30 min after treatment with 1 µM amiloride at 6 hours. Values are means 
± sem, n = 18. *, **, and *** represent P values of <0.05, <0.01, and <0.001 compared 
with control cells. 
 
This experiment was repeated using the hormones individually or together, in order to 
investigate if aldosterone and insulin had a synergistic effect on Ieq, as shown by Wang et 
al. (2008).  In order to investigate previously reported early and late actions of aldosterone, 
cells were prepared in duplicate to allow one set to be used to assess the amiloride-
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sensitive Ieq at 2 hours and one set to assess amiloride-sensitive Ieq at 6 hours (McCormick 
et al., 2005; Verrey et al., 2000). 
After 1 hour of treatment, insulin Ieq was significantly greater than control cells and 
aldosterone treated cells (Ins: 17.3 ± 0.4 µA/cm2; Control: 11.2 ± 0.3 µA/cm2; and Aldo: 
13.5 ± 0.7 µA/cm2, P = <0.01) (Figure 4.2).  By 2 hours, however, the insulin Ieq had 
dropped slightly (16.0 ± 1.9 µA/cm2), whilst the aldosterone Ieq had increased (17.2 ± 1.2 
µA/cm2).  Insulin Ieq remained significantly above control Ieq (9.9 ± 0.3 µA/cm2, P = 
<0.001), but this was not maintained beyond 2 hours (Figure 4.2B).  These data show that 
the Ieq response to insulin is short lived (<2 hours) under these conditions. 
Aldosterone plus insulin had additive stimulation of Ieq, compared to individual 
aldosterone and insulin treatments (Figure 4.2).  A+I-stimulated Ieq was significantly 
greater than control and aldosterone Ieq by 1 hour and insulin Ieq by 2 hours (P = <0.05).  
Overall, A+I-stimulated Ieq showed the greatest sustained elevation (Figure 4.2B).  These 
data indicate that the different treatments altered the ion transport properties of the cell 
monolayer over time.  To find out if this was caused by an increase in ENaC activity, the 





Figure 4.2  Insulin stimulates a small and short-lived increase in transepithelial 
equivalent short circuit current, whereas aldosterone stimulates a larger and more 
sustained increase that peaks earlier when aldosterone is combined with insulin.  
Total equivalent short circuit current (Ieq) calculated for mpkCCDcl4 cells treated as 
described in Figure 4.1, but including 10 nM aldosterone (Aldo) and 1 µM insulin (Ins) 
treatments alone.  A shows Ieq calculated for cells treated up to 2 hours before treatment 
with 1 µM amiloride.  B shows Ieq calculated for cells treated up to 6 hours before 
treatment with 1 µM amiloride.  Values are means ± sem, n = 6 from 0-2 hours and n = 3 
from 2.5-6 hours. 
 
At 2 hours, insulin and aldosterone-stimulated amiloride-sensitive Ieq were significantly 
greater than control Ieq (Ins: 11.0 ± 0.6 µA/cm2; Aldo: 11.4 ± 1.1 µA/cm2; Control: 7.1 ± 
0.3 µA/cm2, P = <0.001) (Figure 4.3A).  A+I amiloride-sensitive Ieq at 2 hours was 
significantly greater than that of all other treatments (A+I: 15.1 ± 0.4 µA/cm2, P = <0.01).  
Insulin and aldosterone-stimulated Ieq was ~4 µA/cm2 higher than control Ieq, whereas A+I-
stimulated Ieq was ~8 µA/cm2 higher than control Ieq at 2 hours.  These data show that the 
Ieq response to A+I was additive, but not synergistic. 
A 6 hours, only aldosterone and aldosterone plus insulin-stimulated amiloride-sensitive Ieq 
were above control cells (Control: 8.6 ± 0.4 µA/cm2; Ins: 9.5 ± 0.3 µA/cm2; Aldo: 18.3 ± 
1.0 µA/cm2; and A+I: 21.4 ± 0.6 µA/cm2, P = <0.001) (Figure 4.3B).  The disappearance 
of insulin-stimulated amiloride-sensitive Ieq from 2 to 6 hours, further suggests that the 
effect of insulin on sodium transport is short lived.  Also, A+I-stimulated amiloride-
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sensitive Ieq was still significantly greater than that of individual aldosterone or insulin at 6 
hours, but insulin no longer induced significant amiloride-sensitive Ieq, suggesting a 
synergistic effect of combined aldosterone plus insulin. 
 
 
Figure 4.3  Aldosterone and aldosterone plus insulin stimulate significant ENaC-
mediated sodium transport at 2 hours and 6 hours, whereas insulin did so only at 2 
hours.  A and B show amiloride-sensitive Ieq calculated from the difference between Ieq 
values before and after 1 µM amiloride treatment of mpkCCDcl4 cells treated for 2 hours 
(A) or 6 hours (B) as described in Figure 4.2.  Values are means ± sem, n = 3. *, **, and 
*** represent P values of <0.05, <0.01, and <0.001. 
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In a separate experiment, stimulation of amiloride-sensitive Ieq by A+I was compared 
between 2 hours and 6 hours exposure (Figure 4.4).  A+I-stimulated amiloride-sensitive Ieq 
was significantly above control at both 2 hours (Control: 7.9 ± 0.6 µA/cm2; A+I: 18.3 ± 1.2 
µA/cm2, P = <0.001) and 6 hours (Control: 8.6 ± 0.3 µA/cm2; A+I: 22.0 ± 0.5 µA/cm2, P = 
<0.01).  This showed that A+I-stimulated amiloride-sensitive Ieq lasted up to 6 hours and 
suggested a further increase beyond 6 hours.  To investigate how long the response was 
maintained and what the peak response was, this experiment was repeated including time 
points at 24 and 48 hours (Figure 4.5). 
 
 
Figure 4.4  Aldosterone plus insulin-stimulated ENaC-mediated sodium transport 
was greater at 6 hours than at 2 hours of exposure.  Amiloride-sensitive Ieq at 2 and 6 
hours, of mpkCCDcl4 cells that were treated as described in Figure 4.2.  Values are means ± 
sem, n = 6. ** represents P = <0.01. 
 
A+I-stimulated amiloride-sensitive Ieq was maintained at around double control cell level 
at 2 hours (Control: 15.5 ± 0.3 µA/cm2; A+I: 31.8 ± 0.3 µA/cm2, P = <0.001), 6 hours 
(Control: 14.2 ± 0.6 µA/cm2; A+I: 36.4 ± 1.1 µA/cm2, P = <0.001) and 24 hours (Control: 
9.2 ± 0.5 µA/cm2; A+I: 19.2 ± 1.2 µA/cm2, P = <0.001), but was completely abolished at 
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48 hours (Control: 4.3 ± 0.5 µA/cm2; A+I: 3.2 ± 0.6 µA/cm2) (Figure 4.5).  For this 
experiment, the same lot of cells was treated multiple times with amiloride at the indicated 
time points.  Amiloride was then washed off and fresh treatment medium replaced.  The 
decrease in vehicle treated control values over time suggests that the cells gradually lost 
their sodium transport capabilities under these experimental conditions.  This transport 
decrease was probably due to the cells being kept in starvation medium throughout the 
experiment, which would have a negative impact on cells due to lack of the essential 
additives in growth medium.  Alternatively, the ion transport capabilities of the cells may 
have been impacted by the repeated treatment with amiloride.  In addition, A+I-stimulated 
amiloride-sensitive Ieq was maintained to at least 24 hours and was maximal at 6 hours 
(Figure 4.5).  These data parallel results in chapter 3, which showed aldosterone-induced 
Sgk1 expression peak at 6 hours and maintained for 24 hours (Figure 3.7). 
 
 
Figure 4.5  Aldosterone plus insulin-stimulated ENaC-mediated Ieq is maintained for 
at least 24 hours and is maximal at 6 hours.  Amiloride-sensitive Ieq calculated from the 
difference between Ieq values before and after 1 µM amiloride treatment of mpkCCDcl4 
cells grown on permeable membrane supports that were starved for 24 hours then treated 
with vehicle control (Ctrl) or aldosterone plus insulin (A+I).  Values are means ± sem, n = 
3. *** represents P = <0.001. 
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4.2.2 LY294002 reduces aldosterone and aldosterone plus insulin -stimulated 
sodium transport 
The response of mpkCCDcl4 cells to aldosterone and insulin has previously been shown to 
be sensitive to the phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin 
(mTOR) inhibitor LY294002 (Wang et al., 2008; Flores et al., 2005; Wang et al., 2001).  
To extend information for the time-dependent effects of PI3K and mTOR-dependent Ieq 
stimulation, the effect of LY294002 on A+I-stimulated amiloride-sensitive Ieq was 
investigated.  Cells were pre-treated with 10 µM LY294002 or vehicle control for 30 min 
before treatment with A+I or vehicle control. Ieq was then measured hourly to 7 hours.  At 
7 hours, 1 µM amiloride was added to cells for 30 min then finally measured to calculate 
the amiloride-sensitive Ieq. 
A+I-stimulated Ieq was significantly greater than control and LY294002-treated cells from 
1 hour (P = <0.01) (Figure 4.6).  LY294002 treatment caused the overall A+I response to 





Figure 4.6  LY294002 causes a lesser magnitude Ieq response to aldosterone plus 
insulin. Ieq of polarised mpkCCDcl4 cells grown on permeable membrane supports that 
were starved for 24 hours then pre-treated with vehicle control or 10 µM LY294002 for 30 
min.  Cells were then treated for 7 hours with vehicle control (Control) or aldosterone + 
insulin (A+I).  After 7 hours of hourly measurement, cells were treated with 1 µM 
amiloride to assess ENaC-mediated Ieq. Values are means ± sem, n = 6. 
 
The partial inhibition of A+I-stimulated Ieq by LY294002 was also observed in the 
amiloride-sensitive Ieq of aldosterone treated cells.  LY294002 caused a significant drop in 
aldosterone-stimulated amiloride-sensitive Ieq at 7 hours (Aldo: 20.2 ± 1.0 µA/cm2; Aldo + 
LY: 9.4 ± 0.9 µA/cm2, P = <0.001) (Figure 4.7).  This was also observed in A+I treated 
cells (A+I: 22.1 ± 2.9 µA/cm2; A+I + LY: 12.6 ± 0.7 µA/cm2, P = <0.001).  As a result of 
this partial inhibition by LY294002, only A+I treated cells, and not aldosterone treated 
cells, showed significantly increased amiloride-sensitive Ieq above control cells at 7 hours 
(Ctrl + LY: 2.3 ± 1.4 µA/cm2, P = <0.01).  These data parallel the Western blot data in 
chapter 3 that showed partial inhibition of aldosterone and aldosterone plus insulin-




Figure 4.7  LY294002 causes a significant decrease in aldosterone and aldosterone 
plus insulin-stimulated ENaC-mediated Ieq at 7 hours.  Amiloride-sensitive Ieq 
calculated from the difference between Ieq values before and after 1 µM amiloride 
treatment of mpkCCDcl4 cells grown on permeable membrane supports.  Cells were starved 
for 24 hours then pre-treated with vehicle or 10 µM LY294002 before treatment with 
vehicle control (Ctrl), aldosterone (Aldo), insulin (Ins) or aldosterone + insulin (A+I).  
Values are means ± sem, n = 6.  ** and *** represent P values of <0.01 and <0.001. 
 
4.2.3 Rapamycin reduces aldosterone plus insulin-stimulated sodium transport 
Mechanistic target of rapamycin (mTOR) has been identified as a key activator of SGK1 
and therefore of ENaC.  There is, however, conflicting evidence that suggests either 
functional complex of mTOR (mTORC1 or mTORC2) may be responsible for 
phosphorylation of SGK1 (Garcia-Martinez and Alessi, 2008b; Hong et al., 2008).  
Rapamycin is considered a selective inhibitor of mTORC1 (Loewith et al., 2002), but 
Sarbassov et al. (2006) showed that prolonged rapamycin treatment also inhibits mTORC2 
(Sarbassov et al., 2006).  Others also suggest that rapamycin may not completely inhibit 
mTORC1 activities (Thoreen et al., 2009; Thoreen and Sabatini, 2009).  In an attempt to 
assess the dependence of aldosterone plus insulin-stimulated Ieq on mTOR, the equivalent 
short circuit current assay was repeated in the presence and absence of 20 nM rapamycin.  
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This concentration of rapamycin specifically inhibits mTORC1, whereas exposure to 100 
nM rapamycin only inhibited formation of mTORC2 after 24 hours (Sarbassov et al., 2006; 
Sarbassov et al., 2004).  Cells were pre-treated for 1 hour with 20 nM rapamycin or vehicle 
control, and then treated with aldosterone plus insulin at 0 hours. 
As expected, A+I-stimulated Ieq was significantly above control cells from 1 hour (Figure 
4.8).  Rapamycin treatment caused the overall A+I response to decrease.  This meant that 
A+I-stimulated Ieq was only significantly above control from 2 hours (P = <0.001), 
compared to 1 hour without rapamycin (P = <0.01).  Rapamycin also significantly reduced 
the peak A+I-stimulated Ieq at 6 hours (A+I: 74.6 ± 3.8 µA/cm2; A+I + Rapa: 59.3 ± 3.0 
µA/cm2, P = <0.001).  This significant, but small inhibition of A+I-stimulated Ieq by 
rapamycin, suggests that mTORC1 plays a small role in A+I-stimulated sodium transport. 
 
 
Figure 4.8  Rapamycin lowers the transepithelial equivalent short circuit current 
response to aldosterone plus insulin.  mpkCCDcl4 cell monolayers were treated with 20 
nM rapamycin (Rapa) or vehicle for 1 hour prior to treatment with aldosterone plus insulin 
(A+I) or vehicle (Control) at 0 hours.  Hourly measurements of Rte and Vte were taken, 
which were then used to calculate Ieq.  At 6 hours, cells were treated with 1 µM amiloride 
to calculate amiloride-sensitive Ieq.  Values are means ± sem, n = 9. 
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A+I-stimulated amiloride-sensitive Ieq was significantly greater than control cells at 6 
hours, both in the presence and absence of rapamycin (A+I + Rapamycin: 32.4 ± 0.8 
µA/cm2; Control + Rapamycin: 13.5 ± 1.6 µA/cm2, P = <0.001) (A+I: 39.1 ± 1.9 µA/cm2; 
Control: 13.5 ± 1.4 µA/cm2, P = <0.001) (Figure 4.9).  However, rapamycin caused a 
significant reduction in A+I-stimulated amiloride-sensitive Ieq compared to A+I treatment 
alone (P = <0.05).  This shows that the inhibition of Ieq by rapamycin was partially due to 
inhibition of amiloride-sensitive Ieq and suggests that A+I-stimulated, ENaC-mediated Na+ 
transport is partially dependent on mTORC1. 
 
 
Figure 4.9  Rapamycin significantly reduced aldosterone plus insulin-stimulated 
ENaC-mediated Ieq at 6 hours.  Amiloride-sensitive or ENaC-mediated Ieq displayed by 
the control and A+I-treated mpkCCDcl4 cell monolayers in the experiment described in 




4.2.4 Effect of overexpressing individual mouse Sgk1 isoforms a-d on ENaC-
mediated sodium transport 
To this point, the data in this study suggests all Sgk1 isoforms have the potential to 
regulate ENaC-mediated sodium transport.  However, the functional specialisations of each 
isoform in regulation of ENaC required further investigation.  In order to identify the effect 
of each isoform on ENaC-mediated Na+ transport required mpkCCDcl4 cells that only 
express one Sgk1 isoform.  In order to achieve this, each Sgk1 isoform was overexpressed 
in mpkCCDcl4 cells by transient transfection coupled with siRNA knockdown of 
endogenous Sgk1 isoforms.  This section focuses on assessing the effect of overexpressing 
individual Sgk1 isoforms on sodium transport. 
Two approaches were used in an attempt to transfect mpkCCDcl4 cells for use on 
permeable membrane supports.  The first approach used Lipofectamine 2000 transfection 
reagent following the manufacturer’s protocol for cells grown on a 24-well plate, but 
applied the transfection mix onto the upper (apical) side of cells seeded on permeable 
membrane supports.  In an attempt to optimise this protocol, cells were seeded for 2 and 6 
days prior to transfection.  The Ieq was then calculated for mpkCCDcl4 cells that were 
transfected after 2 and 6 days of growth (Figure 4.10).  Once cells had been seeded for the 
appropriate amount of time, resistance and potential difference of the monolayer was 
measured before transfection mix was applied (time point -6 h).  The transfection mix was 
incubated on the cells for 6 hours, then monolayer measurements were taken again before 
the growth medium was replaced (time point 0 h).  Measurements were then taken every 6 
hours to assess the stability of the cell monolayer, with growth medium being replaced 
again after 2 days.  Cells were transfected with either human FLAG tagged SGK1a 
(HsSGK1aFLAG), a kinase-dead mutant of the human SGK1a (HsSGK1akdFLAG), a 
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control vector (Vector), or with DNA absent (Untransfected).  Human constructs were used 
because mouse constructs were unavailable at the time. 
After 2 days of growth, mpkCCDcl4 cell monolayers displayed negligible Ieq, which was 
unaltered by exposure of the cells to transfection solution for 6 hours (Ieq = ~2 µA/cm2 at -
6 hours and ~3 µA/cm2 at 0 hours) (Figure 4.10A).  This negligible Ieq showed that the 
cells had yet to form a polarised monolayer.  At 0 hours, cells were given fresh growth 
medium and, subsequently, Ieq immediately increased by ~5 µA/cm2 from 0 to 6 hours.  
This increase continued, but gradually slowed, stabilising at ~10 µA/cm2 at ~24 hours.  The 
Ieq remained stabilised up to 42 hours, when cells were again given fresh growth medium.  
This caused another rapid increase in Ieq, reaching the peak Ieq of ~28 µA/cm2 at 54 hours, 
but, from that point, Ieq steadily decreased in a time-dependent manner to ~15 µA/cm2 at 
90 hours, when cells were treated with 1µM amiloride.  Treatment with amiloride revealed 
that all cells showed an ENaC-mediated Ieq of ~10 µA/cm2 at 90 hours, post-transfection. 
In contrast to the cells transfected after 2 days, the initial Ieq of cells grown for 6 days, prior 
to transfection, was at a basal level of ~10 µA/cm2 (Figure 4.10B).  This higher value was 
probably due to the additional time the cell monolayers were allowed to polarise and form 
stabilised resistance.  As with the cells transfected after 2 days, transfection had a 
negligible effect on Ieq, which remained at ~10 µA/cm2 after 6 hours exposure of the cells 
to transfection solution.  The cells were given fresh growth medium at 6 hours and, which 
stimulated a rapid increase in Ieq to between 30 and 40 µA/cm2 at 18 hours.  This time point 
showed the greatest variation in Ieq between cells of the different transfections suggesting 
an effect of transfection, but with no significant difference.  The cells then regained very 
similar values causing the variation to disappear and the Ieq of all cells to rapidly decrease 
in a time-dependent manner.  This decrease in Ieq continued until cells were given fresh 
growth medium at 42 hours.  This caused another rapid increase in Ieq to a peak of ~50 
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µA/cm2 at 54 hours, the same time-point that 2-day cells peaked at.  From this point, Ieq of 
all cells decreased in a time-dependent manner reaching between 0-10 µA/cm2 at 90 hours.  
At 90 hours, Ieq was so low that amiloride treatment had little effect and revealed no 
significant differences. 
Collectively, these data show that, whilst cells transfected in this way did demonstrate 
growth medium-stimulated Ieq, cells transfected with Sgk1 failed to show any significant 
deviation from control Ieq, suggesting that transfection was unsuccessful.  To test whether 
cells were overexpressing any SGK1 protein, cells were lysed after the experiment prior to 
Western blotting to investigate SGK1 protein expression.  The test Western blot showed no 
difference between overexpressed SGK1 and control lanes (Figure 4.10C), it was therefore 




Figure 4.10  Transepithelial equivalent short circuit current failed to stabilise after 
transfection of mpkCCDcl4 cell monolayers.  A shows Ieq of unpolarised (seeded 2 days) 
mpkCCDcl4 cells transfected on permeable filter supports.  B shows Ieq of polarised (seeded 
6 days) mpkCCDcl4 cells transfected on permeable filter supports.  Cells were given fresh 
growth medium at 0 and 42 hours.  C shows a Western blot to detect Sgk1 protein 
expression in the cell lysates produced.  Values are means ± sem, n = 3. 
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The second transfection protocol was adapted from a method previously described by 
Hallows et al. (2009), which used Lipofectamine 2000 to transfect mpkCCDcl4 cells with 
siRNA for use on permeable membrane supports (Hallows et al., 2009).  This method 
involved transfecting cells while seeded on plastic.  These cells were then incubated for 24 
hours to allow vector protein expression prior to cells being detached using trypsin, and re-
seeded onto permeable filter supports.  This allowed the transfected cells to attach to the 
permeable membrane and generate a cell monolayer for use in the Ieq assay.  The method 
was adapted for use with plasmid DNA according to the Lipofectamine 2000 handbook.  
Once re-seeded, cell monolayer resistance was monitored and culture medium changed 
every 2 days until stable resistance of >3 kΩ was achieved after ~6 days.  Once stable, 
monolayers were starved for 24 hours prior to hormone/vehicle treatment and hourly 
resistance and potential difference measurement.  Monolayers did not show any significant 
differences in Ieq between vector and Sgk1 transfected cells before starvation. 
A+I treatment failed to induce any significant amiloride-sensitive Ieq above that of vehicle 
control at 6 hours, suggesting that the cells had lost their responsiveness to aldosterone 
plus insulin (Figure 4.11A).  Treatment with A+I should have stimulated a maximal 
increase in amiloride-sensitive Ieq of at least double that of vehicle control cells such as 
seen in Figure 4.5.  To test whether the A+I treatment had stimulated Sgk1 protein 
expression, cells were lysed and analysed by Western blotting.  A+I treatment had 
stimulated expression of Sgk1 isoforms as expected, but the Sgk1d (~59 kDa) band did not 
show any elevation in transfected cells compared to control cells (Figure 4.11B).  This 
suggested that: either the transfection was unsuccessful, or that overexpression had 
subsided during the cell treatment process after transfection.  This experiment was then 
repeated using Sgk1a instead of Sgk1d, to see if switching isoforms made any difference to 
the outcome (Figure 4.12). 
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Figure 4.11  Transiently transfected and then re-seeded mpkCCDcl4 cell monolayers 
failed to show both aldosterone plus insulin-stimulated ENaC-mediated equivalent 
short circuit current and Sgk1d overexpression.  mpkCCDcl4 cells seeded on plastic 
were transiently transfected with Sgk1d or vector control using Lipofectamine 2000 
transfection reagent.  Cells were then re-seeded onto permeable filter supports and grown 
until transepithelial resistance stabilised at ≥3 kΩ.  Polarised monolayers were incubated 
with starvation medium for 24 hours then given 10 nM aldosterone plus 1 µM insulin.  
Hourly Rte and Vte measurements were taken to calculate Ieq until application of 1 µM at 6 
hours.  A shows the amiloride-sensitive Ieq at 6 hours.  After amiloride treatment cells were 
lysed and SGK1 expression analysed by Western blotting.  B shows the SGK1 protein 
expression of the mpkCCDcl4 cells monolayers following treatments.  SGK1 isoform 
bands are indicated by arrows.  Values are means ± sem, n = 3. 
 
Results derived were similar to those from the experiment using Sgk1d, with no significant 
stimulation of amiloride-sensitive Ieq by A+I treatment and no variation between vector 
control and Sgk1a transfected cells.  For this experiment, however, cells failed to show any 
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induction of Sgk1 expression caused by either transfection or treatment with A+I (Figure 
4.12B).  This suggested that maybe it was the entire treatment process of transfection, 
trypsinisation, re-seeding and starvation that led cells to be non-responsive.  This 
experiment was then repeated again, including cells for which no DNA was added to the 
transfection, to test whether the presence of foreign DNA was causing the lack of A+I 
stimulation (Figure 4.13). 
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Figure 4.12  Transiently transfected and then re-seeded mpkCCDcl4 cell monolayers 
failed to show aldosterone plus insulin-stimulated ENaC-mediated equivalent short 
circuit current, Sgk1a overexpression, and induction of Sgk1 expression.  Cells were 
treated identically as described in Figure 4.11, except using Sgk1a.  A shows the ENaC-
mediated Ieq at 6 hours.  B shows the SGK1 expression in mpkCCDcl4 cell monolayers 
following current measurement.  Values are means ± sem, n = 3. 
 
For this experiment alone, transfection with Sgk1a enabled A+I treated cells to show an 
amiloride-sensitive Ieq that was significantly greater than the respective control (Sgk1a 
A+I: 10.1 ± 0.6 µA/cm2; Ctrl: 7.8 ± 0.3 µA/cm2, P = <0.05) (Figure 4.13A).  A+I-
stimulated amiloride-sensitive Ieq, although significant, was still far below expectations 
based on previous results (Figure 4.1D).  The small induction of amiloride-sensitive Ieq was 
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paralleled by little or no visible difference between treatments upon examination of Sgk1 
expression by Western blotting (Figure 4.13B).  This further suggests that cells subjected 
to this transfection protocol become unresponsive to A+I treatment, as evidenced by both 
the amiloride-sensitive Ieq and Sgk1 expression data. 
 
 
Figure 4.13  Untransfected control cells also failed to show aldosterone plus insulin-
stimulated ENaC-mediated equivalent short circuit current and induction of Sgk1 
expression.  Cells were treated identically as described in Figure 4.12, except including a 
No DNA control.  A shows the amiloride-sensitive Ieq at 6 hours.  B shows the SGK1 
expression in mpkCCDcl4 cell monolayers following current measurement.  Values are 
means ± sem, n = 3. * represents P = <0.05. 
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4.2.5 Effect of Sgk1 knockdown using siRNA on transepithelial amiloride-
sensitive equivalent short circuit current 
A second approach to investigate the functional specialisations of each isoform in 
regulation of ENaC involved siRNA knockdown of endogenous Sgk1 isoforms.  
mpkCCDcl4 cells were transfected with siRNA targeted against Sgk1 to produce 
knockdown of endogenous Sgk1 expression in order to determine its role in A+I-
stimulated amiloride-sensitive Ieq.  For these experiments, the transfection protocol 
described by Hallows et al. (2009) was employed for transfection of mpkCCDcl4 cells with 
siRNA using Lipofectamine 2000 (Hallows et al., 2009).  Commercially available pan-
SGK1 specific and scrambled control siRNA were used.  The amiloride-sensitive Ieq was 
calculated for cells that were transiently transfected with either Sgk1 siRNA or scrambled 
control siRNA and treated with vehicle or A+I (Figure 4.14).  The first attempt at this 
experiment showed significantly reduced A+I-stimulated amiloride-sensitive Ieq in cells 
transfected with Sgk1 siRNA compared to cells transfected with scrambled siRNA (Figure 
4.14A).  However, this result was not repeatable in the second attempt (Figure 4.14B).  An 
additional experiment was then conducted, where untransfected cells and no siRNA 
transfected cells were included as additional controls.  The results of this experiment 
indicated that it was the re-seeding procedure that removed the ability of mpkCCDcl4 cell 




Figure 4.14  mpkCCDcl4 cells that were transiently transfected with SGK1 siRNA 
failed to show aldosterone plus insulin-stimulated ENaC-mediated equivalent short 
circuit current.  Cells that were seeded on plastic were transfected with scrambled control 
siRNA (Scr), Sgk1 siRNA (Sgk1) or siRNA buffer only (No siRNA) plus control 
untransfected cells.  Following 24 hours growth to allow plasmid expression, cells were re-
seeded onto permeable filter supports and grown until monolayers displayed stabilised 
transepithelial resistance of >3 kΩ.  Monolayers were incubated with starvation medium 
for 24 hours prior to treatment with 10 nM aldosterone plus 1 µM insulin (A+I) or vehicle 
(Ctrl).  After 6 hours of Ieq measurement, cells were given 1 µM amiloride in order to 
calculate ENaC-mediated current.  A and B show ENaC-mediated Ieq of two separate 
experiments, for each n = 3.  C shows ENaC-mediated Ieq for experiments including all 
controls, n = 9.  D shows a representative Western blot of cell lysates from cells lysates 
after the experiment described in C.  Sgk1 expression is detected using anti-SGK1 




4.3.1 Aldosterone and insulin stimulate amiloride-sensitive equivalent short 
circuit current 
Whilst similar data showing stimulation of sodium current in renal cortical collecting duct 
cells by aldosterone, insulin and combined aldosterone plus insulin has been reported in 
several previous studies (de Seigneux et al., 2008; Wang et al., 2008; Michlig et al., 2004; 
Auberson et al., 2003; Summa et al., 2001; Bens et al., 1999), it was important to ensure 
that the cells used in this study retained their responsiveness to these agents.  Results 
obtained support those described in Bens et al. (1999), which showed starved mpkCCDcl4 
cell monolayers exhibited aldosterone-stimulated Ieq in a dose- and time-dependent 
manner.  Further results from the study by Bens et al. (1999) showed that 10 nM 
aldosterone significantly increased Ieq above control cells at 2 hours, which increased to the 
maximum Ieq (four-fold above control cells) at 6 hours, and was maintained up to 8 hours.  
Data derived from the present study furthered the study by Bens et al. (1999) by 
demonstrating the effect of insulin and aldosterone plus insulin treatments, such as seen in 
Wang et al. (2008), and extending the experiment duration to 48 hours.  Data discussed in 
this chapter which show changes in ENaC-mediated Ieq at 2, 6, 24, and 48 hours exposure 
to aldosterone also expand on existing data.  The Ieq response to insulin observed in this 
study was comparable to a rapid, but short-lived insulin-stimulated increase in Ieq described 
for A6 cells, which similarly peaked after 1 hour, but then subsided (Markadieu et al., 
2004).  A6 and mpkCCDcl4 cells showed great similarity in Ieq insulin dose-response 
curves, linking the study of A6 cells to the present data (Nofziger et al., 2005).  In A6-S2 
cells (an A6 clone that is responsive to aldosterone), similar data showing aldosterone and 
aldosterone plus insulin stimulation of Ieq was further increased by transfection with wild-
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type or a constitutively active mutant SGK1, but was not increased by transfection with a 
constitutively inactive mutant SGK1 (Alvarez de la Rosa and Canessa, 2003).  Naray-
Fejes-Toth et al (2004) showed that transfection of primary cultures of rabbit CCD cells 
with SGK1 antisense oligonucleotides removed a 3-3.5-fold increase in Ieq that was 
stimulated by 10 nM aldosterone after 24 hours starvation (Naray-Fejes-Toth et al., 2004a).  
Aldosterone also significantly increased SGK1 mRNA abundance in microselected 
connecting tubules/cortical collecting ducts compared to untreated tissue (Fakitsas et al., 
2007).  Collectively, these data suggest that the stimulation of ENaC-mediated Ieq in mouse 
cortical collecting duct cells by aldosterone and insulin is mediated by Sgk1. 
In related Western blotting data, aldosterone induced Sgk1a, b, and c expression as soon as 
1 hour and maximally induced all isoforms at 6 hours, which was maintained for 24 hours 
(Figure 3.7).  Insulin failed to induce Sgk1 expression at 24 hours, whereas aldosterone 
and aldosterone plus insulin differentially induced Sgk1 isoforms (Figure 3.13).  These 
Western blot data, considered with the data discussed above, suggest that aldosterone and 
aldosterone plus insulin may stimulate ENaC-mediated Na+ transport through increasing 
expression of Sgk1a, b, and c. 
Throughout this chapter, data demonstrate a highly variable basal level of Ieq after 24 hours 
starvation, ranging between ~10-35 µA/cm2, suggesting that, although cells were allowed 
to stabilise and form similar resistance before starvation, their transport properties varied 
between experiments.  This variation was also evident, although to a lesser extent, with the 
basal level of amiloride-sensitive Ieq, which ranged between ~4-14 µA/cm2.  Western 
blotting results in chapter 3 showed that only mouse Sgk1d expression was detectable in 
serum and hormone-starved mpkCCDcl4 cells, suggesting that this isoform may be 
responsible for the basal Ieq (Figures 3.6, 3.7, and 3.13).  Although data in the present study 
showed consistent amiloride-insensitive Ieq of ~30%, the study by Bens et al. (1999) 
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showed that increasing amiloride concentration to 10 µM reduced amiloride-insensitive Ieq 
to ~10%.  This suggests that 1 µM amiloride may be unsuitable to completely block ENaC, 
but may also indicate a role of other 10 µM amiloride-sensitive channels in aldosterone-
stimulated Ieq.  The remaining ~10% of Ieq that is 10 µM amiloride-insensitive was 
probably due to non-ENaC-mediated Na+ transport or transport of other ions such as Cl- 
(Van Huyen et al., 2001). 
These findings could have significant implications for other investigations involving 
SGK1, particular where studies do not take into consideration the existence of more than 
one SGK1 isoform.  This could also have implications for the use of clinical SGK1 
inhibitors, particularly for aldosterone-sensitive therapies, as inhibitors may not be 
effective against all SGK1 isoforms (Lang and Gorlach, 2010).  Furthermore, different 
aldosterone-sensitive SGK1 isoforms may also be linked or associated with the 
development of hypertension or other conditions through their mutation or dysregulation. 
 
4.3.2 Sensitivity of aldosterone and insulin-stimulated ENaC-mediated sodium 
transport to inhibition of activators of SGK1 
Exposing cells to LY294002 and rapamycin reduced the response to aldosterone plus 
insulin in mpkCCDcl4 cells.  Both of these agents also caused aldosterone plus insulin-
stimulated ENaC-mediated Na+ transport to be significantly lower after 6 hours (sections 
4.2.2 and 4.2.3).  LY294002 had similar effects on the Ieq and ENaC-mediated Ieq 
responses to aldosterone alone and also abolished the short-term response to insulin. This 
pattern of inhibition suggests stimulation of Ieq by aldosterone, insulin, or aldosterone plus 
insulin is partially mediated by the PI3K/mTOR pathway and mTORC1.  This supports the 
generally accepted hypothesis that aldosterone and insulin stimulate ENaC-mediated Na+ 
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transport via PI3K and SGK1 (Lee et al., 2008).  In support of the data in section 4.2.2, 
previous publications have also shown that LY294002 inhibits aldosterone and insulin-
stimulated Ieq in A6 (Wang et al., 2001; Record et al., 1996) and mpkCCDcl4 cells (Wang et 
al., 2008; Flores et al., 2005).  These studies, however, did not include identification of 
individually upregulated and inhibited SGK1 isoforms.  LY294002 has been shown to 
inhibit both PI3K and mTOR kinase activities at similar concentrations (Brunn et al., 
1996), suggesting that the effect seen is perhaps due to inhibition of mTOR rather than 
PI3K.  However, use of PIK-90, an inhibitor of the p110-α subunit of PI3K that does not 
inhibit mTOR had an identical effect to LY294002 on aldosterone, insulin and aldosterone 
plus insulin stimulated Ieq (Wang et al., 2008), therefore demonstrating that PI3K is a key 
mediator of aldosterone and aldosterone plus insulin stimulation of Ieq.  This may be 
redundant, as mTOR is part of the PI3K pathway (Liu et al., 2009). 
Phosphorylation and activation of SGK1 has been shown to be elicited by 3-
phosphoinositide-dependent protein kinase-1 (PDPK1) at the T-loop (threonine 256) and 
by mTOR at the hydrophobic motif (serine 422) (Garcia-Martinez and Alessi, 2008b; Mora 
et al., 2004).  mTOR is present in cells in two different active complexes; mTORC1 and 
mTORC2, which have both been implicated in activation of SGK1 (Garcia-Martinez and 
Alessi, 2008b; Hong et al., 2008).  It has recently been shown that mTORC2, rather than 
mTORC1, phosphorylates serine 422 of SGK1 (Dowling et al., 2010; Alessi et al., 2009; 
Garcia-Martinez et al., 2009; Yan et al., 2008), however, data in the present study suggests 
that regulation of ENaC-mediated sodium transport is still partially dependent on the 
rapamycin-sensitive mTORC1.  However, the actions of mTORC1 cannot be completely 
ruled out in the presence of rapamycin as some of its functions have been shown to be 
rapamycin-insensitive (Foster and Fingar, 2010).  In conflict with the present data, Lu et al. 
(2010) showed 0.1 µM rapamycin had no effect on 1 µM aldosterone plus 100 nM insulin-
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stimulated Ieq in mpkCCDcl4 cells (Lu et al., 2010).  This is probably due to the much 
higher concentration of aldosterone used in Lu et al. (2010) compared to the 10 nM 
aldosterone used in this study.  Aldosterone binds to the mineralocorticoid receptor (MR) 
with a Kd of 0.6 nM and the glucocorticoid receptor (GR) with a Kd of 85 nM (Gaeggeler et 
al., 2005), therefore, treatment with 1 µM aldosterone would cause stimulation of Ieq 
through a GR-independent pathway. 
Related Western blot data in section 3.2.10 showed that LY294002 partially inhibits 
aldosterone and aldosterone plus insulin-stimulated Sgk1a, b, and c expression.  These 
findings support the hypothesis that PI3K/mTOR-dependent expression of Sgk1a, b, and c 
may be involved in mediating aldosterone and aldosterone plus insulin-stimulated ENaC-
mediated Na+ transport, however, this is not explained by the current pathway hypothesis.  
These findings extend upon the current knowledge of Sgk1 isoforms and their regulation 
by the PI3K and mTOR pathway.  Increased knowledge about the effects and dependencies 
of the individual isoforms may therefore lead to the identification of novel therapeutic 
targets for treatment of hypertension or other SGK1 linked conditions. 
 
4.3.3 Overexpression and knockdown of Sgk1 in mpkCCDcl4 cells grown on 
permeable filter supports 
Two different protocols were used in the present study in an attempt to achieve 
overexpression of Sgk1 isoforms in mpkCCDcl4 cells grown on permeable filter supports.  
The first protocol was adapted for cells grown on permeable filter supports from the 
protocol used when transfecting cells grown on plastic.  This protocol was tested on cells 
grown for 2 days and 6 days, but, in both cases, failed to modulate aldosterone plus 
insulin-stimulated Ieq or produce Sgk1 isoform overexpression.  The second protocol, 
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previously described by Hallows et al. (2009) to show successful transfection of 
mpkCCDcl4 cells grown on permeable filter supports, also failed to produce cells that 
showed modulated aldosterone plus insulin-stimulated Ieq or Sgk1 overexpression.  
Furthermore, the protocol of Hallows et al. (2009) also failed to produce reduced 
aldosterone plus insulin-stimulated Ieq or knockdown of endogenous Sgk1 when used with 
pan-Sgk1 siRNA.  This repeated failure to show Sgk1 overexpression, or effect of siRNA 
by transient transfection, suggests that either the protocol was unsuitable, that the plasmid 
or siRNA expression had subsided by the time of detection, or that the methods of 
detection were unsuitable.  Data derived by the present study and by Hallows et al. (2009) 
suggest that the protocols were suitable for transient transfection.  The methods of 
detection were also suitable, as both effects on Ieq and Sgk1 expression were tested for.  
Alternatively, since it was necessary to grow the cells on the permeable filter supports for 
several days after transfection in order to allow a polarised monolayer to form, transient 
overexpression could have subsided within this time period. 
Several studies have nevertheless shown the effects of overexpressing certain human or 
mouse SGK1 isoforms on ENaC-mediated sodium transport.  Arteaga et al. (2007) showed 
that inducing overexpression of wild-type 49 kDa or constitutively active mutants of 49 or 
42 kDa isoforms of Sgk1 in A6 cells caused increased amiloride-sensitive Ieq, suggesting 
that only the full-length, 49 kDa isoform of Sgk1a is able to induce ENaC activity in vivo 
(Arteaga et al., 2007).  Studies using Xenopus oocytes showed that coexpression of ENaC 
with human SGK1A increased sodium uptake, but coexpression of ENaC with human 
SGK1D did not (Arteaga et al., 2008; Chen et al., 1999).  Arteaga et al (2008) showed that 
mouse Sgk1d had a much longer half life in mouse brain tissue than mouse Sgk1a, 
consistent with data from the present study showing the presence of mouse Sgk1d in 
mpkCCDcl4 cells at a consistently higher basal level than the other mouse Sgk1 isoforms 
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(Figures 3.6, 3.7, and 3.13) (Arteaga et al., 2008).  Raikwar et al. (2008) showed enhanced 
stability and reduced susceptibility of human SGK1D to ubiquitination compared to human 
SGK1A, and increased expression of αENaC in cells transfected with either isoform. 
Under salt wasting, Sgk1-knockout mice showed impaired ability to retain renal sodium 
(Wulff et al., 2002).  Furthermore, Sgk1-knockout mice also showed resistance to high-fat 
diet-induced hypertension due to an inability to retain salt (Huang et al., 2006).  Huang et 
al. (2004) showed that an sgk1-knockout mouse had limited ability to eliminate renal K+ 
and had significantly impaired amiloride-sensitive transepithelial potential difference 
across isolated collecting ducts, suggesting that the removal of Sgk1 limits the ability of 
ENaC to transport Na+ (Huang et al., 2004).  The knockout of Sgk1 can therefore have 
significant effects on ENaC-mediated sodium transport, highlighting a need to show which 
Sgk1 isoform(s) cause(s) this effect. 
The different isoforms may well perform different roles in the regulation of ENaC-
mediated sodium transport, but further work is needed in order to show the effects of 
individual SGK1 isoforms on Na+ transport.  Stable or specific expression of single SGK1 
isoforms in cells at physiological levels would create a more in vivo-like model for study, 
but would require production of stably transfected cells.  Only a few studies have shown 
overexpression of individual SGK1 isoforms and to date none have shown their individual 
knockdown or knockout.  Future work to achieve this would allow comparison between 
human and mouse SGK1s and identification of their individual roles in regulation of 
sodium transport.  This could show the predisposition or involvement of one or more of the 




 Insulin treatment of mpkCCDcl4 cell monolayers stimulates a significant ~1.5-fold 
increase in Ieq above control Ieq by 1 hour that lasts until 2 hours. 
 Aldosterone treatment of mpkCCDcl4 cell monolayers stimulates a time-dependent 
increase in Ieq from 2 hours that continues to ~2.5-fold above control Ieq at 6 hours. 
 Aldosterone plus insulin treatment of mpkCCDcl4 cell monolayers stimulates a 
time-dependent increase in Ieq from 1 hour that continues to ~3-fold above control 
Ieq at 6 hours. 
 Insulin stimulated ENaC-mediated Na+ transport ~1.5-fold at 2 hours, but not after 
6 hours. 
 Aldosterone stimulated ENaC-mediated Na+ transport ~2-fold at 2 hours and ~2.5-
fold at 6 hours. 
 Aldosterone plus insulin stimulated ENaC-mediated Na+ transport ~2.5-fold at 2 
hours and ~3-fold at 6 hours. 
 Aldosterone plus insulin stimulated ENaC-mediated Na+ transport remained 
significantly above control for 24 hours. 
 LY294002 partially inhibits aldosterone plus insulin stimulated Ieq and ENaC-
mediated Na+ transport. 
 Rapamycin partially inhibits aldosterone plus insulin stimulated Ieq and ENaC-
mediated Na+ transport. 
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Chapter 5 - Localisation and Co-Immunoprecipitation Studies 
as Clues to Regulation of SGK1 
5.1 Introduction 
This thesis and past publications by others have shown that SGK1 is present in multiple 
isoforms in both human and mouse and that these isoforms vary in their N-termini (Figure 
3.1) (Arteaga et al., 2008; Raikwar et al., 2008; Arteaga et al., 2007; Hall, 2007; Simon et 
al., 2007).  These studies also showed that the differing N-termini confer targeted 
intracellular localisation and/or functional specificity to SGK1 isoforms.  For example, 
Raikwar et al. (2008) showed that FLAG-tagged SGK1A was expressed diffusely in the 
cytosol of HEK293 cells grown on plastic, whereas FLAG-tagged SGK1D localised to the 
plasma membrane.  Raikwar et al. (2008) also showed that SGK1D stimulated greater 
ENaC activity than SGK1A in Fisher rat thyroid (FRT) epithelial cells, when cotransfected 
with the SGK1 isoforms and αβγ-ENaC, suggesting that SGK1 needed to be targeted to the 
plasma membrane in order to alter ENaC activity (Raikwar et al., 2008).  The mouse Sgk1 
isoforms described in this thesis each have different N-termini that are unique in size and 
sequence (section 3.2.3), whereas the majority of their amino acid sequences are identical 
(77% of the largest isoform Sgk1d and 97% of the smallest isoform Sgk1c). 
The aim of this chapter was, therefore, to investigate differences in intracellular 
localisation between SGK1 isoforms, which may be due to their different N-termini and 
may impart differential regulation of ENaC.  To this aim, the subcellular localisation of 
endogenous SGK1 isoforms in native mouse and human renal collecting duct tissue was 
investigated by immunofluorescence microscopy using isoform-specific antibodies and 
fluorescent secondary antibodies.  Due to the limited success observed when using the 
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isoform-specific antibodies to detect SGK1 isoforms by Western blotting (section 3.2.11), 
the intracellular localisation of overexpressed FLAG-tagged SGK1 isoforms in transiently 
transfected HEK293T cells was also observed. 
In order to further characterise differences in function between SGK1 isoforms, a co-
immunoprecipitation assay was adapted from a study by Soundararajan et al. (2009) to 
determine the recruitment of SGK1 isoforms to glucocorticoid-induced leucine zipper 
protein 1 (GILZ1).  Phosphorylated SGK1 was shown to be recruited to a complex of 
ENaC-Raf1-Nedd4-2 by GILZ1, which produced a cooperative reduction in the inhibition 
of ENaC by MAPK/ERK and Nedd4-2 (Soundararajan et al., 2009). 
 
5.2 Results 
5.2.1 Fluorescence microscopy of SGK1D in human renal tissue 
In chapter 3, results demonstrated that only isoform-specific antibodies for SGK1B and 
SGK1D were able to detect mouse protein by Western blotting (section 3.2.11).  However, 
in immunofluorescence studies using native human and mouse renal tissue, only the 
SGK1D-specific antibody gave positive immunostaining.  This result may be because 
Sgk1d is more easily detected, due to being expressed at a higher basal level than Sgk1b in 
serum and hormone-starved cells, as shown by Western blotting in Figures 3.6, 3.7, and 
3.13. 
In order to visualise SGK1D localisation in human collecting duct epithelia, healthy human 
kidney tissue sections were co-immunostained using anti-SGK1D 3253 and anti-
aquaporin-2 (AQP2) antibodies.  AQP2 was used as a marker of renal principal cells in 
order to distinguish collecting ducts from other kidney tubules (Leng et al., 2006).  
Appropriate fluorophore-coupled secondary antibodies were used to examine the 
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immunostaining of SGK1D using Alexa Fluor 488 immunofluorescence and AQP2 by 
Alexa Fluor 568 immunofluorescence.  Nuclei were stained using Hoechst 33258 (blue), 
SGK1D staining was coloured green, and AQP2 coloured red, indicating that SGK1D 
staining is sub-apical and/or perinuclear and appears in a punctate pattern as intracellular 
accumulations in collecting duct epithelia (Figure 5.1). 
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Figure 5.1  Immunofluorescence of SGK1D sub-apical intracellular accumulations in 
human renal collecting duct epithelia.  Confocal microscopy images showing Hoechst 
33258 staining of DNA (nuclei) in blue, anti-SGK1D 3253 staining in green, and anti-
aquaporin-2 (AQP2) staining in red.  A shows low power magnification images of the 
three coloured channels, plus a merged image, of a collecting duct, identified by AQP2 
apical membrane staining, with SGK1D intracellular accumulations indicated on the green 
channel image by white arrows.  B shows higher power magnification images, of the same 
human collecting duct in A, again with SGK1D intracellular accumulations, all in the sub-
apical region of the collecting duct epithelium, indicated on the green channel image by 
white arrows.  C shows images of a no primary antibodies control section.  All human 
tissue sections are from the same source kidney. 
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In a repeat experiment, with SGK1D shown in green and AQP2 in red, SGK1D localised 
in similar intracellular accumulations within the collecting duct epithelia, but also appears 
at the cell-cell junctions (Figure 5.2).  To investigate what the intracellular punctate pattern 
of staining may represent, human tissue was co-stained for SGK1D plus markers for 
mitochondria, basal bodies, microtubules and endoplasmic reticulum, individually.  
Despite the use of the different intracellular markers, the quality of tissue staining obtained 
did not allow any definitive conclusions to be made about the identity of the SGK1D 
intracellular accumulations.  Confirmation of the cell-cell junction localisation was also 
attempted through staining for ZO-1, a marker of tight-junctions.  However, due to 
degradation of the human kidney tissue used for this staining, the result was inconclusive.  
In order to make conclusions about exactly where SGK1D localised to in the human 
collecting duct epithelia requires positive identification of the structures shown by the 
intracellular accumulations and cell-cell junction staining. 
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Figure 5.2  Immunofluorescence of SGK1D sub-apical intracellular accumulations 
and cell-cell junction localisation in human renal collecting duct epithelia.  
Microscopy images showing anti-SGK1D 3253 staining in green, and anti-aquaporin-2 
(AQP2) staining in red.  A shows low power magnification images of the two coloured 
channels, plus a merged image, of a collecting duct, identified by AQP2 apical membrane 
staining, with SGK1D intracellular accumulations indicated on the green channel image by 
white arrows and cell-cell junction staining at the boundaries between the cells.  B shows 
the same view in higher power magnification images with the same intracellular 
accumulations near the stained cell boundaries indicated as in A.  C shows images of a no 
primary antibodies control section. 
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5.2.2 Fluorescence microscopy of Sgk1d in mouse renal tissue 
The mouse and human SGK1D amino acid sequences share 93% identity, a level of 
similarity that suggests the intracellular localisation of SGK1D in collecting duct epithelia 
might be conserved between species.  To test this hypothesis, immunostaining of Sgk1d in 
mouse kidney tissue was performed in parallel with the staining of SGK1D in human 
tissue.  Mouse kidney cortex tissue dissected from healthy adult mice was prepared and 
sectioned identically to the human kidney tissue.  Sgk1d in the mouse kidney tissue was 
detected using the same anti-SGK1D 3253 antibody (Cambridge Biosciences) used with 
the human tissue, which was shown to detect mouse Sgk1d previously, by Western blotting 
(Figure 3.14).  Surprisingly, Sgk1d was found to be localised to the basolateral membrane 
of collecting ducts and was also expressed in AQP2-negative tubules (Figure 5.3).  This 
means that mouse Sgk1d in mouse collecting duct tissue shows a completely different 
localisation compared to human SGK1D in human collecting duct tissue. 
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Figure 5.3  Immunofluorescence of Sgk1d basolateral membrane localisation in 
mouse renal tubule epithelia.  Microscopy images showing anti-SGK1D 3253 staining in 
green, and anti-aquaporin-2 (AQP2) staining in red.  A and C show low power 
magnification images of multiple collecting ducts in the two coloured channels, plus a 
merged image.  Sgk1d was found to localise to the basolateral membrane of many tubules, 
indicated on the green channel image by white arrows.  B and D show the same views as A 
and C, but in higher power magnification, showing that collecting ducts and other tubules 
display basolateral Sgk1d staining indicated by white arrows. 
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5.2.3 Fluorescence microscopy of immunostained FLAG-tagged human SGK1 
isoforms in HEK293T cells 
The limitation of only being able to observe SGK1D specific staining in tissue, meant that 
the localisation of human SGK1 isoforms A, B, C and F and mouse Sgk1 isoforms a, b and 
c would have to be examined by other means.  HEK293T cells were transiently transfected 
with human FLAG-tagged SGK1 isoforms, which were then visualised by 
immunofluorescence following their detection using anti-FLAG antibodies.  To try and 
identify the specific localisation of the different SGK1 isoforms, various cellular 
compartment markers were employed, some of which were shown previously to colocalise 
with SGK1.  One such study by Cordas et al. (2007) showed that human SGK1A, tagged 
with autofluorescent fusion protein, colocalised with mitochondria in transfected rabbit 
cortical collecting tubule cell line (RCCT-28A) cells (Cordas et al., 2007).  Also, previous 
work by Hall (2007), showed colocalisation of human SGK1A, B, and D with 
mitochondria in human keratinocytes (Hall, 2007).  These studies were therefore extended 
in the present study to include mouse Sgk1 isoforms using HEK293T cells. 
HEK293T cells were co-transfected with human FLAG-tagged SGK1 isoforms and 
pDsRed-mito (BD Biosciences), which expresses a red fluorescent protein (RFP)-tagged 
target sequence of subunit 8 of human cytochrome c oxidase (COX), and is a marker of 
mitochondria.  Intracellular expression of FLAG-tagged SGK1 isoforms was detected, in 
relation to red fluorescent mitochondria, by confocal microscopy following staining using 
anti-FLAG and fluorescent secondary antibodies.  To compare images, FLAG staining was 
coloured green whilst mitochondrial fluorescence was coloured red, and nuclei, labelled 
using Hoechst 33258, were coloured blue (Figure 5.4).  Results showed that none of the 
SGK1 isoforms appeared to distinctly colocalise with mitochondria, instead, the 
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yellow/orange colouring seen in the merged images, where green and red combine, seems 
to be due to incidental overlapping of the cytosolic network-like SGK1 isoform staining 
with the mitochondria.  The images in Figure 5.4 show that human SGK1A and B were 
localised to an unidentified cytosolic network-like structure (Figure 5.4A and B), whilst 
SGK1C and D were localised diffusely in the cytoplasm (Figure 5.4C and D), and SGK1F 
showed predominantly nuclear localisation, but with some weak cytosolic network-like 




Figure 5.4  Intracellular localisation of FLAG-tagged human SGK1 isoforms A, B, C, 
D and F compared with red fluorescent protein (RFP)-labelled mitochondria in 
HEK293T cells.  A-F each show an image of nuclei staining in blue, FLAG-tagged SGK1 
isoform staining in green, and RFP-mitochondria fluorescence in red, plus a merged image 
of the three colours.  A shows cells cotransfected with FLAG-tagged SGK1A and RFP-
mitochondria.  B shows cells cotransfected with FLAG-tagged SGK1B and RFP-
mitochondria.  C shows cells cotransfected with FLAG-tagged SGK1C and RFP-
mitochondria.  D shows cells cotransfected with FLAG-tagged SGK1D and RFP-
mitochondria.  E shows cells cotransfected with FLAG-tagged SGK1F and RFP-
mitochondria.  F shows the equivalent images for untransfected control cells. 
 
HEK293T cells grown on glass coverslips were transiently transfected with FLAG-tagged 
SGK1 isoforms then fixed for immunostaining.  Intracellular expression of FLAG-tagged 
SGK1 isoforms was detected by immunofluorescence microscopy following staining using 
anti-FLAG and fluorescent secondary antibodies.  Cells were co-stained for actin 
cytoskeleton using Alexa Fluor 633 Phalloidin and nuclei using Hoechst 33258.  Anti-
FLAG staining is coloured green, whilst cytoskeleton staining is coloured red and nuclei 
staining coloured blue (Figure 5.5).  SGK1C is not shown for this experiment because the 
FLAG-tagged SGK1C-transfected cells repeatedly failed to show immunostaining.  These 
images showed that none of the SGK1 isoforms A, B, D or F colocalised with actin 
cytoskeleton, as there was little, or no, overlapping green and red staining (yellow) in any 
of the merged images.  However, this experiment did show that the different SGK1 
isoforms localise to specific regions of the cell, with SGK1A, B and D showing cytosolic 
network-like staining (Figure 5.5A-C), but also some plasma membrane staining for 
SGK1D (Figure 5.5C), and SGK1F showing predominantly nuclear with some weak 




Figure 5.5  Subcellular localisation of FLAG-tagged human SGK1 isoforms A, B, D 
and F compared with phalloidin-stained actin cytoskeleton in HEK293T cells.  A-E 
show images in the same colours and layout as shown in Figure 5.4, but with phalloidin-
stained actin cytoskeleton in red.  A shows cells transfected with SGK1A.  B shows cells 
transfected with SGK1B.  C shows cells transfected with SGK1D.  D shows cells 
transfected with SGK1F.  E shows the equivalent images for untransfected control cells. 
 
Previous studies by Bogusz et al. (2006) and Arteaga et al. (2006) showed that green 
fluorescent protein (GFP)-tagged Sgk1a and hemagglutinin (HA)-tagged Sgk1a colocalised 
with the endoplasmic reticulum (ER) in COS7 cells, using an anti-calnexin antibody 
(Arteaga et al., 2006; Bogusz et al., 2006).  To further investigate the possibility of this 
localisation for any of the SGK1 isoforms, transfected HEK293T cells were co-stained for 
FLAG-tagged SGK1 isoforms and the ER marker calnexin.  FLAG-tagged SGK1 isoform 
staining is shown in green, calnexin staining of ER in red, and nuclei stained with Hoechst 
33258 in blue, with results demonstrating that none of the SGK1 isoforms distinctly 
colocalised with the ER (Figure 5.6).  As with the previous imaging data, the incidental 
overlap of green and red staining produced yellow/orange regions in some of the merged 
images.  Isoform localisations were similar to those shown in Figure 5.5 and Figure 5.4, 
with SGK1A and SGK1B showing cytosolic network-like localisation (Figure 5.6A & B). 
SGK1D was an exception, showing ruffle-like plasma membrane staining in some cells 
and unidentified specks on other cells (Figure 5.6C).  SGK1F showed predominantly 





Figure 5.6  Subcellular localisation of FLAG-tagged human SGK1 isoforms A, B, C, 
D and F compared with calnexin in HEK293T cells.  A-E show images in the same 
colours and layout as shown in Figure 5.4, but with calnexin (endoplasmic reticulum) 
staining in red.  A shows cells transfected with SGK1A.  B shows cells transfected with 
SGK1B.  C shows cells transfected with SGK1D.  D shows cells transfected with SGK1F.  
E shows the equivalent images for untransfected control cells. 
 
5.2.4 Fluorescence microscopy of immunostained FLAG-tagged mouse Sgk1 
isoforms in HEK293T cells 
To investigate the localisation of mouse Sgk1 isoforms a, b, c and d, similar experiments to 
those for human SGK1 isoform localisation were performed.  This also allowed a direct 
comparison of the mouse Sgk1 and human SGK1 isoform localisations to see if any 
differences occurred as a result of amino acid sequence variation between the species.  
HEK293T cells were cotransfected with FLAG-tagged Sgk1 isoforms and pDsRed-mito to 
test for colocalisation of the mouse Sgk1 isoforms with mitochondria.  Mouse FLAG-
tagged Sgk1 isoform staining is shown in green, mitochondria in red, and nuclei in blue 
(Figure 5.7).  Mouse Sgk1 isoforms showed no distinct colocalisation with mitochondria.  
The yellow/orange colouring in the merged images for isoforms a, c and d was, most 
likely, due to incidental overlap of the diffuse/plasma membrane isoform staining and the 
red mitochondria.  However, this experiment did show a specific staining pattern for each 
of the four isoforms.  Mouse Sgk1a showed cytosolic network-like localisation (Figure 
5.7A), whereas Sgk1b showed predominantly nuclear with some cytosolic network-like 
localisation (Figure 5.7B).  Sgk1c showed was diffuse throughout the cell (Figure 5.7C), 
whilst Sgk1d showed predominantly plasma membrane localisation, but also weaker 




Figure 5.7  Intracellular localisation of FLAG-tagged mouse Sgk1 isoforms a, b, c, 
and d compared with red fluorescent protein (RFP)-labelled mitochondria in 
HEK293T cells.  A-E show images in the same colours and layout as shown in Figure 5.4.  
A shows cells cotransfected with FLAG-tagged Sgk1a and RFP-mitochondria.  B shows 
cells cotransfected with FLAG-tagged Sgk1b and RFP-mitochondria.  C shows cells 
cotransfected with FLAG-tagged Sgk1c and RFP-mitochondria.  D shows cells 
cotransfected with FLAG-tagged Sgk1d and RFP-mitochondria.  E shows the equivalent 
images for untransfected control cells. 
 
These experiments were subsequently repeated with the ER marker calnexin.  FLAG-
tagged Sgk1 staining is indicated in green, calnexin staining in red, and nuclei in blue 
(Figure 5.8).  Again, no distinct colocalisation was revealed for any Sgk1 isoforms with 
calnexin.  Sgk1 isoform localisations were very similar to those shown in Figure 5.7, with 
Sgk1a showing cytosolic network-like localisation, Sgk1b showing predominantly nuclear 
with some weaker cytosolic network-like staining.  Slight differences were observed the 
other isoforms in that Sgk1c showed cytosolic network-like localisation similar to Sgk1a, 
and Sgk1d showed predominantly plasma membrane localisation in ruffle-like staining 




Figure 5.8  Intracellular localisation of FLAG-tagged mouse Sgk1 isoforms a, b, c, 
and d compared with red fluorescent protein (RFP)-labelled mitochondria in 
HEK293T cells.  A-E show images in the same colours and layout as shown in Figure 5.4, 
but with calnexin staining in red.  A shows cells cotransfected with FLAG-tagged Sgk1a 
and RFP-mitochondria.  B shows cells cotransfected with FLAG-tagged Sgk1b and RFP-
mitochondria.  C shows cells cotransfected with FLAG-tagged Sgk1c and RFP-
mitochondria.  D shows cells cotransfected with FLAG-tagged Sgk1d and RFP-
mitochondria.  E shows the equivalent images for untransfected control cells. 
 
 
SGK1 isoform Localisation in HEK293T cells No colocalisation with the 
following structures 
Human A Cytosolic network-like Mitochondria, Actin 
cytoskeleton, Endoplasmic 
reticulum. 
Human B Cytosolic network-like As A 
Human C Diffuse cytosolic Mitochondria 
Human D Predominantly plasma membrane 
with some diffuse cytosolic 
As A 
Human F Predominantly nuclear with some 
cytosolic network-like 
As A 
Mouse a Cytosolic network-like Mitochondria, Endoplasmic 
reticulum. 
Mouse b Predominantly nuclear with some 
cytosolic network-like 
As a 
Mouse c Diffuse with cytosolic network-like As a 
Mouse d Predominantly plasma membrane 
with some diffuse cytosolic 
As a 
 
Table 5.1  SGK1 isoform localisation summary. 
 
5.2.5 Co-immunoprecipitation of human SGK1 with GILZ1 
SGK1 and GILZ1 have been shown to be upregulated in renal cortical collecting duct cells 
in response to treatment with aldosterone (Soundararajan et al., 2005; Muller et al., 2003; 
Robert-Nicoud et al., 2001).  Of the four GILZ isoforms that are upregulated by 
aldosterone, only GILZ1 stimulates increased ENaC-mediated Na+ transport in renal 
cortical collecting duct cells (Soundararajan et al., 2007).  Both SGK1 and GILZ1 have 
been shown to negatively regulate the inhibition of ENaC through acting on Nedd4-2 and 
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ERK, respectively  (Bhalla et al., 2006).  However, it has been shown recently that SGK1 
and GILZ1 interact to stimulate ENaC and that this interaction is dependent on SGK1 
being activated and having an intact N-terminus (Soundararajan et al., 2009).  In light of 
this, the assay used in this study was adapted to include the mouse and human SGK1 
isoforms as a method of examining: (1) impact of the different N-termini of the SGK1 
isoforms on their interaction with GILZ1 and (2) any differences in phosphorylation status 
between expressed SGK1 isoforms. 
HEK293T cells were cotransfected with FLAG-tagged SGK1 isoforms plus GILZ1 or GFP 
control.  GILZ1 was then immunoprecipitated from lysates and the presence of SGK1 
isoforms bound to the precipitated GILZ1 protein was determined by Western blotting 
(Figure 5.9).  Arrows indicate the FLAG-tagged SGK1 bands, whereas other bands are 
probably due to nonspecific binding of the anti-FLAG antibody.  FLAG-tagged SGK1 
bands in the precipitate lanes demonstrated that human SGK1 isoforms A, B, C, D and F 
all co-immunoprecipitated with GILZ1, but, based on band intensity, isoforms A and B co-
immunoprecipitated in the greatest amounts.  This result suggests that, of the human SGK1 
isoforms, A and B bind to GILZ1 the most.  The doublet band seen for SGK1F is most 
likely caused by co-detection of a post-translationally modified form of the protein. 
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Figure 5.9  Human SGK1 isoforms A-F all co-immunoprecipitate with GILZ1, but 
SGK1A and SGK1B show the greatest amount of binding.  HEK293T cell lysates, from 
cells cotransfected with FLAG-tagged SGK1 isoforms plus GILZ1 or GFP control, were 
used in co-immunoprecipitation of SGK1 bound to GILZ1 using an anti-GILZ1 antibody.  
Original lysates, the supernatants and precipitated protein were analysed for FLAG-tagged 
SGK1 isoforms by Western blotting using an anti-FLAG antibody (Abcam).  Arrows 
indicate the FLAG-tagged SGK1 bands detected, whereas other bands present are due to 
nonspecific anti-FLAG antibody binding.  This experiment was repeated with similar 
results. 
 
This experiment was repeated using a different anti-FLAG antibody for detection of co-
immunoprecipitated FLAG-tagged SGK1 isoforms to verify the result and to obtain fewer 
nonspecific bands.  However, nonspecific protein bands are again detected in the 
precipitate lanes of the Western blots, but precipitated protein bands for each of the human 
SGK1 isoforms A, B, C, D and F can still be identified (Figure 5.10).  This result again 
suggests that SGK1A and B co-immunoprecipitate with GILZ1 in a greater amount than 
the other isoforms, shown by the FLAG bands for these isoforms being overexposed 
compared with the other isoforms bands.  No FLAG bands seen in the GFP transfected 
control lane confirms that the FLAG-tagged SGK1 bands detected are due to their co-
immunoprecipitation with GILZ1. 
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Figure 5.10  SGK1A and B also appear to co-immunoprecipitate with GILZ1 in 
greater amounts than SGK1 isoforms C, D and F when detected with a different anti-
FLAG antibody.   This experiment used the same procedure as described for Figure 5.9 
except for the use of a different anti-FLAG antibody (Chemicon).  Negative control 
(SGK1B with GFP) showed no co-immunoprecipitation. 
 
5.2.6 Co-immunoprecipitation of mouse Sgk1 with GILZ1 
In order to show relevance of the interaction between human SGK1 isoforms and GILZ1 to 
mouse Sgk1 isoforms, experiments were repeated using the mouse Sgk1 isoforms and 
human GILZ1.  Mouse Gilz1 could not be used because, when tested by Western blotting, 
mouse Gilz1-specific antibody failed to detect overexpressed mouse Gilz1 in transfected 
HEK293T cell lysate.  Therefore human GILZ1 was used, which shares 87% amino acid 
sequence identity with mouse Gilz1.  HEK293T cells were cotransfected, as before, with 
FLAG-tagged mouse Sgk1 isoforms plus GILZ1 or GFP control, followed by their lysis 
and use in immunoprecipitation of GILZ1.  The presence of Sgk1 isoforms bound to the 
precipitated GILZ1 protein was determined by Western blotting to show FLAG-tagged 
Sgk1 isoform expression in the precipitated protein fraction, compared with the 
supernatant or original lysate (Figure 5.11).  Arrows indicate the FLAG-tagged SGK1 
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bands, whereas the other bands are due to nonspecific binding of the anti-FLAG antibody.  
The Chemicon anti-FLAG antibody could not be used in this experiment because it was 
raised in mouse and therefore its use would cause secondary antibody cross-reactivity.  
These data demonstrated that mouse Sgk1 isoforms a, b, c, and d all co-
immunoprecipitated with GILZ1, but not GFP and that Sgk1b gave the most intense band 
in the precipitate, suggesting it bound to GILZ1 the most.  These results were similar to 
those obtained using the human SGK1 isoforms; all the isoforms tested in each species co-




Figure 5.11  Mouse Sgk1 isoforms a-d all co-immunoprecipitate with GILZ1, but 
Sgk1b shows the greatest amount of binding.  HEK293T cell lysates, from cells 
cotransfected with FLAG-tagged Sgk1 isoforms plus GILZ1 or GFP control, were used in 
co-immunoprecipitation of Sgk1 bound to GILZ1 using an anti-GILZ1 antibody.  Original 
lysates, the supernatants and precipitated protein were analysed for FLAG-tagged Sgk1 
isoforms by Western blotting using an anti-FLAG antibody (Abcam).  Arrows indicate the 
FLAG-tagged Sgk1 bands detected, whereas other bands present are due to nonspecific 




5.3.1 Fluorescence microscopy of SGK1D in human and mouse renal tissue 
To date, there have not been any previous studies that have investigated the localisation of 
endogenous SGK1D in either human or mouse renal tissue.  The sub-apical punctate 
staining shown in Figure 5.1 of human SGK1D in human renal tissue shows no similarity 
to any SGK1D localisation seen in cultured cells.  The sub-apical intracellular 
accumulations suggested that SGK1D may be localising to several possible intracellular 
structures, including basal bodies, intracellular vesicles or mitochondria.  Because the co-
staining of SGK1D with basal bodies, microtubules and mitochondria failed, no 
conclusions are possible and the identity of the intracellular structures that SGK1D is 
localising to still requires clarification.  The cell-cell junction staining of SGK1D (Figure 
5.2), could be explained by the plasma membrane localisation of SGK1D observed in 
cultured HEK293T cells (Figure 5.6) and in publications by others (Raikwar et al., 2008; 
Hall, 2007).  Verification of this staining, through colocalisation with ZO-1 was not 
possible, however, due to degradation of the human kidney tissue.  Therefore identification 
of the cell-cell junction structure also requires further verification. 
The basolateral membrane localisation of mouse Sgk1d is comparable to plasma 
membrane staining seen in cultured cells both in this chapter and publications by others 
(Arteaga et al., 2008).  Mouse Sgk1 was also shown to localise to the basolateral 
membrane of collecting ducts in rat kidney, although this study did not distinguish between 
Sgk1 isoforms (Alvarez de la Rosa et al., 2003).  This localisation at the basolateral surface 
suggests that mouse Sgk1d may have a function associated with the Na+/K+-ATPase 
transporter, which is present at the basolateral membrane of collecting duct epithelia, as 
opposed to an effect on ENaC, which is present at the apical membrane.  Several previous 
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studies have shown that aldosterone stimulates Na+/K+-ATPase activity and also that 
SGK1, or what is now known to be SGK1A, stimulated Na+/K+-ATPase activity when co-
expressed in Xenopus oocytes (Zecevic et al., 2004; Verrey et al., 2003; Setiawan et al., 
2002).  However, in epithelial cells, the basolateral localisation of Sgk1d coupled with the 
conserved catalytic domain between Sgk1 isoforms, suggest that Sgk1d may alone, or in 
combination with Sgk1a, mediate aldosterone-stimulated Na+/K+-ATPase activity.  
Experiments to show aldosterone-stimulated Sgk1d activity and colocalisation with 
Na+/K+-ATPase would be needed to verify this hypothesis. 
The images in Figure 5.1 and Figure 5.2 demonstrated that SGK1D expression was not 
confined to the collecting duct, but was also present in other renal tubules.  This was not 
entirely unexpected as SGK1A is reported to have many roles in addition to regulation of 
ENaC, including regulation of NCC in the DCT (Vallon et al., 2009; Lang et al., 2006).  
However, SGK1D is reported to have a greater effect on ENaC than SGK1A, suggesting 
that this isoform may play the prominent role in regulation of ENaC (Raikwar et al., 2008).  
This staining therefore provides insight into the relative distribution of SGK1D in renal 
tissue.  The only relevant previous investigation into the relative tissue distribution of 
SGK1D has been limited to qRT-PCR of a broad range of mouse tissues and 
immunoprecipitation of tagged protein from transgenic mouse whole organ lysates, not 
including kidney (Arteaga et al., 2008).  This investigation concluded that mouse Sgk1d 
was expressed exclusively in brain tissue, despite only examining expression of tagged 
protein in brain, heart, colon, and lung. 
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5.3.2 Fluorescence microscopy of FLAG-tagged SGK1 isoforms in HEK293T 
cells 
No previous studies have investigated the localisation of overexpressed human and mouse 
SGK1 isoforms.  The findings in the present study showing immunostaining of 
overexpressed FLAG-tagged human and mouse SGK1 isoforms in transiently transfected 
HEK293T cells are summarised in Table 5.1.  The majority of the human SGK1 isoforms 
and the equivalent mouse Sgk1 isoforms showed distinct similarity in their localisation.  
Human SGK1A and mouse Sgk1a displayed similar cytosolic network-like localisation.  
Human SGK1C and mouse Sgk1c both displayed similar diffuse localisation.  Human 
SGK1D and mouse Sgk1d, both localised predominantly to the plasma membrane.  
Interestingly, human SGK1B and mouse Sgk1b were the only isoforms conserved between 
species that didn’t show similar localisation.  Human SGK1B showed cytosolic network-
like localisation similar to human SGK1A and mouse Sgk1a.  In contrast, mouse Sgk1b 
displayed a predominantly nuclear localisation that was similar to human SGK1F, the only 
human isoform that is not conserved in mouse.  These different localisations of SGK1 
isoforms within species, yet similar localisations of equivalent SGK1 isoforms between 
species, suggest that they may have specific and conserved functional roles. 
Although no previous studies have compared the localisation of all SGK1 isoforms before, 
several have investigated and found similar localisation of SGK1A alone.  Naray-Fajes-
Toth et al. (2004) showed that yellow fluorescent protein-tagged human SGK1A 
transfected into RCCT-28 cells (a rabbit CCD cell line) displayed a diffuse cytosolic 
localisation (Naray-Fejes-Toth et al., 2004a).  Also, Menniti et al. (2005) showed that 
antibody detection of Myc-tagged human SGK1A transfected into COS7 cells also 
revealed a diffuse cytosolic localisation (Menniti et al., 2005).  In a similar experiment, 
Arteaga et al. (2007) showed cytosolic localisation of HA-tagged mouse Sgk1a in A6 cells 
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(Arteaga et al., 2007).  These three previous studies all used N-terminally tagged SGK1A 
constructs, but, in another study by Raikwar et al. (2008), comparable diffuse cytosolic 
localisation was shown of C-terminally FLAG-tagged human SGK1A in HEK293 cells 
(Raikwar et al., 2008).  This study also showed that the regulated localisation of SGK1A to 
the cytosol is dependent on its N-terminus, as a 60 amino acid-truncated human SGK1A 
showed diffuse localisation throughout the cell (Raikwar et al., 2008).  Raikwar et al 
(2008) also showed plasma membrane localisation of C-terminally FLAG-tagged human 
SGK1D in HEK293 cells (Raikwar et al., 2008).  This shows that N-terminally and C-
terminally FLAG-tagged human SGK1D localised identically in a similar cell type, 
suggesting that tag location did not affect localisation.  The plasma membrane localisation 
of SGK1D may be due to its putative PX domain, which confers affinity for 
phosphoinositide binding.  Arteaga et al. (2008) also described the localisation of mouse 
Sgk1d in transfected CHO cells as plasma membrane and showed that this was due to 
being bound to PI(4,5)P2 (Arteaga et al., 2008).  This paper also found that removal of 
three positive residues in the mouse Sgk1d N-terminus by K21N/K22N/R23G mutations 
caused its translocation from the plasma membrane to the cytosol.  Furthermore, 
F19A/F20A and W27A mutations caused Sgk1d translocation to the nucleus.  This 
suggests that residues at positions 19-23 and 27 of Sgk1d, which are thought to be within 
the PX domain, are critical for its plasma membrane localisation.  The plasma membrane 
localisation and/or phosphoinositide binding of SGK1D may confer its functional 
specificity. 
Data from the present study showed that, although SGK1 isoform localisation in cultured 
cells can be similar to in native tissue (e.g. mouse Sgk1d), it can also be very different (e.g. 
human SGK1D).  This may be because HEK293T cells are not representative of CCD 
cells, but could also be because cells were unpolarised, protein was overexpressed, or 
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isoforms were tagged.  The attachment of any protein tag to the SGK1 isoforms may also 
interfere with their correct localisation.  However, FLAG-tagging has the advantage that it 
involves the attachment of a relatively small epitope compared to fluorescent tags such a 
green fluorescent protein, whose larger size would increase the likelihood of localisation 
interference.  A possible improvement to this investigation is to use polarised mpkCCDcl4 
cells instead of HEK293T cells.  Polarised mpkCCDcl4 cells would show the SGK1 
isoform localisations that are specific to polarised CCD cells.  Although both HEK293T 
cells and mpkCCDcl4 cells were used in this study, mpkCCDcl4 cells did not show high 
enough transfection efficiency for localisation experiments.  HEK293T cells were kept in 
growth medium containing 10% FCS for SGK1 localisation studies, which should have 
stimulated SGK1 activity.  Future studies into SGK1 isoforms to investigate effects on 
localisation could test the effects of treating serum-starved HEK and CCD cells with 
aldosterone on localisation of FLAG-tagged SGK1 isoforms.  Investigation of the changes 
in SGK1 isoform localisation in response to their phosphorylation and activation may 
reveal more about the changes regarding which isoforms are involved in regulation of 
ENaC.  However, this approach still relies on transient transfection, which floods the cell 
with overexpressed protein possibly causing altered or disregulated localisation.  Future 
experiments could target untagged, overexpressed, or endogenous protein, but this requires 
detection using isoform-specific antibodies.  In a previous study, Sahoo et al. (2005) 
showed that endogenous SGK1 localisation in human breast cancer cells was 
predominantly cytosolic and network-like, using a pan-SGK1 antibody, suggesting that this 
staining was accounted for by SGK1A and SGK1B (Sahoo et al., 2005).  The human 
SGK1 isoform-specific antibodies described in this thesis showed decreased specificity 
when used to detect untagged protein for immunofluorescence.  Generation of high-avidity 
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SGK1 isoform-specific antibodies would allow future investigation of differential isoform 
regulation and localisation using immunofluorescence. 
 
5.3.3 Co-immunoprecipitation of SGK1 isoforms with GILZ1 
The result that SGK1A co-immunoprecipitated with GILZ1 (Figure 5.9 and Figure 5.10) 
supports the finding of Soundarajan et al. (2009) that showed a 49 kDa SGK1 band protein 
co-immunoprecipitated with GILZ1 from transfected HEK293T cell lysate (Soundararajan 
et al., 2009).  The results of my experiment using the other human and mouse SGK1 
isoforms are novel.  GILZ1 has been shown to localise in the cytosol, suggesting that 
SGK1 isoforms that share this localisation may interact with it the most.  Only the human 
isoforms SGK1A and B, which showed cytosolic localisation, also showed enhanced 
interaction with GILZ1.  Mouse Sgk1b also showed enhanced interaction with GILZ1, 
despite its predominantly nuclear localisation. 
Further investigation is needed to find out why these isoforms preferentially interact with 
GILZ1 and what role, if any, their intracellular localisation plays.  The co-
immunoprecipitation of SGK1A with GILZ1 was initially shown by Soundarajan et al. 
(2009) and revealed to be part of a regulatory complex that enhances ENaC activation.  In 
the same study, GILZ1, FLAG-SGK1, Raf-1, and Nedd4-2 were shown to colocalise in 
HEK293T cells by fluorescence microscopy, suggesting that both SGK1 action on Nedd4-
2 and GILZ1 action on the ERK signalling pathway may be involved (Soundararajan et al., 
2009).  The MEK1/2 inhibitor, PD98059 has also been shown to partially inhibit 
aldosterone-stimulated Ieq highlighting the involvement of the Ras-GILZ-ERK pathway 
(Michlig et al., 2004).  As yet, it is unknown what region of SGK1A or the other isoforms 
interacts with GILZ1.  The differential interaction between Sgk1 isoforms and GILZ1 in 
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cells overexpressing both proteins, suggests that the differing SGK1 isoform N-termini 
may modulate the interaction.  Experiments described in this thesis and experiments in the 
investigation by Soundarajan et al. (2009) both use tagged SGK1 and, despite showing 
similar results, the tags could have affected the interaction with GILZ1.  Future 
experiments could include investigating whether the interaction with GILZ1 affects SGK1 
isoform localisation.  Further work on the interactions of SGK1 isoforms with ENaC 
regulatory proteins could resolve the identity of a novel ENaC regulatory complex. 
 
5.4 Summary 
 SGK1D shows sub-apical/perinuclear punctate and cell-cell junction localisation in 
human renal collecting duct epithelia. 
 Sgk1d shows basolateral membrane localisation in mouse collecting duct and other 
renal tubule epithelia. 
 FLAG-tagged human SGK1 isoforms A, B, C, D and F do not exclusively 
colocalise with actin cytoskeleton, mitochondria nor endoplasmic reticulum in 
HEK293T cells. 
 FLAG-tagged human SGK1 isoforms A, B, D, and F show cytosolic network-like 
localisation in HEK293T cells. 
 FLAG-atgged human SGK1C shows diffuse cytosolic localisation in HEK293T 
cells. 
 FLAG-tagged human SGK1D shows predominantly plasma membrane localisation 
in HEK293T cells. 
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 FLAG-tagged human SGK1F shows predominantly nuclear localisation in 
HEK293T cells. 
 FLAG-tagged mouse Sgk1 isoforms a, b, c and d do not colocalise with 
mitochondria nor calnexin. 
 FLAG-tagged mouse Sgk1a, b, and c show cytosolic network-like localisation in 
HEK293T cells. 
 FLAG-tagged mouse Sgk1b shows predominantly nuclear localisation in HEK293T 
cells. 
 FLAG-tagged mouse Sgk1d shows predominantly plasma membrane localisation in 
HEK293T cells. 
 FLAG-tagged human SGK1 isoforms A, B, C, D and F all bind with GILZ1, but 
SGK1A and B bind the most. 
 FLAG-tagged mouse Sgk1 isoforms a, b, c and d all bind with GILZ1, but Sgk1b 
binds the most. 
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Chapter 6 - Conclusions 
6.1 Achievement of aims 
Data presented in this thesis shows that mouse mpkCCDcl4 cells express four isoforms of 
Sgk1 (Sgk1a, 1b, 1c, and 1d) and that the expression of these isoforms is regulated by 
aldosterone.  In addition, results from ion transport studies suggest that all four isoforms 
are involved in aldosterone-dependent regulation of the epithelial sodium channel (ENaC).  
Additionally, that human and mouse SGK1 isoforms show specific subcellular distribution 
in both native renal tissue, as well as specific intracellular localisation in cultured 
HEK293T cells.  Overall, this suggests that multiple SGK1 isoforms are involved in the 
regulation of transepithelial Na+ transport in cultured CCD cells and native tissue. 
 
6.2 Review of research path 
At the start of this PhD the SGK1 gene was considered to code for a single protein, 
however, work from human skin cells suggested that multiple human SGK1 variants 
existed.  Potential Sgk1 variant mRNAs were identified by searching the dbEST mouse 
expressed sequence tag database for alternative Sgk1 transcripts.  Four potential mouse 
Sgk1 variant mRNAs were identified that originate from alternative promoter usage and 
RNA splicing and produce four Sgk1 isoforms, which were named Sgk1a, 1b, 1c, and 1d.  
Expression of the four Sgk1 variant mRNAs was confirmed in cultured mouse CCD cells 
and native mouse renal tissue by whole cell/tissue RNA isolation and RT-PCR using 
isoform-specific primers.  The confirmed Sgk1 variants were then cloned into an 
expression vector allowing investigation of their translation products via exogenous 
overexpression in cultured cells and Western blotting for Sgk1 in the cell lysate.  Multiple 
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Sgk1 protein bands were produced by isoform overexpression, of which the most intense 
for each isoform corresponded in size with the putative Sgk1 isoform proteins predicted 
earlier, being ~49 kDa (Sgk1a), ~51 kDa (Sgk1b), ~48 kDa (Sgk1c), and ~60 kDa (Sgk1d). 
The role of Sgk1 isoforms in regulation of Na+ transport in mouse CCD cells was 
investigated firstly by monitoring their induction by aldosterone using different doses and 
time of exposure to, a hormone known to induce Na+ transport.  Aldosterone increased 
expression of Sgk1a, 1b, and 1c suggesting these isoforms likely have roles in aldosterone-
stimulated Na+ transport.  Aldosterone treatment also revealed the endogenous expression 
of Sgk1a, 1b, 1c, whilst Sgk1d was expressed at a high basal level in starved mouse CCD 
cells.  Combined aldosterone plus insulin treatment was also used because previous work 
had shown that combination of hormones induced a larger Na+ transport increase than 
aldosterone alone and insulin alone was also known to increase Sgk1 expression (Wang et 
al., 2008; Gonzalez-Rodriguez et al., 2007).  Aldosterone and aldosterone plus insulin 
induced multiple Sgk1 isoform bands, which were identified by their co-migration with 
exogenous overexpressed Sgk1 isoforms. 
To investigate if changes in Na+ transport correlated with phosphorylation of Sgk1 
isoforms, optimisation of Western blotting using phosphorylated-specific Sgk1 antibodies 
was attempted, but these antibodies only detected phosphorylated human SGK1B and 1C 
and mouse Sgk1c.  In investigation of the regulation of Sgk1 isoforms, aldosterone-
induced Sgk1a, 1b, 1c, and 1d were inhibited by LY294002; an inhibitor of PI3Ks and 
mTOR.  The identity of human and mouse Sgk1b and 1d were further confirmed using 
isoform-specific antibodies. 
In order to relate changes in Sgk1 protein expression to changes in transepithelial Na+ 
transport, parallel Western blotting and Ieq measurement were performed, from cells 
exposed to aldosterone and combined aldosterone plus insulin.  Aldosterone treatment 
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produced a similar time-dependent increase in Na+ transport as Sgk1 isoform expression.  
Treatment with amiloride revealed that the Na+ transport was mostly via ENaC, which is 
known to be regulated by Sgk1.  Inhibition of PI3Ks and mTOR with LY294002 also 
produced a similar reduction in Na+ transport as found for the effects of LY294002 on 
expression of Sgk1 isoforms.  Rapamycin, an inhibitor of mTORC1 activity, also produced 
a small, but significant reduction in Na+ transport, which was unexpected as mTORC2 has 
recently been shown to be the mTOR complex responsible for activation of Sgk1.  
Overexpression and knockdown of Sgk1 in polarised mouse CCD cells was attempted in 
order to study the effects of individual Sgk1 isoforms, however, these approaches were 
unsuccessful. 
Investigation of the native renal tissue or cultured cells localisation of SGK1 isoforms 
suggested that SGK1 isoforms have specialised roles.  Human SGK1D showed sub-apical 
punctate staining, as well as cell-cell junction localisation in collecting ducts of human 
renal tissue.  Mouse Sgk1d showed basolateral localisation in the collecting ducts of mouse 
renal tissue.  In HEK293T cells, SGK1A, B and C showed cytosolic localisation, whereas 
SGK1D showed plasma membrane localisation and SGK1F showed nuclear localisation.  
In the same cell line, mouse Sgk1a and c showed cytosolic localisation, whereas Sgk1b 
showed nuclear localisation and Sgk1d showed plasma membrane localisation.  These data 
showing isoform-specific intracellular localisation, together with the differential 
stimulation of Sgk1 isoforms expression by hormones, as well as the temporal change in 
Na+ transport, collectively suggest that Sgk1 isoforms perform different roles in regulation 
of Na+ transport.  However, these data were not able to measure phosphorylated (active) 
Sgk1 expression due to the failure of detecting phosphorylated Sgk1 by Western blotting.  
Therefore, a co-immunoprecipitation assay was adapted from a study by Soundararajan et 
al. (2009) to look for the recruitment of phosphorylated Sgk1 by GILZ1 to a complex of 
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ENaC-Raf1-Nedd4-2, which was shown to cooperatively reduce the inhibitory effect of 
MAPK/ERK and Nedd4-2 on ENaC activity, respectively.  All SGK1 isoforms interacted 
with GILZ1, but the greatest levels of interaction were between GILZ1 and human SGK1 
isoforms A and B and mouse Sgk1 isoform b, suggesting these isoforms are the most 
active or are selective for the role of cooperative regulation of ENaC with GILZ1. 
 
6.3 Final discussion 
Aldosterone was also found to induce isoforms equivalent to Sgk1a, 1b, and 1c in the study 
by Gonzalez-Rodriguez et al. (2007).  This study also showed that Sgk1 isoform induction 
was retained after lambda phosphatase treatment, whereas higher bands on the Western 
blot were removed, indicating that the Sgk1a, 1b, and 1c bands are not phosphorylated 
forms (Gonzalez-Rodriguez et al., 2007).  In the data presented in chapters 3 and 4, Sgk1d 
was consistently expressed at a higher basal level than the other isoforms in starved mouse 
CCD cells, as well as not being induced to the same extent by aldosterone.  In addition, 
Sgk1d was less affected by LY294002 than the other isoforms.  The apparent greater 
stability of Sgk1d compared to Sgk1a in mouse CCD cells was quantified in the study by 
Raikwar et al. (2008), which showed Sgk1d had a longer half-life than Sgk1a (t1/2 of 
SGK1A: 16 min, and SGK1D: 119 min).  Therefore, stimulation of cells with hormones 
such as aldosterone would first lead to a selective increase in Sgk1d activity, followed by 
later increase in other isoforms. 
In Sgk1 isoform overexpression studies the unidentified 56 kDa Sgk1 band present in the 
Western blot of synthesised Sgk1b could be a multi-phosphorylated Sgk1b protein with an 
increase in apparent size by 5 kDa, but this would require synthesised protein to potentially 
become phosphorylated.  Overexpressing PDPK1 with Sgk1 isoforms to induce their 
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phosphorylation only worked for human SGK1B and C and mouse Sgk1c, suggesting that 
the Sgk1 isoforms have different phosphorylation profiles.  It has been reported that 
phosphorylation of serine 422 (by mTORC2) is required for phosphorylation of threonine 
256 (by PDPK1) to take place, but my experiments suggest this is not the case for human 
SGK1B and C and mouse Sgk1c. 
Sgk1d contains a putative PX domain, which is characterised by phosphoinositide binding 
primarily to PtdIns(3)P, although PX domains can also bind other PtdIns forms as well 
(Vanhaesebroeck et al., 2010).  Rab5 has been shown to recruit class III PI3K to early 
endosomes creating a possible route for Sgk1d recruitment to recycling/degrading ENaC in 
endosomes (Backer, 2008; Lu et al., 2007).  Class III PI3K also interacts with Rab7, which 
is thought to recruit class III PI3K to late endosomes causing an accumulation of 
PtdIns(3)P (Backer, 2008).  This data presents endosomes as a possible localisation of 
SGK1D in native human renal tissue, although the intracellular accumulations producing 
the punctate staining of SGK1D were probably too large to be endosomes. 
 
6.4 Relevance of findings 
Research, thus far, has identified many different roles for SGK1 in various tissue types 
throughout the body, but the research conducted only considered that one isoform of SGK1 
was involved.  Clearly, the demonstration by my work and others that have now shown 
that multiple SGK1 isoforms exist makes it important that future research considers more 
than just SGK1A. This thesis has shown that multiple mouse Sgk1 isoforms are 
differentially induced by aldosterone in parallel with induced Na+ transport.  The isoforms 
appear to exhibit different intracellular localisation and interact differentially with GILZ1, 
indicating that mouse Sgk1 isoforms are likely to have specialised functions in the 
 167
regulation of Na+ transport.  It is therefore highly likely that SGK1 isoforms also have 
specialised functions in the other tissue types where the original SGK1 was only 
considered before.  SGK1 isoforms could therefore be responsible for many as yet 
unidentified effects in tissues throughout the body. 
The identification of multiple SGK1 isoforms involved in regulation of CCD Na+ transport 
suggests that several proteins, in addition to the original SGK1 (1A), may be involved or 
underlie dysregulated Na+ transport and hypertension.  Polymorphisms in SGK1 have 
already been linked to certain types of hypertension (Lang et al., 2009a) and SGK1 
knockout mice produce a phenotype with an inability to retain salt when given a low-salt 
diet, as well as fail to excrete K+ when given a high K+ diet (Fejes-Toth et al., 2008; Huang 
et al., 2004; Wulff et al., 2002).  Dysregulation of SGK1 isoforms could also be implicated 
in cystic fibrosis as SGK1A has been shown to regulate CFTR (Sato et al., 2007).  
Additionally, SGK1 isoforms could potentially be involved in development of diabetes as 
polymorphisms in the SGK1 gene have been linked to variations in blood pressure and 
predisposal to obesity and type 2 diabetes (Schwab et al., 2008).  SGK1A has also been 
shown to be upregulated by conditions associated with type 2 diabetes and is thought to be 
involved in development of diabetic nephropathy (Lang et al., 2009b). 
Various pharmacological inhibitors of components of the SGK1 signalling pathway are 
used in clinical treatment such as sirolimus (rapamycin), which is used as an 
immunosuppressant particularly in kidney transplants, but it has been shown to cause renal 
Na+, K+, and Mg2+ wasting resulting in hypovolemia (da Silva et al., 2009).  LY294002 
inhibits class I PI3Ks and its use has provided evidence for targeting PI3K in treatment of 
tumour cells (Liu et al., 2009).  However, LY294002 is not used clinically because of off-
target effects, as it inhibits CK2, mTOR, and GSK3β (Gharbi et al., 2007) as well as cAMP 
phosphodiesterase 2 (PDE2) (Abbott and Thompson, 2004), and valosin-containing protein 
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(VCP) (Halawani and Latterich, 2006).  Heterocyclic indazole derivatives have recently 
been suggested as inhibitors of SGK1 for the clinical treatment of many conditions 
including hypertension, diabetes, and kidney, heart, and lung fibrosis (Lang and Gorlach, 
2010).  Mechanistic target of rapamycin (mTOR) inhibitors, temsirolimus and everolimus, 
are currently approved for treatment of renal cell carcinoma (RCC) (Azim et al., 2010), 
whereas others such as deforolimus (Mita et al., 2008) are in clinical development.  These 
clinical applications for inhibitors of SGK1 and associated proteins show the importance of 
the pathway and suggest that multiple SGK1 isoforms may complicate interpretations of 
the effects of these inhibitors, but also provide potential targets for future pharmacological 
therapeutics. 
 
6.5 Future work 
Further work is required to identify the roles of individual SGK1 isoforms in regulation of 
ENaC-mediated Na+ transport in CCD cells.  As discussed in chapter 4, this could be 
achieved by examining the effects of overexpression of individual Sgk1 isoforms or 
knockdown of endogenous Sgk1 on amiloride-sensitive equivalent short circuit current in 
mpkCCDcl4 cell monolayers.  However, difficulty to transfect monolayers of mpkCCDcl4 
cells grown on Transwells using Lipofectamine 2000 suggests other methods of 
transfection should be used in future.  Transfection methods shown to successfully 
transfect mpkCCDcl4 cells include Nucleofection with plasmid DNA (Soundararajan et al., 
2005) and siRNA (Raikwar et al., 2010), and retroviral transfection (Auberson et al., 
2003).  Alternatively, stable transfection of cells with an expression vector conferring 
specific antibiotic resistance could be used to generate stable cell lines expressing 
individual Sgk1 isoforms.  Knockdown of Sgk1 in mpkCCDcl4 cells using siRNA has not 
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been shown to date, but many studies using different cell types, siRNAs, or transfection 
methods show siRNA-mediated knockdown of SGK1.  Alternative knockdown approaches 
to siRNA include micro RNA, short hairpin RNA, and antisense RNA. 
An additional approach to examining the roles of individual SGK1 isoforms involves their 
individual knockdown using isoform-specific siRNA or other RNAi technique.  Instead of 
simply overexpressing or knocking down SGK1 isoforms, their individual kinase activity 
could be modified to allow investigation of their roles.  For example, this could involve the 
creation of kinase dead (K127M), constitutively active (T256D/S422D), or non-
phosphorylatable (T256A/S422A) mutant Sgk1 isoforms, such as shown for human and 
mouse SGK1A (Chang et al., 2007; Leong et al., 2003).  Modified Sgk1 isoforms could 
also be used to investigate the origins of the alternative transcription products using site-
directed mutagenesis to individually substitute the alternative start methionines and thus 
remove and identify Sgk1 isoform Western blot bands.  Furthermore, investigation of the 
functions of SGK1 isoforms would be greatly improved by creation of mouse Sgk1 
isoform-specific antibodies, more sensitive human SGK1 isoform-specific antibodies and 
phosphorylated-isoform-specific antibodies, allowing investigation of isoform-specific 
expression or localisation changes and subcellular distribution of all SGK1 isoforms in 
native tissues. 
Other potential approaches for SGK1 isoform-specific study include creation of isoform-
specific knockout mouse models to assess dependence on different isoforms in vivo.  Also, 
quantitative RT-PCR could be used to show variations in the relative level of different 
isoform mRNA expression and further investigate the effects of hormone stimulation.  
Coexpression of individual SGK1 isoforms with ENaC in Xenopus oocytes could show the 
direct isoform-specific effects on ENaC activity.  This study into isoforms of SGK1 could 
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